

ICAM-4 MATERIALS AND METHODS

This application is a continuation-in-part of U.S. Patent Application Serial No. 08/656,984, filed June 6, 1996 and currently pending, is a continuation-in-part of U.S. Patent Application Serial No. 08/481,130, filed June 7, 1995 and currently pending, which is a continuation-in-part of U.S. Patent Application Serial No. 08/245,295, filed May 18, 1994 and currently pending, which in turn is a continuation-in-part of U.S. Patent Application Serial No. 08/102,852, filed August 5, 1993 and now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 08/009,266, filed January 22, 1993 and now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 07/894,061, filed June 5, 1992 and now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 07/889,724, filed May 26, 1992 and now abandoned which is a continuation-in-part of co-pending U.S. Patent Application Serial No. 07/827,689, filed January 27, 1992 and now abandoned.

FIELD OF THE INVENTION

The present invention relates generally to cellular adhesion molecules and more particularly to the cloning and expression of DNA encoding a heretofore unknown polypeptide designated "ICAM-4" which possesses structural relatedness to the intercellular adhesion molecules ICAM-1, ICAM-2, and ICAM-R.

BACKGROUND OF THE INVENTION

Research spanning the last decade has significantly elucidated the molecular events attending cell-cell interactions in the body, especially those events involved in the movement and activation of cells in the immune system, and more recently, those involved in development and normal physiological function of cells in the nervous system. See generally, Springer, *Nature*, 346: 425-434 (1990) regarding cells of the immune system, and

Yoshihara, *et al. Neurosci.Res.* 10:83-105 (1991) and Sonderegger and Rathjen, *J.Cell Biol.* 119:1387-1394 (1992) regarding cells of the nervous system. Cell surface proteins, and especially the so-called Cellular Adhesion Molecules ("CAMs") have correspondingly been the subject of pharmaceutical research and development having as its goal intervention in the processes of leukocyte extravasation to sites of inflammation and leukocyte movement to distinct target tissues, as well as neuronal differentiation and formation of complex neuronal circuitry. The isolation and characterization of cellular adhesion molecules; the cloning and expression of DNA sequences encoding such molecules, and the development of therapeutic and diagnostic agents relevant to inflammatory processes and development and function of the nervous system have also been the subject of numerous U.S. and foreign applications for Letters Patent. See Edwards, *Current Opinion in Therapeutic Patents*, 1(11): 1617-1630 (1991) and particularly the published "patent literature references" cited therein.

Of fundamental interest to the background of the present invention are the prior identification and characterization of certain mediators of cell adhesion events, the "leukointegrins," LFA-1, MAC-1 and gp 150.95 (referred to in WHO nomenclature as CD18/CD11a, CD18/CD11b, and CD18/CD11c, respectively) which form a subfamily of heterodimeric "integrin" cell surface proteins present on B lymphocytes, T lymphocytes, monocytes and granulocytes. See, e.g., Table 1 of Springer, *supra*, at page 429. Also of interest are other single chain adhesion molecules (CAMs) that have been implicated in leukocyte activation, adhesion, motility and the like, which are events attendant to the inflammatory process. For example, it is presently believed that prior to the leukocyte extravasation which characterizes inflammatory processes, activation of integrins constitutively expressed on leukocytes occurs and is followed by a tight ligand/receptor interaction between the integrins (e.g., LFA-1) and one or both of two distinct intercellular adhesion molecules (ICAMs) designated ICAM-1 and ICAM-2 which are

expressed on blood vessel endothelial cell surfaces and on other leukocytes.

Like the other CAMs characterized to date, [e.g., vascular adhesion molecule (VCAM-1) as described in PCT WO 90/13300 published November 15, 1990; and platelet endothelial cell adhesion molecule (PECAM-1) as described in Newman *et al.*, *Science*, 247: 1219-1222 (1990) and PCT WO 91/10683 published July 25, 1991], ICAM-1 and ICAM-2 are structurally homologous to other members of the immunoglobulin gene superfamily in that the extracellular portion of each is comprised of a series of domains sharing a similar carboxy terminal motif. A "typical" immunoglobulin-like domain contains a loop structure usually anchored by a disulfide bond between two cysteines at the extremity of each loop. ICAM-1 includes five immunoglobulin-like domains; ICAM-2, which differs from ICAM-1 in terms of cell distribution, includes two such domains; PECAM-1 includes six; VCAM includes six or seven, depending on splice variations, and so on. Moreover, CAMs typically include a hydrophobic "transmembrane" region believed to participate in orientation of the molecule at the cell surface and a carboxy terminal "cytoplasmic" region. Graphic models of the operative disposition of CAMs generally show the molecule anchored in the cell membrane at the transmembrane region with the cytoplasmic "tail" extending into the cell cytoplasm and one or more immunoglobulin-like loops extending outward from the cell surface.

A number of neuronal cells express surface receptors with extracellular Ig-like domains, structurally similar to the ICAMs. See for example, Yoshihara, *et al.*, *supra*. In addition to Ig-like domains, many adhesion molecules of the nervous system also contain tandemly repeated fibronectin-like sequences in the extracellular domain.

A variety of therapeutic uses has been projected for intercellular adhesion molecules, including uses premised on the ability of ICAM-1 to bind human rhinovirus. European Patent Application 468 257 A published January 29, 1992, for example, addresses the development of multimeric configura-

tions and forms of ICAM-1 (including full length and truncated molecular forms) proposed to have enhanced ligand/receptor binding activity, especially in binding to viruses, lymphocyte associated antigens and pathogens such as *Plasmodium falciparum*.

- 5 In a like manner, a variety of uses has been projected for proteins immunologically related to intercellular adhesion molecules. WO91/16928, published November 14, 1991, for example, addresses humanized chimeric anti-ICAM-1 antibodies and their use in treatment of specific and non-specific inflammation, viral infection and asthma. Anti-
10 ICAM-1 antibodies and fragments thereof are described as useful in treatment of endotoxic shock in WO92/04034, published March 19, 1992. Inhibition of ICAM-1 dependent inflammatory responses with anti-ICAM-1 anti-idiotypic antibodies and antibody fragments is addressed in WO92/06119, published April 16, 1992.
- 15 ----- Despite the fundamental insights into cell adhesion phenomena which have been gained by the identification and characterization of intercellular adhesion proteins such as ICAM-1 and lymphocyte interactive integrins such as LFA-1, the picture is far from complete. It is generally
----- believed that numerous other proteins are involved in inflammatory processes
20 and in targeted lymphocyte movement throughout the body. For example, U.S. Patent Application Serial Nos. 07/827,689, 07/889,724, 07/894,061 and 08/009,266 and corresponding published PCT Application WO 93/14776 (published August 5, 1993) disclose the cloning and expression of an ICAM-Related protein, ICAM-R. The disclosures of these applications are
25 specifically incorporated by reference herein and the DNA and amino acid sequences of ICAM-R are set out in SEQ ID NO. 4 herein. This new ligand has been found to be expressed on human lymphocytes, monocytes and granulocytes.

- Of particular interest to the present application, still another
30 ICAM-like surface molecule was identified which has a tissue specific

expression unlike that of any known ICAM molecule. Mori, *et al.*,
[*Proc.Natl.Acad.Sci.(USA)* 84:3921-3925 (1987)] reported identification of a
telencephalon-specific antigen in rabbit brain, specifically immunoreactive
with monoclonal antibody 271A6. This surface antigen was named
5 telencephalin. Imamura, *et al.*, [*Neurosci.Letts.* 119:118-121 (1990)], using
a polyclonal antibody to assess localized expression, asserted that expression
of telencephalin in visual cortex of cats showed variation in layers of the
tissue, and also reported telencephalin expression was variable as a function
of development. Oka, *et al.*, [*Neuroscience* 35:93-103 (1990)] subsequently
10 reported isolation of telencephalin using monoclonal antibody 271A6. The
publication reports a molecular weight for the surface molecule of about 500
kD and that the molecule was composed of four subunits, each with a native
molecular weight of 130 kD and approximately 100 kD following *N*-glycanase
treatment. Yoshihiro, *et al.*, [*Neuroscience*, Research Supplement 18, p. S83
15 (1994)], reported the cDNA and amino acid sequences for rabbit telencephalin
at the 17th Annual Meeting of the Japan Neuroscience Society in Nagoya,
Japan, December 7-9, 1993, and the 23rd Annual Meeting of the Society for
Neuroscience in Washington, D.C., November 9, 1993 [Society for
Neuroscience Abstracts-19 (1-3)-p. 646 (1993)]. The deduced amino acid
20 sequence reported suggested that the 130 kD telencephalon is an integral
membrane protein with nine extracellular immunoglobulin (Ig)-like domains.
The distal eight of these domains showed homology to other ICAM Ig-like
domains. This same information was reported by Yoshihara, *et al.*, in *Neuron*
12:543-553 (1994).

25 There thus continues to be a need in the art for the discovery
of additional proteins participating in human cell-cell interactions and
especially a need for information serving to specifically identify and
characterize such proteins in terms of their amino acid sequence. Moreover,
to the extent that such molecules might form the basis for the development of
30 therapeutic and diagnostic agents, it is essential that the DNA encoding them

be elucidated. Such seminal information would *inter alia*, provide for the large scale production of the proteins, allow for the identification of cells naturally producing them, and permit the preparation of antibody substances or other novel binding proteins specifically reactive therewith and/or inhibitory of ligand/receptor binding reactions in which they are involved.

BRIEF SUMMARY OF THE INVENTION

In one of its aspects, the present invention provides purified and isolated polynucleotides (e.g., DNA sequences, RNA transcripts and anti-sense oligonucleotides thereof) encoding a novel polypeptide, "ICAM-4," as well as polypeptide variants (including fragments and deletion, substitution, and addition analogs) thereof which display one or more ligand/receptor binding biological activities and/or immunological properties specific to ICAM-4. ICAM-4-specific ligand/receptor binding biological activities encompass interactions of both the ICAM-4 extracellular and cytoplasmic domains with other molecules (e.g., in processes of cell-cell adhesion and/or signal transduction). Preferred DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. A presently preferred polynucleotide is set out in SEQ ID NO: 1 and encodes rat species ICAM-4. Biological replicas (i.e., copies of isolated DNA sequences made *in vivo* or *in vitro*) of DNA sequences of the invention are contemplated. Also provided are autonomously replicating recombinant constructions such as plasmid and viral DNA vectors incorporating ICAM-4 sequences and especially vectors wherein DNA encoding ICAM-4 or an ICAM-4 variant is operatively linked to an endogenous or exogenous expression control DNA sequence.

According to another aspect of the invention, host cells, especially unicellular host cells such as procaryotic and eucaryotic cells, are stably transformed with DNA sequences of the invention in a manner allowing the desired polypeptides to be expressed therein. Host cells expressing such

ICAM-4 and ICAM-4 variant products can serve a variety of useful purposes. To the extent that the expressed products are "displayed" on host cell surfaces, the cells may constitute a valuable immunogen for the development of antibody substances specifically immunoreactive with ICAM-4 and ICAM-4 variants. Host cells of the invention are conspicuously useful in methods for the large scale production of ICAM-4 and ICAM-4 variants wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown.

Novel ICAM-4 of the invention may be obtained as isolates from natural cell sources, but, along with ICAM-4 variant products, are preferably produced by recombinant procedures involving host cells of the invention. A presently preferred amino acid sequence for an ICAM-4 polypeptide is set out in SEQ ID NO: 2. The products may be obtained in fully or partially glycosylated, partially or wholly de-glycosylated, or non-glycosylated forms, depending on the host cell selected for recombinant production and/or post-isolation processing. ICAM-4 variants of the invention may comprise water soluble or insoluble monomeric, multimeric or cyclic ICAM-4 fragments which include all or part of one or more of the domain regions specified above and having a biological or immunological property of ICAM-4 including, *e.g.*, the ability to bind to a binding partner of ICAM-4 and/or inhibit binding of ICAM-4 to a natural binding partner. ICAM-4 variants of the invention may also comprise polypeptide analogs wherein one or more of the specified amino acids is deleted or replaced: (1) without loss, and preferably with enhancement, of one or more biological activities or immunological characteristics specific for ICAM-4; or (2) with specific disablement of a particular ligand/receptor binding function. Analog polypeptides including additional amino acid (*e.g.*, lysine or cysteine) residues that facilitate multimer formation are contemplated.

Also comprehended by the present invention are antibody substances (*e.g.*, monoclonal and polyclonal antibodies, antibody fragments,

single chain antibodies, chimeric antibodies, CDR-grafted antibodies and the like) and other binding proteins (*e.g.*, polypeptides and peptides) which are specific (*i.e.*, non-reactive with the ICAM-1, ICAM-2, and ICAM-R intercellular adhesion molecules to which ICAM-4 is structurally related) for
5 ICAM-4 or ICAM-4 variants. The invention also comprehends hybridoma cell lines which specifically secrete monoclonal antibodies of the invention. Presently preferred hybridomas of the invention include those designated 127A, 127H, 173E, 179I, and 179H. Antibody substances can be developed using isolated natural or recombinant ICAM-4 or ICAM-4 variants or cells
10 expressing such products on their surfaces. Binding proteins of the invention are additionally useful for characterization of binding site structure(s) (*e.g.*, epitopes and/or sensitivity of binding properties to modifications in ICAM-4 amino acid sequence).

Binding proteins are useful, in turn, in compositions for
15 immunization as well as for purifying polypeptides of the invention and identifying cells displaying the polypeptides on their surfaces. They are also manifestly useful in modulating (*i.e.*, blocking, inhibiting or stimulating) ligand/receptor binding biological activities involving ICAM-4, especially those ICAM-4 effector functions involved in specific and non-specific immune
20 system responses. Anti-idiotypic antibodies specific for anti-ICAM-4 antibody substances and uses of such anti-idiotypic antibody substances in modulating immune responses are also contemplated. The invention further provides methods of screening for neuropathology in an individual comprising the steps of: a) obtaining a fluid sample from the individual; b) contacting the
25 sample with an antibody specifically immunoreactive with ICAM-4; c) quantitating the level of ICAM-4/antibody binding in the sample; and d) comparing the level of ICAM-4/antibody binding in the sample to the level of ICAM-4/antibody binding in individuals (controls) known to be free of the neuropathology. Assays for the detection and quantification of ICAM-4 on
30 cell surfaces and in body fluids, such as serum or cerebrospinal fluid, may

involve, for example, a single antibody substance or multiple antibody substances in a "sandwich" assay format. In detecting ICAM-4 in a body fluid, antibodies of the invention are also useful for assessing the occurrence of neuropathologies which can be correlated to increased levels of circulating

5 ICAM-4. Such neuropathologies include, but are not limited to, cerebral ischemia (*i.e.*, stroke) resulting from various disorders including, for example, thrombosis, embolism, cerebral aneurysmal hemorrhage, vasospasm, and the like. Quantitation of circulating ICAM-4 can also distinguish between various forms of epilepsy and may also permit determination of the stage of AIDS

10 progression. Still other neurodegenerative disorders for which measurement of circulating ICAM-4 can be useful for diagnosis include various forms of Alzheimer's disease and other cortical dementias (such as Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy), subcortical dementias (including Parkinson's disease, Huntington's disease, and

15 progressive supranuclear); a number of the primary psychiatric disorders (such as depression, schizophrenia and psychosis), as well as nongenetic dementias arising from, for example, infections, vasculitis, metabolic and nutritional disorders (*e.g.*, thyroid, vitamin B12 deficiency), vascular disorders (multiple infarct, lacunar state, Binswanger's disease), toxic encephalopathies (*e.g.*,

20 exposure to carbon monoxide, heavy metals or other industrial pollutants) and tumors.

The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA

25 for ICAM-4 makes possible the isolation by DNA/DNA hybridization of genomic DNA sequences encoding ICAM-4 and specifying ICAM-4 expression control regulatory sequences such as promoters, operators and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention and under stringent conditions are likewise expected to allow

30 the isolation of DNAs encoding allelic variants of ICAM-4, other structurally

related proteins sharing one or more of the biological and/or immunological properties specific to ICAM-4, and proteins homologous to ICAM-4 from other species. DNAs of the invention are useful in DNA/RNA hybridization assays to detect the capacity of cells to synthesize ICAM-4. Also made
5 available by the invention are anti-sense polynucleotides relevant to regulating expression of ICAM-4 by those cells which ordinarily express the same. As another series of examples, knowledge of the DNA and amino acid sequences of ICAM-4 makes possible the generation by recombinant means of ICAM-4 variants such as hybrid fusion proteins (sometimes referred to as "immuno-
10 adhesions") characterized by the presence of ICAM-4 protein sequences and immunoglobulin heavy chain constant regions and/or hinge regions. See, Capon *et al.*, *Nature*, 337: 525-531 (1989); Ashkenazi *et al.*, *P.N.A.S. (USA)*, 88: 10535-10539 (1991); and PCT WO 89/02922, published April 6, 1989. ICAM-4 variant fusion proteins may also include, for example, selected
15 ~~extracellular domains of ICAM-4 and portions of other cell-adhesion~~ molecules.

DNA of the invention also permits identification of untranslated DNA sequences which specifically promote expression of polynucleotides operatively linked to the promoter regions. Identification and use of such
20 promoter sequences are particularly desirable in instances, for example gene transfer, which can specifically require heterologous gene expression in a limited neuronal environment. The invention also comprehends vectors comprising promoters of the invention, as well as chimeric gene constructs wherein the promoter of the invention is operatively linked to a heterologous
25 polynucleotide sequence and a transcription termination signal.

The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of ICAM-4 and definition of those molecules with which it will interact on extracellular and intracellular levels. The idiotypes of anti-ICAM-
30 4 monoclonal antibodies of the invention are representative of such molecules

and may mimic natural binding proteins (peptides and polypeptides) through which ICAM-4 intercellular and intracellular activities are modulated or by which ICAM-4 modulates intercellular and intracellular events. Alternately, they may represent new classes of modulators of ICAM-4 activities. Anti-idiotypic antibodies, in turn, may represent new classes of biologically active ICAM-4 equivalents. *In vitro* assays for identifying antibodies or other compounds that modulate the activity of ICAM-4 may involve, for example, immobilizing ICAM-4 or a natural ligand to which ICAM-4 binds, detectably labelling the nonimmobilized binding partner, incubating the binding partners together and determining the effect of a test compound on the amount of label bound wherein a reduction in the label bound in the presence of the test compound compared to the amount of label bound in the absence of the test compound indicates that the test agent is an inhibitor of ICAM-4 binding.

The DNA sequence information provided by the present invention also makes possible the development, by homologous recombination or "knockout" strategies [see, e.g., Kameuchi, *Science*, 244: 1288-1292 (1989)], of rodents that fail to express a functional ICAM-4 protein or that express a variant ICAM-4 protein. Such rodents are useful as models for studying the activities of ICAM-4 and ICAM-4 modulators *in vivo*.

DETAILED DESCRIPTION OF THE INVENTION

The disclosures of parent U.S. Patent Application Serial No. 08/102,852, filed August 5, 1993, are specifically incorporated by reference. The examples of that application address, *inter alia*: design and construction of oligonucleotide probes for PCR amplification of ICAM related DNAs; use of the probes to amplify a human genomic fragment homologous to, but distinct from DNAs encoding ICAM-1 and ICAM-2; screening of cDNA libraries with the genomic fragment to isolate additional ICAM-R coding sequences; screening of cDNA libraries to isolate a full length human cDNA sequence encoding ICAM-R; characterization of DNA and amino acid

sequence information for ICAM-R, especially as related to ICAM-1 and ICAM-2; development of mammalian host cells expressing ICAM-R; assessment of indications of ICAM-R participation in adhesion events involving CD18-dependent and CD18-independent pathways; inhibition of cell adhesion to ICAM-R by ICAM-R-derived peptides; expression of variants of ICAM-R; preparation and characterization of anti-ICAM-R antibodies and fragments thereof; mapping of ICAM-R epitopes recognized by anti-ICAM-R monoclonal antibodies; assessment of the distribution and biochemical characterization of ICAM-R and RNA encoding the same; assessment of ICAM-R in homotypic cell-cell adhesion and immune cell activation/proliferation; characterization of ICAM-R monoclonal antibodies; and assessment of differential phosphorylation and cytoskeletal associations of the cytoplasmic domain of ICAM-R. Also disclosed was the identification of a rodent ICAM-encoding DNA that, at the time, appeared to be the rat homolog of human ICAM-R, and the use of this DNA to construct and express DNAs encoding glutathione-S-transferase fusion proteins. The detailed description of how this rodent DNA was identified can be found in the parent application (U.S.S.N. 08/102,852) in Example 6, and is reproduced herein as Example 1. As more of the rodent ICAM-coding sequence was identified, it became apparent that the rodent ICAM DNA did not encode a rat species homolog of human ICAM-R, but, in fact, encoded a novel ICAM polypeptide, herein named ICAM-4. In order to appreciate the events which led to the identification of ICAM-4, a chronology is provided which is followed by a detailed description of the invention.

A first rodent genomic ICAM-4 sequence was identified which encoded a region homologous to domain 2 (herein SEQ ID NO: 3, and SEQ ID NO: 23 of U.S.S.N. 08/102,852) of human ICAM-R (herein as SEQ ID NO: 4). A second, overlapping genomic DNA (herein SEQ ID NO: 5, and SEQ ID NO: 26 of U.S.S.N. 08/102,852) was also identified which encoded both the domain 2 region of SEQ ID NO: 3, and sequences for ICAM-1.

Using SEQ ID NO: 3 as a probe, a rodent spleen cDNA (herein SEQ ID NO: 6, and SEQ ID NO: 25 in U.S.S.N. 08/102,852) was identified which encoded domains 2 through 5 as well as a fifth domain not previously observed as an ICAM domain. At this time, these newly identified rodent DNAs appeared to encode a rodent homolog of human ICAM-R, however alignment of 3' regions of these DNAs with other ICAMs proved difficult.

The subsequent isolation of a 1 kb cDNA clone from a rat spleen library, and amplification of an RT-PCR fragment indicated that a portion of both the cDNA and genomic clones had not been sequenced.

Another RT-PCR amplification product (SEQ ID NO: 7) confirmed this omission. It was determined that a fragment of 177 bp was excised from the genomic and cDNA clones by *EcoRI* digestion of the clones to isolate these sequences from λ phage for DNA sequencing studies. Reanalysis of SEQ ID NOs: 5 and 6 in light of these other sequences permitted identification of more

accurate and complete sequences for the originally isolated genomic and cDNA clones, presented in corrected form herein as SEQ ID NOs: 8 and 9.

In order to identify a complete coding sequence for ICAM-4, a rat brain cDNA (SEQ ID NO: 10) was isolated, and 5' end sequence determined by 5' rapid amplification of cDNA ends (5' RACE), the amplification product set forth in SEQ ID NO: 11. Combining information from the RT-PCR clone (SEQ ID NO: 7), the brain cDNA (SEQ ID NO: 10) and the RACE amplification product (SEQ ID NO: 11) permitted identification of the complete coding sequence for ICAM-4 (SEQ ID NO: 1).

The present invention is thus illustrated by the following examples. More particularly, Example 1 addresses cloning of a partial rodent ICAM-4 DNA. Example 2 describes Northern blot analysis of rodent ICAM-4 transcription. Example 3 describes isolation of a full length rodent ICAM-4 cDNA. Example 4 relates the *in situ* hybridization of rodent ICAM-4 in brain tissue. Example 5 addresses generation of ICAM-4 fusion proteins in prokaryotes. Example 6 describes production of monoclonal antibodies

- specific for rat ICAM-4/GST fusion proteins. Example 7 describes expression of soluble rat ICAM-4 proteins in a baculovirus expression system. Example 8 addresses production of monoclonal antibodies specific for rat ICAM-4 expressed in a baculovirus system. Example 9 describes immunocytochemical analysis of rat ICAM-4 expression. Example 10 relates cloning of a human genomic ICAM-4-encoding DNA. Example 11 addresses cloning of a human ICAM-4-encoding cDNA. Example 12 describes Northern analysis of human ICAM-4 expression. Example 13 describes generation of human ICAM-4/GST fusion proteins. Example 14 addresses production of monoclonal antibodies immunospecific for human ICAM-4. Example 15 describes development of a capture assay for determining the concentration of soluble ICAM-4 in a particular fluid. Example 16 applies the capture assay method in assessing ICAM-4 concentration in the serum of stroke patients. Example 17 relates to assessment of ICAM-4 transcription in a rat epilepsy model.
- 15 ~~Example 18 describes measurement of circulating ICAM-4 concentration as an assessment of various neurodegenerative disorders. Example 19 addresses cloning of a promoter region for human ICAM-4.~~

EXAMPLE 1

Cloning of Rat ICAM-Related DNA

20 A. Isolation of a Rat Genomic ICAM-Related Domain 2 DNA

A rat genomic library constructed in λ EMBL3 was screened with [32 P]-labeled probe generated by PCR from DNA encoding human ICAM-3 domain 2. The sequence of the probe is set forth in SEQ ID NO: 12. Library plaques were transferred to Hybond N+ nylon membranes (Amersham, Arlington Heights, IL). Screening of all cDNA and genomic libraries was performed according to standard protocols. Prehybridization and hybridizations were carried out in a solution of 40-50% formamide, 5X Denhardt's, 5X SSPE and 1.0% SDS at 42°C. Probes ([32 P]-labeled) were added at a concentration of 10^5 - 10^6 cpm/ml of hybridization solution.

Following 16-18 hours of hybridization, nylon membranes were washed extensively at room temperature in 2X SSPE with 0.1% SDS and subsequently exposed to X-ray film at -80°C overnight. Positive plaques were subjected to one or more rounds of hybridization to obtain clonal phage. DNA prepared from lysate of the positive clones was subcloned into pBS+ and sequenced.

A first genomic clone encoding a rat ICAM-related domain 2 was identified that was determined to be homologous to domain 2 regions in other ICAM family members (see for example, Table 1 of U.S. Patent Application Serial No. 08/102,852), yet was distinct from the previously reported nucleotide sequences for rat ICAM-1 [Kita, *et al.*, *Biochem. Biophys. Acta* 1131:108-110 (1992)] or mouse ICAM-2 [Xu, *et al.*, *J. Immunol.* 149:2560-2565 (1992)]. The nucleic acid and deduced amino acid sequences for this clone were disclosed in the co-pending parents to the present application as purportedly variant forms of rat ICAM-R and were set forth as SEQ ID NOs: 23 and 24, respectively, in U.S.S.N. 08/102,852. Herein, these same sequences are set out in SEQ ID NOs: 3 and 13, respectively.

A second, overlapping clone was also identified with the same probes and was determined to contain the ICAM domain 2 sequence of SEQ ID NO: 3 and 5' DNA encoding at least part of rat ICAM-1. The nucleic acid sequence for this clone was set forth in the co-pending parent to the present application as SEQ ID NO: 26 and is set forth herein as SEQ ID NO: 5. This second clone indicated that the ICAM-related gene fragment of the first clone and the gene encoding rat ICAM-1 are located on the same rat chromosome within 5 kb of each other.

B. Isolation of Rat ICAM-Related cDNA

In order to identify a more complete protein coding sequence for the ICAM-related polypeptide, [³²P]-labeled DNA encoding the domain 2 sequence from the rat genomic clone identified in Section A (SEQ ID NO: 3), *supra*, was used to screen a number of cDNA libraries from various rat

and mouse cell types, including rat macrophage (Clontech, Palo Alto, CA), peripheral blood lymphocyte (PBL) (Clontech), T cell (constructed in-house), and spleen (Clontech), and mouse PBL (Clontech), T cell (constructed in-house), and B cell (constructed in-house).

5 A single clone was identified in a rat spleen cDNA library (Clontech) which contained five Ig-like domains, four of which were homologous to domains 2 through 5 in both ICAM-1 and ICAM-R. Moreover, this clone included 3' DNA encoding an apparent fifth Ig-like
10 polypeptide. In addition, the clone contained an unusual 3' sequence subsequently determined to be a partial intron (discussed *infra*) located between domains 4 and 5, suggesting that the clone was the product of an immature or aberrantly spliced transcript. The presence of the unique domain and the determination that the 3' region did not properly align with other
15 known ICAMs suggested that the ICAM-related DNA potentially encoded a novel rat ICAM polypeptide. The nucleic acid sequence for this clone was set forth in the parent to the present application as SEQ ID NO: 25; herein the nucleic acid sequence for this spleen cDNA clone is set forth in SEQ ID NO: 6.

20 C. Re-analysis of Rat cDNA and Genomic DNAs

Subsequent to the August 5, 1993 filing of U.S. Patent Application Serial No. 08/102,852, it was determined that the partial rat spleen cDNA clone (SEQ ID NO: 25 in the parent and SEQ ID NO: 6 herein) and the rat liver genomic clone (SEQ ID NO: 26 of the parent and SEQ ID
25 NO: 5 herein) were missing an internal 177 bp EcoRI fragment that was part of each of these clones but lost in a subcloning step when the library inserts were removed from the λ vector with *EcoRI* digestion and ligated into a sequencing vector. The observation that the cDNA and genomic clones might be missing a coding fragment became apparent upon alignment of the rat

genomic and cDNA sequences with various RT-PCR amplification products, including SEQ ID NO: 7, which revealed a gap in the rat sequence.

Subsequent isolation and sequence alignment of a cDNA from a spleen library using the spleen cDNA clone (SEQ ID NO: 6) as a probe provided a first indication that a portion of the spleen cDNA and genomic clones were not sequenced. Further confirmation of this idea became apparent upon amplification of an RT-PCR fragment, spanning domains 3 through 5, using a 5' primer (RRD3 5' Xho, containing a 5' *Xho*I restriction site to facilitate cloning) set out in SEQ ID NO: 14, and a 3' primer (RRD5 3' Hind, containing a *Hind*III site to facilitate cloning) set out in SEQ ID NO: 15.

GAACTCGAGGCCATGCCTCCACTTTCC (SEQ ID NO: 14)

CCATAAGCTTTATTCCACCGTGACAGCCAC (SEQ ID NO: 15)

Alignment of these two DNAs clearly revealed that the cDNA and genomic clones had lost a fragment prior to sequencing; this idea was further supported following sequencing of the RT-PCR DNA discussed *infra*. It was concluded that restriction digestion with *Eco*RI to remove the cDNA and genomic fragments prior to sequencing resulted in the excision of a 177 bp fragment that was not detected visually in the agarose gel separation of the clones from the λ phage sequences. Subsequent sequence analysis confirmed the location of two *Eco*RI sites flanking a 177 bp fragment in both of the original clones.

The 177 bp *Eco*RI fragment is situated between nucleotides 719 and 896 in the rat partial cDNA clone as set out in SEQ ID NO: 9 and between nucleotides 2812 and 2989 in the partial genomic clone as set out in SEQ ID NO: 8.

25 D. DNA Isolated by RT-PCR Clone

RT-PCR was utilized to generate more complete sequence information for the rat ICAM-related gene. Sequence information from the genomic clone (SEQ ID NO: 3) was used to design sense primers complementary to a region 5' of the protein coding region, as determined from the

cDNA clone, and antisense primers designed complementary to coding sequences and regions 3' to the coding sequence in the cDNA clone (SEQ ID NO: 6).

Template cDNA for PCR reactions was prepared as follows.

5 Approximately 2 μ g of poly A⁺RNA isolated from rat spleen cells was denatured by heating at 65°C in a 10 μ l volume. Following denaturation, 0.1 μ l RNasin (Invitrogen, San Diego, CA), 5 μ l 5X RTase Buffer (BRL, Bethesda, MD), 2 μ l random hexamer (pd(N)6 at 100 μ g/ml) (Pharmacia, Piscataway, NJ), 6 μ l dNTPs (2 mM each) and 2 μ l AMV RTase (BRL) were
10 added and the reaction was incubated at 42°C for 60-90 min. Reactions were stored at -20°C until needed.

An initial series of experiments was conducted to identify oligonucleotides primer pairs that produced an amplification product in PCR reactions using rat spleen cDNA as the template. Various 5' sense primers
15 were paired in PCR with a 3' primer which was designed to be complementary to an internal, coding sequence; the 3' primer was designated RRD2 3-1 and is set forth in SEQ ID NO: 16.

AACGTGCGGAGCTGTCTG (SEQ ID NO: 16)

(In the ultimately isolated RT-PCR product, SEQ ID NO: 7, *infra*, primer
20 RRD2 3-1 corresponded to nucleotides 719 through 736.) Similarly, various 3' antisense primers were paired with a 5' primer designed complementary to another internal, coding sequence; the 5' primer in these reactions was designated RGen3900S and is set forth in SEQ ID NO: 17.

ACGGAATTCTGAAGCCATCAACGCCAGG (SEQ ID NO: 17)

25 (In SEQ ID NO: 7, *infra*, primer RGen3900S corresponded to nucleotides 1719 through 1736.) Based on the size of the amplification products and the ability of these products to hybridize with the partial cDNA clone, one pair of primers was determined to be most efficient and was used in subsequent PCR amplifications. The 5' primer was designated RGen780S (SEQ ID NO:
30 18) and the 3' primer was designated RGen4550AS (SEQ ID NO: 19).

CATGAATTCCGAATCTTGAGTGGGATG (SEQ ID NO: 18)

ATAGAATTCCTCGGGACACCTGTAGCC (SEQ ID NO: 19)

(In SEQ ID NO: 7, *infra*, primer RGen780S corresponded to nucleotides 1 through 18, and primer RGen4550AS corresponded to nucleotides 2197 through 2214.)

This primer pair was used in PCR under a variety of conditions to optimize amplification. A total of 15 different PCR buffers that varied in pH and Mg^{++} concentration were used at two different annealing temperatures, and a sample of the product from each reaction was separated on a 1% agarose gel. Because no amplification product could be detected by visual inspection of the ethidium bromide stained gel from any of the reaction conditions, more sensitive Southern hybridization was employed to detect the PCR products.

Aliquots of the amplified DNA were separated by electrophoresis, transferred to a Hybond-N+ nylon membrane using conventional Southern blotting wicking techniques, and hybridized with the entire rat cDNA which was [^{32}P]-labeled. Hybridization conditions were essentially as described for the library screening procedure in Section A, *supra*. Autoradiography indicated that a small amount of DNA of approximately 2.2 kb had been generated in two of the reactions, and the remainder of the amplification product from the two reactions was separated on an agarose gel. The 2.2 kb region was eluted from the gel, even though no band was evident upon visual inspection, and used as a template in another PCR reaction using the same primers (SEQ ID NOs: 18 and 19), Tris-HCl buffer, pH 8.0, containing 1 mM Mg^{++} , and 55°C annealing temperature. The amplification product from the secondary PCR was visible in the gel and was eluted and cloned into a pBS⁺ plasmid (Stratagene, La Jolla, CA) for sequence analysis.

The resulting RT-PCR clone was determined to contain 2214 bp as set forth in SEQ ID NO: 7. The clone encoded domains 2 through 6 found in the rat spleen cDNA clone, an additional amino terminal domain 1,

an additional carboxy terminal domain 7, and 164 bp of what appeared to be a further carboxy terminal domain 8. Immediately 5' to domain 1 was an additional 144 bp sequence presumed to have been derived from an intron between the leader and the first domain. This clone did not contain a 5' leader sequence or 3' transmembrane and cytoplasmic regions. In addition to the previously identified domain 6 in the spleen cDNA clone, the 7th and 8th domains in the RT-PCR clone supported the hypothesis that this clone was a novel rodent ICAM.

EXAMPLE 2

10 Northern Blot Analysis

In order to further investigate the possibility that the ICAM-related clones identified in Example 1 encoded a novel ICAM polypeptide as suggested by the unique Ig-like domains, tissue specific expression was examined by Northern blot analysis to permit comparison with the previously reported expression patterns of human ICAMs [ICAM-1, Dustin, *et al.*, *J.Immunol.* 137:245-254 (1986); ICAM-2, Staunton, *et al.*, *Nature* 339:61-64 (1989); ICAM-R, de Fourgerolles and Springer, *J.Exp.Med.* 175:185-190 (1992)].

20 Total cellular RNA from rat lung, brain, spinal cord, liver, digestive tract, thymus, lymph nodes, and spleen was prepared using STAT60 RNA isolation reagents (Tel-test "B", Inc, Friendswood, Texas) according to the manufacturer's suggested protocol. Poly A⁺ RNA was purified from total RNA using oligo dT cellulose columns. Approximately 5 µg of RNA derived from each tissue was separated on a 1% formaldehyde agarose gel, and transferred to hybond-C nitrocellulose membranes (Amersham).

25 A fragment of the rat spleen cDNA from Example 1 corresponding to domains 2 through 4 (nucleotides 1 through 724 in SEQ ID NO: 6) was subcloned into pBluescript SK⁺ (Stratagene) and an antisense riboprobe was generated by *in vitro* transcription using ³²P-labeled UTP and approximately 500 ng of linearized template according to a manufacturer's

30

(Boehringer Mannheim, Indianapolis, IN) suggested protocol. The membrane-bound RNA was prehybridized in a solution containing 50% formamide, 5X SSC, 1X PE (50 mM Tris-HCl, pH 7.5, 0.1% sodium pyrophosphate, 0.2% polyvinylpyrrolidone, 0.2% ficoll, 5 mM EDTA, 1% SDS) and 150 μ g/ml denatured salmon sperm DNA. The radiolabeled probe was denatured by boiling and added to the prehybridization solution to a final concentration of 1×10^6 cpm/ml. Hybridization was allowed to proceed for 16-18 hours at 65°C. The membranes were then washed at 65°C in 2X SSC containing 0.1% SDS and subsequently exposed to X-ray film for 3-16 hours.

10 The Northern blot analysis indicated that the ICAM-related cDNA identified in Example 1 was expressed only in rat brain, a tissue specificity not previously reported for any other ICAM polypeptides. This expression pattern, in combination with the unique Ig-like domains not known to exist in other ICAM polypeptides, indicated that the ICAM-related clone
15 was a novel member of the ICAM family of proteins, and was named ICAM-4.

The fact that the initially identified cDNA clones were detected in a rat spleen library suggested that a subset of cells in the spleen may express ICAM-4 at low levels. However, a properly spliced clone could not
20 be detected in numerous hemopoietic cDNA libraries which led to doubt if ICAM-4 protein is actually expressed in tissue other than brain. One explanation for the detection of ICAM-4 cDNA in spleen is that the sensitivity of PCR may have amplified a trace amount of transcript even though these tissues do not express the encoded protein.

25

EXAMPLE 3

Isolation of Full Length Rat ICAM-4 cDNA

A. Identification of a Rat Brain cDNA Clone

In view of the tissue specific expression of ICAM-4, brain tissue mRNA was utilized in an attempt to isolate a full length cDNA

encoding ICAM-4. Two probes, one complementary to domains 1 through 2 and a second complementary to domains 3 through 5 of the spleen cDNA clone identified in Example 1 (SEQ ID NO: 7), were radiolabeled and used to screen a rat brain cDNA library in λ gt10 which was previously constructed in-house. Hybridization conditions were as described in Example 1, and positive plaques were subjected to one or more rounds of screening to obtain clonal phage.

Nine positive clones were identified, two of which hybridized to both probes. The longest of the two clones, designated clone 7, contained 2550 bp encoding four of the five Ig-like domains found in the probe cDNA. In addition, clone 7 encoded four other Ig-like domains not found in the probe. Putative transmembrane and cytoplasmic domains were identified which were followed by a stop codon, a poly-adenylation signal, and a poly A tail. Clone 7 was lacking at least one 5' Ig-like domain as determined by comparison to the RT-PCR clone (SEQ ID NO: 7), and also lacked a leader sequence; re-screening of the library did not yield any longer clones which contained these sequences. The nucleic acid sequence for clone 7 is set forth in SEQ ID NO: 10.

B. Determination of the 5' End

In order to isolate domain 1 and other 5' sequences, a PCR technique termed 5' Rapid Amplification of cDNA Ends (RACE) [PCR Protocols: A Guide to Methods and Applications, Innis, et al., (eds) Academic Press: New York (1990) pp:28-38] was employed using a 5' RACE kit (Clontech). This technique utilizes an internal primer paired with a second primer complementary to an adapter sequence ligated to the 5' end of cDNA library molecules. PCR with this primer pair will therefore amplify and facilitate identification of the intervening sequences. Overlapping sequence information can then be used to generate a complete sequence of the gene.

RACE-ready cDNA from rat brain (supplied with kit) was used in a PCR with the kit oligonucleotide and an antisense primer based on an internal ICAM-4 sequence. The 3' antisense primer, designated Spot714AS, was designed according to an ICAM-4 domain 4 sequence and is set forth in SEQ ID NO: 20.

CARGGTGACAAGGGCTCG (SEQ ID NO: 20)

The amplification product resulting from this primer pair was subsequently subjected to a secondary PCR using the same 5' kit primer paired with a 3' primer complementary to a region in ICAM-4 domain 1. The second 3' primer was designated RRACE2 and is set forth in SEQ ID NO: 21.

TATGAATTGAGTTGAGCCACAGCGAGC (SEQ ID NO: 21)

Each primer used in the secondary PCR contained an *Eco*R1 site to facilitate cloning of the resulting amplification products into pBS⁺ (Stratagene). The resulting plasmid DNA which contained the 5' end of the gene was identified by hybridization to a rat ICAM-4 domains 1 and 2 probe, corresponding to nucleotides 1 through 736 in SEQ ID NO: 7. Partial sequence information for domain 1 and the hydrophobic leader was determined from the resulting amplification product.

The product from the 5' RACE method was a DNA fragment 222 bp long containing 60 bp upstream of the initiating methionine residue, an 82 bp leader sequence, and an 80 bp sequence from domain 1. The amplification product is set forth in SEQ ID NO: 11.

C. Full Length Sequence of Rat ICAM-4

A composite clone of the full length ICAM-4 was constructed from the sequence information derived from the 5' RACE method (SEQ ID NO: 11), the RT-PCR clone (SEQ ID NO: 7) and the brain cDNA clone 7 (SEQ ID NO: 10). The full length gene for rat ICAM-4 was determined to contain 2985 bp with a single open reading frame encoding a deduced 917 amino acid protein. A putative Kozak sequence is located upstream of the

methionine residue in the leader sequence. A 27 amino acid hydrophobic leader sequence is followed by nine Ig-like domains, a transmembrane region and a 58 amino acid cytoplasmic tail. - The composite ICAM-4 cDNA is set for in SEQ ID NO: 1, and the deduced amino acid sequence is set forth in
5 SEQ ID NO: 2.

Like other ICAM polypeptides, ICAM-4 contains extracellular, transmembrane, and cytoplasmic domains. In the extracellular domain, the amino terminus of ICAM-4 is a leader sequence comprising amino acids 1 through 27 which is followed by nine immunoglobulin (Ig)-like domains, a
10 characteristic unique to ICAM-4 in that ICAM-1, ICAM-2, and ICAM-R contain five, two, and five extracellular Ig-like domain, respectively. In ICAM-4, domain 1 comprises amino acids 28 through 118; domain 2 comprises amino acids 119 through 224; domain 3 comprises amino acids 225 through 321; domain 4 comprises amino acids 322 through 405; domain 5
15 comprises amino acids 406 through 488; domain 6 comprises amino acids 489 through 569; domain 7 comprises amino acids 570 through 662; domain 8 comprises amino acids 663 through 742; and domain 9 comprises amino acids 743 through 830. Within each domain, a characteristic "loop" structure is formed by a disulfide bond between cysteine residues located generally at
20 opposite ends of the domain amino acid sequence. Other structural features of ICAM-4 include the transmembrane region comprising amino acids 831 through 859 and the cytoplasmic region comprising amino acids 860 through 917.

Comparison of amino acid sequence homology of each domain
25 in rat ICAM-4 with the other members of the ICAM family was limited to the corresponding sequences of human ICAM-1, ICAM-2, and ICAM-R since sequence information for all three rodent homologs has not been previously reported. In the first domain, the rodent ICAM-4 shows 21, 30, and 28 percent identity with human ICAM-1, ICAM-2, and ICAM-R, respectively.
30 The second domain is more conserved, with the amino acid percent identities

being 60, 42 and 62 with ICAM-1, -2, and -3, respectively. Domains 3-5 show percent identities of 48, 49, and 40 with ICAM-1 and 60, 59 and 29 respectively for ICAM-R. Interestingly, rat ICAM-4 domains 6 through 8 are most homologous with domain 5 (ranging from 29-42% identical), possibly arising from a gene segment duplication event. The ninth and final extracellular domain aligns poorly with other ICAM domains but has 22% identity with the 3rd and 6th domains of human VCAM-1, another member of the Ig family of protein which participate in cell adhesion. The cytoplasmic tail is 58 amino acids long. This is longer than the other members of the ICAM family wherein human ICAM-1, -2, and -3 contain 28, 26, and 37 amino acids, respectively. As with the ninth domain, rat ICAM-4 cytoplasmic tail is most homologous with the cytoplasmic tail of human VCAM-1, which contains only 19 amino acids. The membrane proximal 19 amino acids of rat ICAM-4 share 7 amino acid residues with VCAM-1 (37%).

Finally, functional binding to LFA-1 (CD11a/CD18) maps to the first domain in the ICAMs. Vonderheide *et al.*, [J. Cell. Biol., 125:215-222 (1994)] identified a sequence motif purportedly involved in integrin binding. Despite the relatively low homology between rat ICAM-4 and other ICAMs in domain 1, this binding sequence motif is conserved, suggesting that rat ICAM-4 may be a ligand for LFA-1 and perhaps other integrins.

EXAMPLE 4

In situ Hybridization in Brain Tissue

In order to localize the specific brain tissue which expressed ICAM-4, *in situ* hybridization with ICAM-4 domain 1 and ICAM-4 domains 3 through 4 anti-sense riboprobes was employed. The probes were labeled by *in vitro* transcription using ³⁵S-labeled UTP.

Frozen tissue sections of normal rat brain were fixed in 4% paraformaldehyde for 20 minutes, rinsed and dehydrated, and the fixed RNA denatured for 2 minutes in 2X SSC, 70% formamide at 70°C prior to

hybridization. Tissue sections were hybridized overnight at 50°C in a solution containing 50% formamide, 0.3 M NaCl, 20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10% dextran sulfate, 1X Denhardt, 0.5-mg/ml yeast RNA, 100 mM DTT and a probe concentration of 50,000 cpm/ μ l. Slides were washed once
5 in 4X SSC, 10 mM DTT at room temperature for 60 minutes, once in 50% formamide, 2X SSC, 10 mM DTT at 60°C for 40 minutes, and once in each 2X SSC and 1X SSC for 30 minutes each at room temperature. Specificity of hybridization was determined in parallel experiments performed with the same protocol but also including a more stringent wash in 50% formamide,
10 1X SSC, 10 mM DTT at 60°C for 40 minutes. After washing, the slides were dipped in NTB2 emulsion (Kodak, Rochester, NY) and exposed from 2 to 21 days before being developed and counter-stained. Negative controls included sense probes generated from ICAM-4 domain 1 and ICAM-4 domain 3 through 4 sense riboprobes, in addition to a human immunodeficiency virus
15 (HIV-1) riboprobe.

The signal detected in brain tissue was primarily localized in the gray matter with the strongest signal in the cerebral cortex and hippocampus. The hybridization profile was consistent with ICAM-4 expression primarily
in cerebral neurons.

20 EXAMPLE 5

Generation of ICAM-4 fusion proteins

Rat ICAM-4/glutathione S-transferase (GST) fusion proteins were generated using the prokaryote expression vector pGEX (Pharmacia, Alameda, CA) in order to generate monoclonal antibodies against specific
25 ICAM-4 polypeptide fragments.

PCR primers corresponding to the 5' and 3' ends of domain 1 and the 5' and 3' ends of domain 2 were used to amplify DNA fragments encoding the individual domains. The resulting fragments were separately cloned into an *EcoRI* site of pGEX-2T; DNA sequence analysis confirmed the

correct orientation and reading frame. Transformants were subsequently screened for their ability to produce fusion protein of the appropriate molecular weight.

Both ICAM-4 domain 1/GST and ICAM-4 domain 2/GST fusion proteins remained in the insoluble fraction after the bacteria were lysed by sonication in PBS containing 1 % SDS. The insoluble protein fraction from 100 ml cultures were boiled in SDS loading dye and separated on a 10% preparative polyacrylamide-SDS gel. The gel was stained in ice cold 0.4 M KCl and the fusion protein bands were excised. Fusion proteins were electroeluted from the gel slices in dialysis tubing in buffer containing 25 mM Tris-HCl and 192 mM glycine. Approximate protein concentration was determined by OD₂₈₀ and purity of the preparation was determined on SDS-PAGE stained with Coomassie blue.

EXAMPLE 6

Production of Monoclonal Antibodies Against Rat ICAM-4/GST Fusion Proteins

Balb/c mice were immunized by subcutaneous injection with 40-50 μ g ICAM-4 domain-2/GST fusion protein (described in Example 5) emulsified in Freund's complete adjuvant (FCA). Two weeks later, the mice were again immunized by subcutaneous injection with the same protein, emulsified however in Freund's incomplete adjuvant. Two final intraperitoneal immunizations given two weeks after the second immunization included soluble antigen with no adjuvant given at two week intervals. Serum from each immunized mouse was assayed by ELISA for its ability to specifically react with rat ICAM-4 produced by the baculovirus expression system described *infra*.

The spleen from mouse #1654 was sterilely removed and placed in 10 ml serum-free RPMI 1640. A single-cell suspension was formed by grinding the spleen tissue between frosted ends of two glass microscope slides submerged in serum free RPMI 1640 (Gibco, Burlington, Ottawa, Canada)

supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 μ g/ml streptomycin. The cell suspension was filtered through a sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, NJ), and washed twice with RPMI followed by centrifuging at 200 x g for 5 minutes. The resulting pellet from the final wash was resuspended in 20 ml serum-free RPMI. Thymocytes taken from three naive Balb/c mice were prepared in an identical manner.

Prior to fusion, NS-1 myeloma cells were maintained in log phase growth in RPMI with 11 % Fetalclone serum (FBS) (Hyclone Laboratories, Logan, Utah) for three days. Once harvested, the cells were centrifuged at 200 x g for 5 minutes, and the pellet was washed twice as described in the foregoing paragraph. After washing, the cell suspension was brought to a final volume of 10 ml in serum free RPMI. A 20 μ l aliquot was removed and diluted 1:50 with serum free RPMI, and a 20 μ l aliquot of this dilution was removed, mixed with 20 μ l 0.4 % trypan blue stain in 0.85 % saline (Gibco), loaded onto a hemacytometer (Baxter Healthcare, Deerfield, IL) and the cells counted. Approximately 2.425×10^8 spleen cells were combined with 4.85×10^7 NS-1 cells, the mixture centrifuged and the supernatant removed. The resulting pellet was dislodged by tapping the tube and 2 ml of 50 % PEG 1500 in 75 mM Hepes, pH 8.0, (Boehringer Mannheim, Indianapolis, IN) was added with stirring over the course of 1 minute. Subsequently, an additional 14 ml serum free RPMI was added over 7 minutes. The cell suspension was centrifuged at 200 x g for 10 minutes and the supernatant discarded. The pellet was resuspended in 200 ml RPMI containing 15 % FBS, 100 μ M sodium hypoxanthine, 0.4 μ M aminopterin, 16 μ M thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5×10^6 thymocytes/ml. The suspension was first placed in a 225 cm² flask (Corning, Essex, United Kingdom) at 37°C for four hours before being dispensed into ten 96-well flat bottom tissue culture plates (Corning) at 200 μ l/well. Cells in the plates were fed on days 3, 4, 5, and 6 post fusion by aspirating approximately 100 μ l

from each well with a 20 G needle (Becton Dickinson), and adding 100 μ l/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes.

5 The fusion plates were screened initially by antigen capture ELISA as follows. Immulon 4 plates (Dynatech, Cambridge, MA) were coated overnight at 4°C with 100 ng/well of either domain 1-GST or domain 2-GST fusion protein in 50 mM carbonate buffer. The plates were blocked with 100 μ l/well 0.5 % fish skin gelatin (Sigma, St. Louis, MO) in PBS for 30 minutes at 37°C. After blocking, the plates were washed 3X with PBS 10 containing 0.05 % Tween 20 (PBST) and 50 μ l/well of hybridoma supernatant from each fusion was added. After incubation at 37°C for 30 minutes, the plates were washed as described above, and 50 μ l of a 1:3500 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG (Fc) (Jackson ImmunoResearch, West Grove, Pennsylvania) was added. Plates were again 15 incubated for 30 minutes and washed 4X with PBST. Substrate, 100 μ l/well, consisting of 1 mg/ml o-phenylene diamine (Sigma) and 0.1 μ l/ml 30 % H₂O₂ in 100 mM citrate, pH 4.5, was added. The color reaction was allowed to proceed 10 minutes and quenched with the addition of 50 μ l/well of 15 % H₂SO₄. Absorbance at 490 nm was then determined on an automated plate 20 reader (Dynatech).

Wells which were positive for domain 2-GST protein, but not for domain 1-GST protein, were then screened by ELISA against a Baculovirus supernatant (described *infra*). ELISA was performed as described above except that the Immulon 4 plates were initially coated overnight with 25 Baculovirus supernatant diluted 1:4 in 50 mM carbonate buffer. Three wells (103A, 103B and 103F) were cloned two to three times, successively, by doubling dilution in RPMI, 15 % FBS, 100 μ M sodium hypoxanthine, 16 μ M thymidine, and 10 units/ml IL-6. Wells of clone plates were scored visually after 4 days and the number of colonies in the least dense wells was recorded. 30 Selected wells of each cloning were again assayed by ELISA after 7 to 10

days against either domain 1-GST protein and domain 2-GST protein, or Baculovirus supernatant.

5 The monoclonal antibodies produced by the hybridomas were isotyped by ELISA. Immulon 4 plates (Dynatech) were coated at 4°C with 50 µl/well goat anti-mouse IgA, IgG, or IgM (Organon Teknika, Durham, NC) diluted 1:5000 in 50 mM carbonate buffer, pH 9.6. Wells were blocked for 30 minutes at 37°C with 1% BSA in PBS, washed 3X with PBST. A 1:10 dilution of hybridoma culture supernatant (50 µl) was added to each plate, incubated, and washed as above. After removal of the last wash, 50 µl
10 horseradish peroxidase-conjugated rabbit anti-mouse IgG₁, G_{2a}, G_{2b}, or G₃ (Zymed, San Francisco, CA) (diluted 1:1000 in PBST with 1% normal goat serum) was added. Plates were incubated as above, washed 4X with PBST and 100 µl substrate, was added. The color reaction was quenched after 5 minutes with addition of 50 µl 15% H₂SO₄, and absorbance at 490 nm
15 determined on a plate reader (Dynatech).

Results indicated that antibodies 103A, 103B, and 103F were all IgG₁ isotype. These antibodies were subsequently used in immunocytochemical analyses, Western blotting, and for purification of protein expressed in baculovirus.

20

EXAMPLE 7

Baculovirus Expression of Rat ICAM-4

A baculovirus expression system (Invitrogen) was used to generate soluble protein corresponding to domains 1 through 6 of ICAM-4. Because the leader sequence for ICAM-4 was not known at the time, the
25 expression construct was made containing the coding sequence for ICAM-4 fused 3' to the ICAM-1 leader sequence in proper reading frame. Specific details regarding construction of the ICAM-1/ICAM-4 expression plasmid is as follows.

Rat ICAM-1 DNA encoding the five Ig-like domains was amplified by PCR using primers which incorporated several features to facilitate construction of the fusion plasmid. The 5' oligonucleotide primer included *Hind*III and *Bgl*III sites, in addition to a consensus Kozak sequence upstream of the first methionine in the leader sequence. The 3' oligonucleotide primer included a coding sequence for six histidines followed by a stop codon and a *Hind*III cloning site. The PCR amplification product was cloned into a *Hind*III-digested pBS⁺ vector and sequence analysis confirmed the appropriate construction. An internal *Sma*I site in the ICAM-1 leader sequence and another *Sma*I site in the vector's multiple cloning region (3' to ICAM-1 Ig-like domain 5) were digested which removed most of the ICAM-1 coding sequence. After these manipulations, the linearized, blunt-ended vector contained a portion of the upstream multiple cloning region (those restriction sites 5' of the original *Hind*III site in the multiple cloning region), the Kozak sequence and most of the ICAM-1 leader sequence.

The coding sequence for rat ICAM-4 domains 1 through 6 was amplified by PCR utilizing primers designed to permit cloning of this sequence into the linearized vector described above. The 5' oligonucleotide primer included an *Eco*RV site and the codons needed to complete the ICAM-1 leader sequence. The 3' oligonucleotide primer included codons for six histidine residues, a stop codon, and *Hind*III and *Eco*RV restriction sites. The amplification product from this PCR was digested with *Eco*RV to produce a blunt-ended sequence which was then ligated into the blunt-ended *Sma*I-digested pBS⁺ linearized vector. The entire sequence containing the ICAM-1 leader sequence 5' to the ICAM-4 domains 1 through 6 was removed from the construct with *Bgl*III and *Hind*III digestion and the purified ICAM-1/ICAM-4 fusion sequence cloned directly into a *Bgl*III/*Hind*III-digested pBluesac III vector (Invitrogen).

Protein production by the recombinant virus was assayed for by ELISA, initially using immune sera from mice immunized with rat ICAM-4

domain-2/GST fusion protein described in Example 5. In later work, monoclonal antibodies generated from those mice were used to purify ICAM-4 protein produced by the recombinant baculovirus in SF9 cells.

EXAMPLE 8

Production of Monoclonal Antibodies Against Baculovirus-expressed Rat ICAM-4

Rat ICAM-4 domains 1-6 were expressed in the baculovirus expression system as described in Example 7. The recombinant protein was purified using monoclonal antibody 103A (as described in Example 6).

Briefly, 30 mg of purified monoclonal 103A (in 100 mM sodium borate, 500 mM sodium chloride) were coupled to three grams of Activated Cyanogen Bromide Sepharose 4B (Pharmacia, Piscataway, NJ). Baculovirus supernatant containing recombinant rat ICAM-4 (domains 1-6) was loaded on the Sepharose column overnight at 4°C. The column was washed in calcium- magnesium-free phosphate buffered saline (CMF-PBS) and bound material was eluted in 50 mM citric acid, 500 mM NaCl pH 4.0. The sample was neutralized with 1/10 volume Tris pH 10 and stored at -20°C. The purified protein separated on SDS-PAGE appeared greater than 90% pure and migrated at approximately 80 kD.

Mice were immunized with the purified recombinant rat ICAM-4 domains 1-6 protein in a similar manner as described in Example 6. The spleen from mouse #1945 was used for fusion #127. The fusion protocol was as described in Example 6. The fusion wells were screened by ELISA on the recombinant ICAM-4 protein. The secondary screen included immunocytochemistry on rat brain sections (as below described in Example 9). Four additional antibodies specific for rat ICAM-4 were cloned out of this fusion: 127A, 127E, 127F and 127H. The immunocytochemical staining pattern of each antibody on rat brain sections was the same as observed with monoclonal antibody 103A (see Example 9). The monoclonal antibodies were tested for their ability to bind the D1/GST and D2/GST fusion proteins (described in

Example 5). Monoclonal antibody 127A recognized the D1/GST fusion protein and 127H recognized the D2/GST fusion protein. These two distinct binding specificities along with the others that did not bind either GST protein suggest that at least 3 different epitopes were being recognized by the panel of antibodies. Hybridomas 127A and 127H were deposited May 31, 1995 and June 1, 1995, respectively, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and assigned Accession Numbers HB11905 and HB11911, respectively.

EXAMPLE 9

10 **Immunocytochemistry of Rat ICAM-4 Expression**

Immunocytochemistry with monoclonal antibody 103A was performed to localize the protein production within the rat brain.

A brain was harvested from a normal adult female Lewis rat, sagittally sectioned, and washed in RNase-free 1X PBS on ice for 30 min.

15 The brain sections were then placed in Tissue Tek II cryomolds (Miles Laboratories, Inc., Naperville, IL) with a small amount of O.C.T. compound (Miles, Inc., Elkhart, IN). The brains were centered in the cryomold, the cryomold filled with OCT compound, then placed in a container with 2-methylbutane (Aldrich Chemical Company, Inc., Milwaukee, WI) and the

20 container placed in liquid nitrogen. Once the tissue and OCT compound in the cryomold were frozen, the blocks were stored at -80°C until sectioning.

The tissue was sectioned at 6 μ m thickness, adhered to Vectabond (Vector Laboratories, Inc., Burlingame, CA) coated slides and allowed to air-dry at room temperature overnight until use. The sections were

25 fixed in ethyl ether (Malinckrodt, Paris, KY) for 5 minutes at room temperature. Once the slides were removed from the ether, the reagent was allowed to evaporate. Each tissue section was blocked with 150 μ l 50% Normal rat serum (Sigma) and 2% bovine serum albumin (BSA) (Sigma) in 1X PBS (made with sodium phosphates only) for 30 minutes at room temperature.

After blocking, the solution was gently blotted from the sections and the purified supernatant antibody 103A (1.65 mg/ml) was diluted 1:10 in the blocking solution and 150 μ l applied to each tissue section. The slides were placed in a humidity chamber and incubated at 4°C overnight.

5 The next day the antibody solution was blotted gently from the section and the slides washed three times in 1X PBS for four minutes in each wash. The excess PBS was aspirated from the slide and 100 μ l of the secondary, rat anti mouse-biotin conjugated antibody (Jackson Immuno-
10 Research Laboratories), diluted 1:100 in a solution of 10% normal rat serum and 2% BSA in 1X PBS, applied to the tissues. Incubation was allowed to proceed for one hour at room temperature. The sections were washed two times in 1X PBS for four minutes in each wash, then 100 μ l of ABC reagent from an Elite Rat IgG Vectastain ABC kit (Vector Laboratories, Inc.,
15 Burlingame, CA), prepared according to the product insert, was applied to each section. Incubation was allowed to proceed for 30 minutes at room temperature. After incubation, the slides were washed two times in 1X PBS (four minutes each wash) and 150 μ l of Vector VIP Peroxidase Substrate Solution (Vector Laboratories, Inc., Burlingame, CA) applied to each section for approximately ten minutes. After color development, the sections were
20 rinsed under running tap water for five minutes, counterstained with Mayer's hematoxylin (Sigma) for 20 seconds, and rinsed again in gently running tap water for five minutes. The slides were dehydrated across a graded series of ethanols, passed through xylene and mounted with Accumount 60 (Stephens Scientific, Riverdale, NJ).

25 Immunohistochemistry of rat brain sections stained with mAb 103A indicated that rat ICAM-4 is expressed in the neuronal cells of the hippocampus. Staining pattern suggested that the protein might be limited to the neuronal processes (dendrites). Brain sections stained in a similar manner with an irrelevant antibody or second step reagent alone do not show the
30 distinct expression pattern seen with MAb 103A.

EXAMPLE 10

Cloning of a Human ICAM-4 Genomic DNA

During the cloning of rat ICAM-4 from genomic DNA, it was discovered that ICAM-4 and ICAM-1 were located within 5 kb of each other and this information was utilized in an attempt to clone the human homologue of ICAM-4.

Genome Systems Inc. (St. Louis, MO) amplified fragments in a human P1 library by PCR using human ICAM-1 domain 3 primers, a sense primer designed complementary to human ICAM-1 domain 3 (H-1/D3 S) and an antisense primer designed complementary to human ICAM-1 domain 3 (H-1/D3 AS). These primers are set forth in SEQ ID NOs: 22 and 23, respectively.

CCGGGTCCTAGAGGTGGACACGCA (SEQ ID NO: 22)

TGCAGTGTCTCCTGGCTCTGGTTC (SEQ ID NO: 23)

Two clones, designated 1566 and 1567, were identified and subjected to further analysis. Both P1 clones contained approximately 75-95 kb genomic DNA inserts. The clones were digested with *Bam*H1, separated with agarose gel electrophoresis, and blotted onto nylon membranes. Southern blots hybridization were performed under either low stringency (30% formamide) or high stringency (60% formamide) at 42°C with human ICAM-1, ICAM-3 or rat ICAM-4 radiolabeled probes; other constituents of the hybridization solution were as described in Example 1. The low stringency hybridization series was washed at room temperature in 2X SSPE containing 0.1% SDS. The high stringency hybridization was washed at 65°C in 0.2X SSPE containing 0.1% SDS. The washed membranes were exposed to X-ray film for 3.5 hours.

The differential hybridization indicated that human ICAM-1 was contained on a 5.5 kb *Bam*H1 fragment while human ICAM-3 was located on

a 4.0 kb and a 1.5 kb *Bam*H1 fragment. The human ICAM-1 and ICAM-R fragments were subcloned into pBS+ and their identity confirmed by limited sequence analysis.

5 A 7.0 kb *Bam*H1 fragment that hybridized with rat ICAM-4 under high stringency conditions was subcloned and further fragmented with *Rsa*I restriction digestion. Three *Rsa*I fragments that hybridized with rat ICAM-4 were identified and their sequences determined. Based on homology to rat ICAM-4, these fragments appeared to contain domains 2, 3, 4, 5 and part of domain 6.

10 EXAMPLE 11

Cloning of a Human ICAM-4 cDNA

The fragments of genomic DNA corresponding to domains 2-5 of human ICAM-4 (described in Example 10) were used as probes to screen a λ gt10 Human hippocampus cDNA library (Clontech, Palo Alto, CA). The
15 library screening protocol was essentially as described in Example 1.

The longest human ICAM-4 clone (#18) that was found in that library was only 992 bp (SEQ ID: 24) and corresponded to roughly the middle of the predicted 3-kb gene. The 992 bp DNA insert from clone-18 (SEQ ID: 24) was used as a probe to screen a λ ZAPII human hippocampus cDNA
20 library (Stratagene, La Jolla, CA). This library yielded a number of positive clones. The longest clone, #34, was 2775 bp (SEQ ID: 25). Based on alignments to the full length rat ICAM-4, it was predicted that this clone was missing the leader sequence and approximately 30 bp at the 5' end of domain 1. The poly A⁺ tail at the 3' end was missing, but the translation stop codon
25 was present.

A fragment of DNA corresponding to the first 3 domains (nucleotides 1 to 840 in clone #34) was used as a probe to screen a λ gt10 cDNA library derived from human cerebral cortex (Clontech, Palo Alto, CA). One clone, 16-1 (SEQ ID: 26), was identified as having 1557 bp, and

included 39 bp of 5' untranslated DNA, a leader sequence and sequence information through the fifth domain. Overlapping clones #34 (SEQ ID: 25) and 16-1 (SEQ ID: 26) were used to generate a composite of the full length human ICAM-4 sequence (SEQ ID: 27).

5 The full length gene is 2927 bp long and encodes a 924 amino acid protein. The ICAM-4 nucleotide sequence is set out in SEQ ID NO: 27 and the amino acid sequence is set out in SEQ ID NO: 28. Sequence alignment with the full length rat ICAM-4 gene (SEQ ID: 11) revealed an overall DNA sequence identity of 82% and 85% identity at the amino acid level. The apparent 9 Ig like extracellular domain structure of the protein is conserved between rat and human. The leader sequence extends from amino acid 1 to 28; domain 1 from amino acid 29 to 117; domain 2 from amino acid 118 to 224; domain 3 from amino acid 225 to 320; domain 4 from amino acid 321 to 405; domain 5 from amino acid 406 to 488; domain 6 from amino acid 489 to 570; domain 7 from amino acid 571 to 663; domain 8 from amino acid 664 to 743; domain 9 from amino acid 744 to 837; the transmembrane region from amino acid 838 to 857 and the cytoplasmic tail from amino acid 858 to 924.

Human ICAM-4 (HuICAM-4), in addition to being genetically
20 linked to ICAM-1 and ICAM-R, also showed certain common structural features that group them together as a family of molecules. A domain by domain alignment of HuICAM-4 with the other members of the ICAM family shows varying degrees of homology. Domain 1 amino acid sequence of HuICAM-4 is 21, 30 and 26% identical to domain 1 of ICAMs 1, 2 and 3 respectively. Domain 2 of HuICAM-4 is 61, 39 and 62% identical to ICAMs 1, 2 and 3 respectively. Domain 3 of HuICAM-4 is 50 and 65% identical to ICAMs 1 and 3 respectively. Domain 4 of HuICAM-4 is 54 and 64% identical to ICAMs 1 and 3 respectively. Domains 5-8 of HuICAM-4 are most homologous to the fifth domains of ICAM-1 and 3, with percent
25 identities ranging from 33-47 for ICAM-1 domain 5 and 21-31 for ICAM-R
30

domain 5. The ninth domain of HuICAM-4 aligns poorly with the other members of the ICAM family but is homologous to domains 3 (24 % identical) and 6 (23 % identical) of HuICAM-1.

EXAMPLE 12

5 Northern Analysis of Human ICAM-4 Expression

Two human multiple tissue Northern (MTN) blots were purchased from Clontech (Palo Alto, CA). These contained at least 2 μ g of poly A⁺ RNA from 16 different human tissues (as shown in Table 1) run on a denaturing formaldehyde 1.2% agarose gel and transferred to nylon
10 membrane. The blots were prehybridized for three hours at 42°C in 10 ml of a solution containing 5X SSPE, 10X Denhardts solution, 50% formamide, 2% SDS and 100 μ g/ml denatured salmon sperm DNA. The blots were hybridized in the above solution with a radiolabeled human ICAM-4 probe
15 (clone #18, SEQ ID: 24) for 16 hours at 42°C. The following day, the blots were washed in a solution of 0.1X SSC/0.1% SDS at room temperature followed by a wash at 50°C. The blots were exposed to x-ray film at -80°C for 24 hours. Results of the analysis are shown below in Table 1.

Only the lane containing RNA from the brain hybridized to the ICAM-4 probe, giving a single band at approximately 3 kb. Longer exposure
20 (five days) confirmed that only the brain had a detectable level of message. In order to determine if all lanes contained comparable amounts of RNA of comparable quality, the same blot was hybridized with a control β -actin probe. Blots were stripped of the ICAM-4 probe by treatment with a boiling solution of 0.1% SDS for 15 minutes, and subsequently probed in a similar manner
25 with a β actin probe provided by the manufacturer. Except for minor variation in amounts, all lanes were shown to have good quality RNA.

TABLE 1

Northern Tissue Analysis of Human ICAM-4 Expression

		—PROBE—	
	<u>Tissue</u>	<u>ICAM-4</u>	<u>β-Actin</u>
5	Heart	-	+++
	Brain	+	++
	Placenta	-	+++
	Lung	-	+++
	Liver	-	+++
10	Skeletal muscle	-	+++++
	Kidney	-	+++
	Pancreas	-	++
	Spleen	-	+++
	Thymus	-	+++
15	Prostate	-	+++
	Testis	-	+++
	Ovary	-	+++
	Small intestine	-	+++
	Colon	-	+++
20	Peripheral blood-leukocyte	-	+++

Two additional Northern blots were purchased from Clontech that contained poly A⁺ RNA from 16 different sub-regions of human brain (as shown in Table 2). Blots were probed in a manner similar to that used for tissue analysis and results are shown in Table 2. RNA quality and quantity loaded was checked by probing the blots with a β actin probe.

All of the regions that showed ICAM-4 expression are part of the telencephalon, with the exception of the thalamus which is considered part of the diencephalon. The hippocampus and cerebral cortex appeared to have the highest level of expression. The transcript size in all cases was the same, 3 kb. The exquisite tissue distribution of the ICAM-4 expression suggests that the promoter region may contain elements that confer the observed developmental and spatial expression of the gene product. The utility of such information may provide insight into the understanding of control of neural gene expression in general.

TABLE 2

Northern Brain Cell Type Analysis of Human ICAM-4 Expression

		PROBE	
		ICAM-4	β -Actin
5	Amygdala	++	+++
	Caudate nucleus	++	+++
	Corpus callosum	+	+++
	Hippocampus	++	+++
	Hypothalamus	-	+++
10	Substantia nigra	-	+++
	Subthalamic nucleus	+	+++
	Thalamus	+	+++
	Cerebellum	-	+++
	Cerebral cortex	+++	+++
15	Medulla	-	+++
	Spinal cord	-	+++
	Occipital pole	++	+++
	Frontal lobe	++	+++
	Temporal lobe	++	+++
20	Putamen	++	+++

EXAMPLE 13

Generation of Human ICAM-4/IgG Fusion Proteins

Human ICAM-4/IgG1 fusion proteins expression plasmids were constructed to produce proteins for generating monoclonal antibodies and for use in adhesion assays to identify potential ICAM-4 ligands. Two constructs were made; the first included DNA encoding domains 1-3 of HuICAM-4 and the second, domains 4-8. Both were linked to the Fc region of human IgG1 in vector pDCS1 that uses the cytomegalovirus (CMV) promoter to drive expression and the signal sequence from IgG4 to facilitate secretion of the molecules.

PCR primers (shown below as SEQ ID NOs: 29-32) were designed to generate the necessary DNA fragments for sub-cloning. The "sense" primer for the 5' end of domain 1 (HI4-D1(s), SEQ ID NO: 29) was designed to fill in 30 base pairs of domain 1 missing in clone #34. Primers

HI4-D1(S) (SEQ ID NO: 29) and HI4-D3(AS) (SEQ ID NO: 30) were used to generate a DNA fragment encoding domains 1-3 of human ICAM-4, corresponding to a region in SEQ ID NO: 1 from nucleotide 130 to nucleotide 996. Primers HI4-D3(S) (SEQ ID NO: 31) and HI4-D8(AS) (SEQ ID NO: 32) were used to generate a DNA fragment encoding domains 4-8 of human ICAM-4, corresponding to a region in SEQ ID NO: 30 from nucleotide 997 to nucleotide 2268. Each 5' primer encoded a *Bam*HI restriction site (GGATCC, indicated in bold below) and each 3' (antisense) primer contained a *Xho*I site (CTCGAG, indicated in bold below) to facilitate subcloning 5' to the IgG1 gene. All oligonucleotides contain spacer nucleotides (underlined, below) at the 5' end to permit restriction digestion.

HI4-D1(S) (SEQ ID NO: 29)
GTACTTACAGGATCCGCGGTCTCGCAG-
GAGCCCTTCTGGGCGGACCTACAGCCTGCGTGGCGTTC

15 HI4-D3(AS) (SEQ ID NO: 30)
ATTCTCTCGAGGATGGTCACGTTCTCCCGG

HI4-D4(S) (SEQ ID NO: 31)
ATTCTGGATCCTACAGCTTCCCGGCACCACTC

20 HI4-D8(AS) (SEQ ID NO: 32)
ATTCTCTCGAGTTCCACGCCCACAGTGACGG

PCR reactions were carried out in a 50 μ l volume using buffers supplied by Perkin Elmer with the AmpliTaq enzyme. Primers were added at a final concentration of 10 μ g/ml and all four dNTPs were included at 2 mM. The reactions were continued through 30 cycles of denaturation (94°C for four minutes), annealing (50°C for two minutes) and extension (72°C for one minute). PCR products were visualized on agarose gels and an aliquot of

each reaction was used to subclone the PCR products into vector pCRII (Invitrogen, San Diego, CA). Sequence analysis was performed to detect possible errors resulting from the amplification process and to confirm proper orientation. Appropriate clones were digested with *Bam*HI and *Xho*I and fragments separated with agarose gel electrophoresis. Purified fragments were ligated into a pDCS1 vector previously digested with *Bam*HI and *Xho*I and the resulting plasmids were sequenced to confirm proper orientation and reading frame.

Human ICAM-4 domains 1-3 and 4-8/IgG1 fusion proteins were obtained following transient transfection of the expression plasmids into COS7 cells and isolation of the secreted protein from the culture media. Transfection was carried out as follows. Adherent COS7 cells at approximately 50-60% confluence were washed with CMF-PBS and subsequently contacted with 10-15 μ g of plasmid DNA in 7.5 ml serum-free DMEM media (Gibco, Gaithersburg, MD) containing 6 μ l of 0.25 M chloroquine (Sigma, St. Louis, MO). An additional 7.5 ml of serum-free media containing 150 μ l of DEAE dextran (50 mg/ml) (Sigma, St. Louis, MO) were added and the plates incubated 2-3 hours before the media was removed and replaced with 10% DMSO (Mallinckrodt, McGaw Park, Illinois) in PBS. After a one minute incubation, the DMSO solution was removed and replaced with fresh media containing 5% FBS. Each transfection included multiple plates, and media from cells expressing the same protein were pooled for protein isolation.

Media were collected every three days over the course of 3-4 harvests. Proteins were purified using a 0.4 - 0.8 ml Procep A column (Bioprocessing Ltd, England) pre-equilibrated with 35 mM Tris, 150 mM NaCl, pH 7.5. Culture media was loaded onto the column two times at a flow rate of less than 60 column volumes per hour. The column was washed one time with each of 20 column volumes of Tris/NaCl buffer, 20 column volumes of 0.55 M diethanolamine, pH 8.5, and 20 column volumes of 50 mM citric acid, pH 5.0. The fusion proteins were eluted into one ml fractions

using 50 mM citric acid pH 3.0 and each fraction was neutralized with 1/10 volume 1 M Tris, pH 9.5. Protein concentration was determined by OD₂₈₀, and purity was determined using SDS-PAGE.

5 A significant contamination from bovine IgG (present in the FBS) was noted. Even though the domains 1-3 fusion protein was predicted to be smaller than the domains 4-8 fusion protein, both migrated at approximately 90 kD. One possible explanation for the observation is that the smaller domains 1-3 fusion protein may be more heavily glycosylated than the larger domains 4-8 fusion protein.

10 In addition to use of the purified proteins for monoclonal antibody production, described below, the proteins will also be used in adhesion assays to identify ICAM-4 ligands.

EXAMPLE 14

Monoclonal Antibody Production

15 The purified protein described in Example 13 was utilized to generate monoclonal antibodies using an immunization protocol as described in Example 6.

20 The spleen from mouse #2250 (immunized with HuICAM-4 D1-3/IgG1) was used for fusion 172 and the spleen from mouse #2272 (immunized with HuICAM-4 D4-8/IgG1) was used for fusion 173. The fusion protocol utilized was as described in Example 6. Fusion plates were screened by ELISA (essentially as described in Example 6) using each HuICAM-4/IgG1 fusion protein. Fusion well supernatants that recognized the immunogen protein, and no other, were considered for cloning. Immunocytochemistry on
25 human hippocampus sections was used as a secondary screen.

One primary clone from each fusion was positive by immunocytochemistry and was cloned. One of the two clones failed to grow upon cloning, leaving only one candidate to pursue, clone 173E which was derived from the HuICAM-4 D4-8/IgG1 immunized mouse. Hybridoma 173E was

deposited June 1, 1995 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and assigned Accession Number HB11912.

5 From another fusion derived from a mouse immunized with a soluble ICAM-4 fragment corresponding to domains 1-3, six clones (179A, 179B, 179D, 179H, 179I, and 179K) were found to be specific for HuICAM4 domains 1 through 3 (D1-3). All six antibodies in the 179 series bound to the dendritic processes in the dentate gyrus, as well as the polymorphic and pyramidal cell layers. The monoclonal antibody 179A stained neuronal cell
10 bodies from these areas in addition to the dendritic processes. The hybridoma cell lines producing antibodies 179I and 179H were deposited on June 10, 1996 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville Maryland, 20852 and assigned Accession Numbers HB 12123 and HB 12124, respectively.

15 Additional fusions are similarly performed to generate other antibodies specifically immunoreactive with particular ICAM-4 regions.

EXAMPLE 15

Capture Assay Development

20 The six monoclonal antibodies from fusion 179 were tested in various combinations for their ability to capture and detect soluble ICAM-4 in solution. The assay, as described below, was established in order to evaluate soluble ICAM-4 levels in human fluids in relation to normal and disease conditions.

25 Antibody 179I was coated on Immulon 4 (Dynatech) 96 well plates at 3 μ g/ml, 125 μ l/well for two hours at 37°C. The antibody solution was removed by aspiration and the wells were blocked for 30 minutes at room temperature with 300 μ l of blocking solution containing 5% Teleostean gelatin in calcium-free, magnesium-free PBS (CMF-PBS). The blocking solution was removed by aspiration, a 100 μ l of sample fluid diluted in Omni Diluent

(CMF-PBS, 1 % gelatin, and 0.05 % Tween 20) was added to each well, and the mixture incubated at 37°C for 30 minutes. The plates were washed three times with PBST (CMF-PBS, 0.05 % Tween 20). Antibody 179H was biotinylated at 1.5 mg/ml using NHS-LC-Biotin (Pierce) following suggested manufacturer's protocol, diluted 1:2000, and added to the wells (100 µl/well). The resulting mixture was incubated for 30 minutes at 37°C and the plates washed three times with PBST. Streptavidin-HRP (Pierce) was added (100 µl, 0.25 µg/ml) to each well and this mixture incubated at 37°C for 30 minutes. The plates were washed four times with PBST before addition of 100 µl of Tetramethylbenzidine (Sigma) (10 mg/ml stock in DMSO) diluted 1:100 in buffered substrate (13.6 g/L sodium acetate trihydrate, pH to 5.5 with 1 M citric acid, with 150 µl/L 30% hydrogen peroxide added just prior to developing). The reaction was allowed to develop for 30 minutes at room temperature in the dark, after which the reaction was stopped with addition of 50 µl/well 15 % H₂SO₄. The absorbance was read at 450 nm.

Results indicated that the assay was capable of detecting soluble HuICAM-4 D1-3 recombinant protein at a concentration as low as 5-10 ng/ml with the linear portion of the curve being in the 10 - 100 ng/ml range. No cross-reactivity to HuICAM4 D4-8 was observed when this protein region was tested at 1 and 10 µg/ml.

EXAMPLE 16

Assessment of Soluble ICAM-4 in Serum from Stroke Patients

In order to assess the role of ICAM-4 in neurologic diseases and conditions, serum from twenty-eight patients suffering from acute stroke and twenty young healthy volunteers (not age matched) was assayed as described above for differences in serum concentration of soluble ICAM-4.

Results indicated that serum from the healthy volunteers had no detectable level of ICAM-4. Twenty out of twenty-eight acute stroke patients, however, had detectable levels of soluble ICAM-4. The signal from the

positive stroke patients corresponded to a range of 5-38 ng/ml of the standard (soluble ICAM-4 D1-3 recombinant protein).

EXAMPLE 17

ICAM-4 mRNA Levels in Hippocampus in a Rat Model of Epilepsy

5 Levels of rat ICAM-4 mRNA expressed were assessed in hippocampus of rats treated in a manner to create a kindling epileptogenesis animal model [Lothman, *et al.*, *Brain Res.* 360:83-91 (1985)]. In the model, the rat hippocampus is stimulated with a series of subconvulsive electric shocks through an electrode implanted in the region of the brain which
10 gradually elicits severe behavioral seizures. The kindling process involves twelve stimulations per day administered every other day for eight days. Once fully kindled, a single stimulus can elicit behavioral seizures and histologic changes that are similar to human epilepsy. Fully kindled rats received two stimulations per day over a two week period and animals were
15 sacrificed 24 hours after the last stimulation. The hippocampus was removed and dissected for RNA preparation.

 Total RNA was prepared from each sample using the guanidinium/phenol/chloroform extraction procedure [Chomezynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987)]. RNA was separated on denaturing
20 formaldehyde agarose gels, transferred to nylon membranes, and hybridized with radiolabelled rat ICAM-4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specific DNA probes. GAPDH is a basally-expressed gene that is commonly used as a control to detect lane to lane variation in the amount of RNA loaded on a gel. Fluctuations in the ratio of the ICAM-4/GAPDH are
25 interpreted as changes in the level of ICAM-4 expression. Hybridizing bands for ICAM-4 and GAPDH were quantitated with a phosphorimager and a ratio of ICAM-4/GAPDH determined.

 The ratio of ICAM-4/GAPDH was significantly higher in the control animals that were not kindled (n=5) compared to the kindled test

group (n=5), suggesting that ICAM-4 was down regulated as a consequence of the kindling process. It should be noted, however, that the control group did not undergo any sham treatment so the possibility exists that ICAM-4 mRNA levels were modulated in response to the surgical treatment associated with kindling.

EXAMPLE 18

Serum ICAM-4 Concentration as a Marker for Neurodegenerative Disorders

Circulating serum concentrations of ICAM-4 were assessed as a possible indicator for various neurodegenerative disorders. Serum and/or plasma samples from anonymous donors were assayed as described in Example 16 above and compared to samples drawn from control donors with no previous history of neurological disorders.

Control Donors

In order to establish a baseline average for circulating ICAM-4 in normal healthy individuals, serum samples from 100 donors were examined. The results showed that twelve individuals (12%) had circulating levels of ICAM-4 greater than 10 ng/ml. Of these twelve, the ICAM-4 concentration in five samples averaged 10-20 ng/ml, three samples showed an average ICAM-4 concentration of 20-100 ng/ml, two samples showed ICAM-4 levels between 100-500 ng/ml, and two samples contained ICAM-4 at a concentration in excess of 500 ng/ml.

Samples were taken at the same time from both donors with very high levels at varying timepoints over an eight month period to assess the stability of the observations over time. It was observed that over a period of months, the readings did fluctuate. No medical information was available on these donors, making correlations with the ICAM-4 levels and the physical well-being of the donors not possible. When both serum and plasma samples

were prepared from the same individual, no difference was observed in the level of ICAM-4 present.

5 This observation indicated that an assay for soluble ICAM-4 would be versatile in its use of either serum or plasma. In addition, the results indicated that ICAM-4 is very stable in blood, suggesting that an elevated level of ICAM-4 as a result of some pathological state probably would not be transient. Finally, because of the apparent stability of ICAM-4 in a blood environment, assays for soluble ICAM-4 can utilize blood bank samples thus reducing the need for fresh blood with each assay.

10 In order to determine if the methods of collection and/or storage affected the observations, the stability of ICAM-4 serum was assessed by treating samples from the one individual with the highest level of circulating ICAM-4 in a variety of ways followed by a measurement of the levels of ICAM-4. Neither incubation at 37°C for 24 hours nor from one to three
15 freeze/thaw cycles altered the level of detectable ICAM-4 in the serum.

Donors with Epilepsy

The serum concentration of ICAM-4 in samples from twenty patients with Temporal Lobe Epilepsy (TLE) was measured and compared to serum samples from control group patients that had experienced Grand Mal
20 Seizures (38 different patients), Syncope (8 patients) or were normal healthy donors (20 individuals). The assay method described in Example 15 was again employed and the results expressed as ng/ml relative to the internal standard used for the assay, soluble HuICAM-4 D1-3 recombinant protein (described in Example 13).

25 Serum from all 20 patients with TLE had measurable levels of ICAM-4 with an average of approximately 140 ng/ml. In serum samples from all 3 control groups, including the Grand Mal Seizure group, ICAM-4 concentration averaged below 10 ng/ml. These observations suggest that an individual's ICAM-4 serum level may represent a biochemical marker which

can distinguish between focused seizures, like those experienced in TLE, and more generalized Grand Mal Seizures.

Donors with AIDS

5 Serum concentration of ICAM-4 in the sera from a limited number of AIDS patients was also examined. The patients were grouped according to CD4 counts and the presence of any signs of dementia. A first group comprised sixteen early stage, asymptomatic patients with CD4 counts greater than 500 were tested. A second group comprised seven later stage patients with CD4 counts less than 300; signs of dementia were not
10 determined for this group. The last group comprised nine late stage AIDS patients, each showing signs of dementia.

The results showed that serum samples from four of the sixteen (25%) early stage, asymptomatic patients had detectable levels of soluble ICAM-4; three of the four samples had an ICAM-4 concentration in excess
15 of 500 ng/ml. Four of the seven (57%) serum samples from later stage patients were also positive for ICAM-4, with two of the four having ICAM-4 concentrations in excess of 500 ng/ml. Samples from the late stage patients showing signs of dementia had no detectable levels of ICAM-4. The results of this preliminary study suggest that ICAM-4 may be an early marker of the
20 neurodegeneration associated with AIDS dementia.

Donors with Other Neurodegenerative Diseases

The results from the study of serum from epilepsy and AIDS donors suggest that ICAM-4 levels in the blood may reflect damage to the neurons that normally express it. There are a number of other neurologic
25 diseases that might also show, as part of their etiology, damage to specific ICAM-4 expressing neurons that could result in changes in the serum concentration of ICAM-4 in the periphery.

For example, Alzheimer's disease is associated with extensive neuronal damage in the regions of the telencephalon where ICAM-4 is expressed. Assessment of ICAM-4 levels in serum from patients with the Early-onset Familial forms of the disease, as well as patients with the sporadic form of the disease, may provide a marker for the various stages of the disease thereby permitting assessment of possible therapeutic interventions.

As another example, because other cortical dementias, such as Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy, are sometimes mistaken for Alzheimer's, but may be distinguishable from each other and from Alzheimer's disease through serum ICAM-4 analysis. As another example, serum ICAM-4 concentration in patients suffering from a subcortical dementia, including Parkinson's disease, Huntington's disease, and progressive supranuclear, may be elevated as a result of common pathological indications of this class of disorders.

~~As another example, a number of the primary psychiatric disorders, such as depression, schizophrenia and psychosis, are characterized in part by degrees of neurodegeneration that might be associated with detectable levels of ICAM-4 in the blood.~~

As another example, elevated levels of ICAM-4 may be associated with a number of nongenetic dementias arising from infections, vasculitis, metabolic and nutritional disorders (e.g., thyroid, vitamin B12 deficiency), vascular disorders (multiple infarct, lacunar state, Binswanger's disease), toxic encephalopathies (e.g., exposure to carbon monoxide, heavy metals or other industrial pollutants) and tumors.

EXAMPLE 19

Cloning and Analysis of Human ICAM-4 Upstream Regulatory DNA

ICAM-4 gene expression is spatially and temporally regulated, with expression limited to the most anterior or ventral region of the brain, the telencephalon. In an attempt to identify gene sequences responsible for the

restricted transcriptional regulation of ICAM-4, the nucleotide region 5' to human ICAM-4 coding sequences was examined.

A 2607 base pair *Bam*HI/*Pst*I fragment derived from a 7.0 kb genomic *Bam*HI fragment (described in Example 10) was sequenced and found to contain 1684 nucleotides upstream of the ATG start codon. The complete sequence for this upstream region is set out in SEQ ID NO: 33. With respect to the position of the ICAM-4 coding region, the "A" in ATG start codon (numbered in SEQ ID NO: 33 as nucleotides 1685-1687) is designated the +1 nucleotide and the nucleotide immediately 5' to the A⁺¹ nucleotide is designated -1. Thus the entire sequence is shown as extending from nucleotide -1684 to nucleotide +3, corresponding to numbering in the Sequence Listing nucleotide 1 to nucleotide 1687.

Based on the genomic HuICAM-4 sequence, oligonucleotides were synthesized and used in PCR to generate DNA molecules of various lengths within the upstream regulatory region. Each oligonucleotide set out in Table 3 contained a spacer region (shown in italics) approximately 6-10 bp to allow enzymatic digestion of the PCR product, an *Nhe*I or *Hind*III restriction site (shown in bold), and a specific hybridization primer sequence (underlined). The oligonucleotide names contain numbers that designate its location within the upstream regulatory region. In the PCR amplifications, oligonucleotides were paired as shown in Table 4 to generate DNA fragments containing specific regions of the upstream regulatory region.

The restriction sites and spacer region generated within each oligonucleotide allowed for enzymatic digestion and subsequent directional cloning of individual PCR products into the pGL3 Basic Vector (Promega, Madison, WI) which contains a luciferase reporter gene immediately downstream of a multiple cloning site (MCS). Promoter activity cloned into the MCS region of the vector drives expression of the luciferase reporter gene in transfected cell lines, and light production from expressed luciferase can be measured as an indicator of promoter activity. The pGL3 Basic Vector has

TABLE 3

PCR Primers Used to Amplify HuICAM-4 Upstream Regions

	HI4-19(AS)	<u>CAGAACTAAGCTTACAGGAGGCGAGGAGAGCGCGAG</u> (SEQ ID NO: 34)
5	HI4-114	<u>CAACAATGCTAGCCAAGCGCAACTCTGTCTC</u> (SEQ ID NO: 35)
	HI4-149	<u>CAACAATGCTAGCCTTGGAACCAAGTTACC</u> (SEQ ID NO: 36)
10	HI4-206	<u>CAACAATGCTAGCAGGAGCTTAGCGCACGCTCG</u> (SEQ ID NO: 37)
	HI4-270	<u>CAACAATGCTAGCCATGCCGGCCTCCACGTAG</u> (SEQ ID NO: 38)
	HI4-408	<u>CAACAATGCTAGCGTCCAGCTTATTATCATG</u> (SEQ ID NO: 39)
15	HI4-480	<u>CAACAATGCTAGCCTTAGTCCCCAAATGTATC</u> (SEQ ID NO: 40)
	HI4-560	<u>CAACAATGCTAGCGGAGAAGGATCAGTGAG</u> (SEQ ID NO: 41)
20	HI4-817	<u>CAACAATGCTAGCCTCCACCCACCGAGCAGAAG</u> (SEQ ID NO: 42)

no promoter and therefore served as the negative control, while a pGL3 vector containing an SV40 promoter served as a positive control. The sequence of each expression construct was verified by restriction analysis and DNA sequencing.

25 Plasmids containing each of the amplified sequences described in Table 4 were transfected into mammalian cells using a Transfection MBS Mammalian Transfection Kit (Stratagene, La Jolla, CA) according to manufacturer's suggested protocol. Each plasmid was introduced into two different cell lines, COS 7 and NT2 Precursor Cells (Ntera2/D1 from

Stratagene). COS 7 cells are a commonly used simian fibroblast-like cell line transformed with SV40 making them well suited for driving expression of a gene under control of the SV40 promoter in cells transfected with the positive control pGL3 Promoter Vector. NT2 precursor cells are a committed neuronal precursor cell line, and while they do not express ICAM-4, they may be more representative of a cell type that does express ICAM-4.

TABLE 4

Primers Paired and Regions Amplified

	<u>Oligonucleotide Pairs</u>	<u>Corresponding Upstream Regulatory Region</u>
10	HI4-19 (AS) with HI4-114	-19 → -114
	HI4-19 (AS) with HI4-149	-19 → -149
	HI4-19 (AS) with HI4-206	-19 → -206
	HI4-19 (AS) with HI4-270	-19 → -270
	HI4-19 (AS) with HI4-408	-19 → -408
15	HI4-19 (AS) with HI4-480	-19 → -480
	HI4-19 (AS) with HI4-560	-19 → -560
	HI4-19 (AS) with HI4-817	-19 → -817

Each well of a 6 well flat bottom tissue culture plate (Falcon) was seeded with 2.5×10^5 cells. Transfections of COS 7 and NT2 cells were done side by side in duplicate using 5 μ g of plasmid DNA for each well. The cells were cultured at 37°C for 48 hours, lysed and assayed for luciferase activity with a Luciferase Assay System (Promega).

Results of the experiment, summarized in Table 5, indicate a high level of promoter activity contained within the -408 through -19 and -480 through -19 regions of the upstream regulatory region of ICAM-4 in NT2 cells. Because NT2 cells are of neuronal origin, they may express certain transcription factors recognizing the ICAM-4 promoter that are not found in other cell types. The highest level of promoter activity in COS cell

transfectants was obtained with the plasmid containing nucleotides -560 through -19. While the positive control pGL3 Promoter Vector worked well in COS cells, it showed very low promoter activity in NT2 cells, thus illustrating a cell type specific preference for certain promoter sequences.

TABLE 5

<u>Promoter Activity of 5' ICAM-4 Regions</u>		
Upstream Region	Luminescence	
	<u>COS</u>	<u>NT2</u>
-114 through -19	0.003	0.376
-149 through -19	0.008	0.628
-206 through -19	0.443	0.622
-270 through -19	0.056	1.140
-408 through -19	0.401	7.970
-480 through -19	0.274	4.630
-560 through -19	3.227	1.232
-817 through -19	0.035	4.453
pGL3 Promoter Vector	29.070	0.063
pGL3 Basic Vector	0.008	0.014

Since neither COS 7 or NT2 cells normally express ICAM-4, the same experiment will be repeated using primary cultured rat hippocampal neurons which do express ICAM-4 and necessarily express transcriptional machinery required for ICAM-4 promoter activity. By transfecting the individual promoter constructs described herein, as well as others, into the more natural environment, it may be possible to identify more precisely which nucleotides in the upstream regulatory region are responsible for tight regulation of the ICAM-4 gene in the brain.

The foregoing illustrative examples relate to presently preferred embodiments of the invention and numerous modifications and variations thereof will be expected to occur to those skilled in the art. Thus only such limitations as appear in the appended claims should be placed upon the scope of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Gallatin, W. Michael
Kilgannon, Patrick D.
- (ii) TITLE OF INVENTION: ICAM-4 Materials and Methods
- (iii) NUMBER OF SEQUENCES: 42
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 - (B) STREET: 233 South Wacker Drive, 6300 Sears Tower
 - (C) CITY: Chicago
 - (D) STATE: Illinois
 - (E) COUNTRY: United States of America
 - (F) ZIP: 60606-6402
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- ~~(vii)~~ PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/827,689
 - (B) FILING DATE: 27-JAN-1992
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/889,724
 - (B) FILING DATE: 26-MAY-1992
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/894,061
 - (B) FILING DATE: 05-JUN-1992
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/009,266
 - (B) FILING DATE: 22-JAN-1993
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/102,852
 - (B) FILING DATE: 05-AUG-1993
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/245,295
 - (B) FILING DATE: 18-MAY-1994
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/485,604
 - (B) FILING DATE: 07-JUN-1995
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: WILLIAMS, JR. JOSEPH A.
 - (B) REGISTRATION NUMBER: 38,659
 - (C) REFERENCE/DOCKET NUMBER: 27866/33321

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 312-474-6300
- (B) TELEFAX: 312-474-0448
- (C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2988 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 61..2814

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATTCGATCA CTCGCGCTCC CCTCGCCTTC TGCCTCTCTCC CCTCCCTGGC AGCGGCGGCA	60
ATG CCG GGG CCT TCA CCA GGG CTG CGC CGA ACG CTC CTC GGC CTC TGG	108
Met Pro Gly Pro Ser Pro Gly Leu Arg Arg Thr Leu Leu Gly Leu Trp	
1 5 10 15	
GCT GCC CTG GGC CTG GGG ATC CTA GGC ATC TCA GCG GTC GCG CTA GAA	156
Ala Ala Leu Gly Leu Gly Ile Leu Gly Ile Ser Ala Val Ala Leu Glu	
20 25 30	
CCT TTC TGG GCG GAC CTT CAG CCC CGC GTG GCG CTC GTG GAG CGC GGG	204
Pro Phe Trp Ala Asp Leu Gln Pro Arg Val Ala Leu Val Glu Arg Gly	
35 40 45	
GGC TCG CTG TGG CTC AAC TGC AGC ACT AAC TGT CCG AGG CCG GAG CGC	252
Gly Ser Leu Trp Leu Asn Cys Ser Thr Asn Cys Pro Arg Pro Glu Arg	
50 55 60	
GGT GGC CTG GAG ACC TCG CTA CGC CGA AAC GGG ACC CAG AGG GGT CTG	300
Gly Gly Leu Glu Thr Ser Leu Arg Arg Asn Gly Thr Gln Arg Gly Leu	
65 70 75 80	
CGC TGG CTG GCT CGA CAG CTG GTG GAC ATC CGA GAG CCT GAA ACC CAG	348
Arg Trp Leu Ala Arg Gln Leu Val Asp Ile Arg Glu Pro Glu Thr Gln	
85 90 95	
CCG GTC TGC TTC TTC CGC TGC GCG CGC CGC ACA CTC CAA GCG CGT GGG	396
Pro Val Cys Phe Phe Arg Cys Ala Arg Arg Thr Leu Gln Ala Arg Gly	
100 105 110	
CTC ATC CGA ACT TTC CAG CGA CCG GAT CGG GTA GAG CTA GTG CCT CTG	444
Leu Ile Arg Thr Phe Gln Arg Pro Asp Arg Val Glu Leu Val Pro Leu	
115 120 125	
CCT CCT TGG CAG CCT GTA GGT GAG AAC TTC ACC TTG AGC TGC AGG GTC	492
Pro Pro Trp Gln Pro Val Gly Glu Asn Phe Thr Leu Ser Cys Arg Val	
130 135 140	
CCG GGG GCA GGA CCC CGA GCG AGC CTC ACA TTG ACC TTG CTG CGA GGC	540
Pro Gly Ala Gly Pro Arg Ala Ser Leu Thr Leu Thr Leu Leu Arg Gly	
145 150 155 160	

GGC	CAG	GAG	CTG	ATT	CGC	CGA	AGT	TTC	GTA	GGC	GAG	CCA	CCC	CGA	GCT	588
Gly	Gln	Glu	Leu	Ile	Arg	Arg	Ser	Phe	Val	Gly	Glu	Pro	Pro	Arg	Ala	
				165					170					175		
CGG	GGT	GCG	ATG	CTC	ACC	GCC	ACG	GTC	CTG	GCG	CGC	AGA	GAG	GAT	CAC	636
Arg	Gly	Ala	Met	Leu	Thr	Ala	Thr	Val	Leu	Ala	Arg	Arg	Glu	Asp	His	
			180					185					190			
AGG	GCC	AAT	TTC	TCA	TGC	CTC	GCG	GAG	CTT	GAC	CTG	CGG	CCA	CAC	GGC	684
Arg	Ala	Asn	Phe	Ser	Cys	Leu	Ala	Glu	Leu	Asp	Leu	Arg	Pro	His	Gly	
		195					200					205				
TTG	GGA	CTG	TTT	GCA	AAC	AGC	TCA	GCC	CCC	AGA	CAG	CTC	CGC	ACG	TTT	732
Leu	Gly	Leu	Phe	Ala	Asn	Ser	Ser	Ala	Pro	Arg	Gln	Leu	Arg	Thr	Phe	
	210					215					220					
GCC	ATG	CCT	CCA	CTT	TCC	CCG	AGC	CTT	ATT	GCC	CCA	CGA	TTC	TTA	GAA	780
Ala	Met	Pro	Pro	Leu	Ser	Pro	Ser	Leu	Ile	Ala	Pro	Arg	Phe	Leu	Glu	
	225				230					235					240	
GTG	GGC	TCA	GAA	AGG	CCG	GTG	ACT	TGC	ACT	TTG	GAT	GGA	CTG	TTT	CCT	828
Val	Gly	Ser	Glu	Arg	Pro	Val	Thr	Cys	Thr	Leu	Asp	Gly	Leu	Phe	Pro	
				245				250						255		
GCC	CCA	GAA	GCC	GGG	GTT	TAC	CTC	TCT	CTG	GGA	GAT	CAG	AGG	CTT	CAT	876
Ala	Pro	Glu	Ala	Gly	Val	Tyr	Leu	Ser	Leu	Gly	Asp	Gln	Arg	Leu	His	
			260				265					270				
CCT	AAT	GTG	ACC	CTC	GAC	GGG	GAG	AGC	CTT	GTG	GCC	ACT	GCC	ACA	GCT	924
Pro	Asn	Val	Thr	Leu	Asp	Gly	Glu	Ser	Leu	Val	Ala	Thr	Ala	Thr	Ala	
		275					280					285				
ACA	GCA	AGT	GAA	GAA	CAG	GAA	GGC	ACC	AAA	CAG	CTG	ATG	TGC	ATC	GTG	972
Thr	Ala	Ser	Glu	Glu	Gln	Glu	Gly	Thr	Lys	Gln	Leu	Met	Cys	Ile	Val	
	290					295					300					
ACC	CTC	GGG	GGC	GAA	AGC	AGG	GAG	ACC	CAG	GAA	AAC	CTG	ACT	GTC	TAC	1020
Thr	Leu	Gly	Gly	Glu	Ser	Arg	Glu	Thr	Gln	Glu	Asn	Leu	Thr	Val	Tyr	
	305				310					315				320		
AGC	TTC	CCG	GCT	CCT	CTT	CTG	ACT	TTA	AGT	GAG	CCA	GAA	GCC	CCC	GAG	1068
Ser	Phe	Pro	Ala	Pro	Leu	Leu	Thr	Leu	Ser	Glu	Pro	Glu	Ala	Pro	Glu	
				325					330					335		
GGA	AAG	ATG	GTG	ACC	GTA	AGC	TGC	TGG	GCA	GGG	GCC	CGA	GCC	CTT	GTC	1116
Gly	Lys	Met	Val	Thr	Val	Ser	Cys	Trp	Ala	Gly	Ala	Arg	Ala	Leu	Val	
			340				345						350			
ACC	TTG	GAG	GGA	ATT	CCA	GCT	GCG	GTC	CCT	GGG	CAG	CCC	GCT	GAG	CTC	1164
Thr	Leu	Glu	Gly	Ile	Pro	Ala	Ala	Val	Pro	Gly	Gln	Pro	Ala	Glu	Leu	
		355					360					365				
CAG	TTA	AAT	GTC	ACA	AAG	AAT	GAC	GAC	AAG	CGG	GGC	TTC	TTC	TGC	GAC	1212
Gln	Leu	Asn	Val	Thr	Lys	Asn	Asp	Asp	Lys	Arg	Gly	Phe	Phe	Cys	Asp	
	370					375					380					
GCT	GCC	CTC	GAT	GTG	GAC	GGG	GAA	ACT	CTG	AGA	AAG	AAC	CAG	AGC	TCT	1260
Ala	Ala	Leu	Asp	Val	Asp	Gly	Glu	Thr	Leu	Arg	Lys	Asn	Gln	Ser	Ser	
	385				390					395				400		
GAG	CTT	CGT	GTT	CTG	TAC	GCA	CCT	CGG	CTG	GAT	GAC	TTG	GAC	TGT	CCC	1308
Glu	Leu	Arg	Val	Leu	Tyr	Ala	Pro	Arg	Leu	Asp	Asp	Leu	Asp	Cys	Pro	
				405					410					415		

AGG	AGC	TGG	ACG	TGG	CCA	GAG	GGT	CCA	GAG	CAG	ACC	CTC	CAC	TGC	GAG	1356
Arg	Ser	Trp	Thr	Trp	Pro	Glu	Gly	Pro	Glu	Gln	Thr	Leu	His	Cys	Glu	
			420					425					430			
GCC	CGT	GGA	AAC	CCT	GAG	CCC	TCC	GTG	CAC	TGT	GCA	AGG	CCT	GAC	GGT	1404
Ala	Arg	Gly	Asn	Pro	Glu	Pro	Ser	Val	His	Cys	Ala	Arg	Pro	Asp	Gly	
		435					440					445				
GGG	GCG	GTG	CTA	GCG	CTG	GGC	CTG	TTG	GGT	CCA	GTG	ACC	CGT	GCC	CTC	1452
Gly	Ala	Val	Leu	Ala	Leu	Gly	Leu	Leu	Gly	Pro	Val	Thr	Arg	Ala	Leu	
	450				455						460					
GCG	GGC	ACT	TAC	CGA	TGT	ACA	GCA	ATC	AAT	GGG	CAA	GGC	CAG	GCG	GTC	1500
Ala	Gly	Thr	Tyr	Arg	Cys	Thr	Ala	Ile	Asn	Gly	Gln	Gly	Gln	Ala	Val	
465					470				475						480	
AAG	GAT	GTG	ACC	CTG	ACT	GTG	GAA	TAT	GCC	CCA	GCG	CTG	GAC	AGT	GTA	1548
Lys	Asp	Val	Thr	Leu	Thr	Val	Glu	Tyr	Ala	Pro	Ala	Leu	Asp	Ser	Val	
			485					490					495			
GGC	TGC	CCA	GAA	CGT	ATT	ACT	TGG	CTG	GAG	GGG	ACA	GAG	GCA	TCG	CTT	1596
Gly	Cys	Pro	Glu	Arg	Ile	Thr	Trp	Leu	Glu	Gly	Thr	Glu	Ala	Ser	Leu	
			500				505					510				
AGC	TGT	GTG	GCA	CAC	GGG	GTC	CCA	CCA	CCT	AGC	GTG	AGC	TGT	GTG	CGC	1644
Ser	Cys	Val	Ala	His	Gly	Val	Pro	Pro	Pro	Ser	Val	Ser	Cys	Val	Arg	
		515					520					525				
TCT	GGA	AAG	GAG	GAA	GTC	ATG	GAA	GGG	CCC	CTG	CGT	GTG	GCC	CGG	GAG	1692
Ser	Gly	Lys	Glu	Glu	Val	Met	Glu	Gly	Pro	Leu	Arg	Val	Ala	Arg	Glu	
	530					535					540					
CAC	GCT	GGC	ACT	TAC	CGA	TGC	GAA	GCC	ATC	AAC	GCC	AGG	GGA	TCA	GCG	1740
His	Ala	Gly	Thr	Tyr	Arg	Cys	Glu	Ala	Ile	Asn	Ala	Arg	Gly	Ser	Ala	
545					550				555						560	
GCC	AAA	AAT	GTG	GCT	GTC	ACG	GTG	GAA	TAT	GGT	CCC	AGT	TTT	GAG	GAG	1788
Ala	Lys	Asn	Val	Ala	Val	Thr	Val	Glu	Tyr	Gly	Pro	Ser	Phe	Glu	Glu	
			565						570					575		
TTG	GGC	TGC	CCC	AGC	AAC	TGG	ACT	TGG	GTA	GAA	GGA	TCT	GGA	AAA	CTG	1836
Leu	Gly	Cys	Pro	Ser	Asn	Trp	Thr	Trp	Val	Glu	Gly	Ser	Gly	Lys	Leu	
			580					585					590			
TTT	TCC	TGT	GAA	GTT	GAT	GGG	AAG	CCG	GAA	CCA	CGC	GTG	GAG	TGC	GTG	1884
Phe	Ser	Cys	Glu	Val	Asp	Gly	Lys	Pro	Glu	Pro	Arg	Val	Glu	Cys	Val	
		595				600						605				
GGC	TCG	GAG	GGT	GCA	AGC	GAA	GGG	GTA	GTG	TTG	CCC	CTG	GTG	TCC	TCG	1932
Gly	Ser	Glu	Gly	Ala	Ser	Glu	Gly	Val	Val	Leu	Pro	Leu	Val	Ser	Ser	
	610					615					620					
AAC	TCT	GGT	TCC	AGA	AAC	TCT	ATG	ACT	CCT	GGT	AAC	CTG	TCA	CCG	GGT	1980
Asn	Ser	Gly	Ser	Arg	Asn	Ser	Met	Thr	Pro	Gly	Asn	Leu	Ser	Pro	Gly	
625					630				635						640	
ATT	TAC	CTC	TGC	AAC	GCC	ACC	AAC	CGG	CAT	GGC	TCC	ACA	GTC	AAA	ACA	2028
Ile	Tyr	Leu	Cys	Asn	Ala	Thr	Asn	Arg	His	Gly	Ser	Thr	Val	Lys	Thr	
				645				650					655			
GTC	GTC	GTG	AGC	GCG	GAA	TCA	CCG	CCA	CAG	ATG	GAT	GAA	TCC	AGT	TGC	2076
Val	Val	Val	Ser	Ala	Glu	Ser	Pro	Pro	Gln	Met	Asp	Glu	Ser	Ser	Cys	
			660				665						670			

CCG	AGT	CAC	CAG	ACA	CTG	TGG	CTG	GAA	GGA	GCC	GAG	GCT	ACT	GCG	CTG	GCC	2124
Pro	Ser	His	Gln	Thr	Trp	Leu	Glu	Gly	Ala	Glu	Ala	Thr	Ala	Leu	Ala		
		675					680						685				
TGC	AGT	GCC	AGA	GGC	CGC	CCC	TCT	CCA	CGC	GTG	CGC	TGT	TCC	AGG	GAA	2172	
Cys	Ser	Ala	Arg	Gly	Arg	Pro	Ser	Pro	Arg	Val	Arg	Cys	Ser	Arg	Glu		
		690				695					700						
GGT	GCA	GCC	AGG	CTG	GAG	AGG	CTA	CAG	GTG	TCC	CGA	GAG	GAT	GCG	GGG	2220	
Gly	Ala	Ala	Arg	Leu	Glu	Arg	Leu	Gln	Val	Ser	Arg	Glu	Asp	Ala	Gly		
		705			710				715						720		
ACC	TAC	CTG	TGT	GTG	GCT	ACC	AAC	GCG	CAT	GGC	ACG	GAT	TCA	CGG	ACC	2268	
Thr	Tyr	Leu	Cys	Val	Ala	Thr	Asn	Ala	His	Gly	Thr	Asp	Ser	Arg	Thr		
				725					730					735			
GTC	ACT	GTG	GGT	GTG	GAA	TAC	CGG	CCT	GTG	GTG	GCT	GAG	CTG	GCA	GCC	2316	
Val	Thr	Val	Gly	Val	Glu	Tyr	Arg	Pro	Val	Val	Ala	Glu	Leu	Ala	Ala		
			740					745					750				
TCG	CCC	CCA	AGC	GTG	CGG	CCT	GGC	GGA	AAC	TTC	ACT	CTG	ACC	TGC	CGT	2364	
Ser	Pro	Pro	Ser	Val	Arg	Pro	Gly	Gly	Asn	Phe	Thr	Leu	Thr	Cys	Arg		
		755					760					765					
GCA	GAG	GCC	TGG	CCT	CCA	GCC	CAG	ATC	AGC	TGG	CGC	GCG	CCC	CCG	GGA	2412	
Ala	Glu	Ala	Trp	Pro	Pro	Ala	Gln	Ile	Ser	Trp	Arg	Ala	Pro	Pro	Gly		
		770				775					780						
GCT	CTC	AAC	CTC	GGT	CTC	TCC	AGC	AAC	AAC	AGC	ACG	CTG	AGC	GTG	GCG	2460	
Ala	Leu	Asn	Leu	Gly	Leu	Ser	Ser	Asn	Asn	Ser	Thr	Leu	Ser	Val	Ala		
		785			790					795					800		
GGT	GCC	ATG	GGC	AGC	CAT	GGT	GGC	GAG	TAT	GAG	TGC	GCA	GCC	ACC	AAT	2508	
Gly	Ala	Met	Gly	Ser	His	Gly	Gly	Glu	Tyr	Glu	Cys	Ala	Ala	Thr	Asn		
				805					810					815			
GCG	CAT	GGG	CGC	CAC	GCA	CGG	CGC	ATC	ACG	GTG	CGC	GTG	GCC	GGT	CCA	2556	
Ala	His	Gly	Arg	His	Ala	Arg	Arg	Ile	Thr	Val	Arg	Val	Ala	Gly	Pro		
			820					825					830				
TGG	CTG	TGG	GTC	GCT	GTG	GGC	GGT	GCG	GCA	GGG	GGC	GCG	GCG	CTG	CTG	2604	
Trp	Leu	Trp	Val	Ala	Val	Gly	Gly	Ala	Ala	Gly	Gly	Ala	Ala	Leu	Leu		
		835					840					845					
GCC	GCA	GGG	GCC	GGC	CTG	GCC	TTC	TAC	GTG	CAG	TCC	ACC	GCT	TGC	AAG	2652	
Ala	Ala	Gly	Ala	Gly	Leu	Ala	Phe	Tyr	Val	Gln	Ser	Thr	Ala	Cys	Lys		
		850				855					860						
AAG	GGA	GAG	TAC	AAC	GTC	CAG	GAG	GCT	GAG	AGC	TCA	GGC	GAG	GCG	GTG	2700	
Lys	Gly	Glu	Tyr	Asn	Val	Gln	Glu	Ala	Glu	Ser	Ser	Gly	Glu	Ala	Val		
		865			870					875					880		
TGT	CTC	AAT	GGC	GCG	GGC	GGG	ACA	CCG	GGT	GCA	GAA	GGC	GGA	GCA	GAG	2748	
Cys	Leu	Asn	Gly	Ala	Gly	Gly	Thr	Pro	Gly	Ala	Glu	Gly	Gly	Ala	Glu		
				885					890					895			
ACC	CCC	GGC	ACT	GCC	GAG	TCA	CCT	GCA	GAT	GGC	GAG	GTT	TTC	GCC	ATC	2796	
Thr	Pro	Gly	Thr	Ala	Glu	Ser	Pro	Ala	Asp	Gly	Glu	Val	Phe	Ala	Ile		
			900					905					910				
CAG	CTG	ACA	TCT	TCC	TGAGCCTGTA	TCCAGCTCCC	CCAGGGGCCT	CGAAAGCACA								2851	
Gln	Leu	Thr	Ser	Ser													
		915															

GGGGTGGACG TATGTATTGT TCACTCTCTA TTTATTCAAC TCCAGGGGCG TCGTCCCCGT	2911
TTTCTACCCA TTCCCTTAAT AAAGTTTTTA TAGGAGAAAA AAAAAAAAAA AAAAAAAAAA	2971
AAAAAAAAAA AAAAAA	2988

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 917 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Pro	Gly	Pro	Ser	Pro	Gly	Leu	Arg	Arg	Thr	Leu	Leu	Gly	Leu	Trp
1				5					10					15	
Ala	Ala	Leu	Gly	Leu	Gly	Ile	Leu	Gly	Ile	Ser	Ala	Val	Ala	Leu	Glu
			20					25					30		
Pro	Phe	Trp	Ala	Asp	Leu	Gln	Pro	Arg	Val	Ala	Leu	Val	Glu	Arg	Gly
		35					40					45			
Gly	Ser	Leu	Trp	Leu	Asn	Cys	Ser	Thr	Asn	Cys	Pro	Arg	Pro	Glu	Arg
	50					55					60				
Gly	Gly	Leu	Glu	Thr	Ser	Leu	Arg	Arg	Asn	Gly	Thr	Gln	Arg	Gly	Leu
	65				70					75					80
Arg	Trp	Leu	Ala	Arg	Gln	Leu	Val	Asp	Ile	Arg	Glu	Pro	Glu	Thr	Gln
				85					90					95	
Pro	Val	Cys	Phe	Phe	Arg	Cys	Ala	Arg	Arg	Thr	Leu	Gln	Ala	Arg	Gly
			100					105					110		
Leu	Ile	Arg	Thr	Phe	Gln	Arg	Pro	Asp	Arg	Val	Glu	Leu	Val	Pro	Leu
		115					120					125			
Pro	Pro	Trp	Gln	Pro	Val	Gly	Glu	Asn	Phe	Thr	Leu	Ser	Cys	Arg	Val
	130					135					140				
Pro	Gly	Ala	Gly	Pro	Arg	Ala	Ser	Leu	Thr	Leu	Thr	Leu	Leu	Arg	Gly
	145				150				155					160	
Gly	Gln	Glu	Leu	Ile	Arg	Arg	Ser	Phe	Val	Gly	Glu	Pro	Pro	Arg	Ala
			165						170					175	
Arg	Gly	Ala	Met	Leu	Thr	Ala	Thr	Val	Leu	Ala	Arg	Arg	Glu	Asp	His
			180					185					190		
Arg	Ala	Asn	Phe	Ser	Cys	Leu	Ala	Glu	Leu	Asp	Leu	Arg	Pro	His	Gly
		195				200					205				
Leu	Gly	Leu	Phe	Ala	Asn	Ser	Ser	Ala	Pro	Arg	Gln	Leu	Arg	Thr	Phe
	210					215					220				
Ala	Met	Pro	Pro	Leu	Ser	Pro	Ser	Leu	Ile	Ala	Pro	Arg	Phe	Leu	Glu
	225				230					235				240	

Val Gly Ser Glu Arg Pro Val Thr Cys Thr Leu Asp Gly Leu Phe Pro
245 250 255

Ala Pro Glu Ala Gly Val Tyr Leu Ser Leu Gly Asp Gln Arg Leu His
260 265 270

Pro Asn Val Thr Leu Asp Gly Glu Ser Leu Val Ala Thr Ala Thr Ala
275 280 285

Thr Ala Ser Glu Glu Gln Glu Gly Thr Lys Gln Leu Met Cys Ile Val
290 295 300

Thr Leu Gly Gly Glu Ser Arg Glu Thr Gln Glu Asn Leu Thr Val Tyr
305 310 315 320

Ser Phe Pro Ala Pro Leu Leu Thr Leu Ser Glu Pro Glu Ala Pro Glu
325 330 335

Gly Lys Met Val Thr Val Ser Cys Trp Ala Gly Ala Arg Ala Leu Val
340 345 350

Thr Leu Glu Gly Ile Pro Ala Ala Val Pro Gly Gln Pro Ala Glu Leu
355 360 365

Gln Leu Asn Val Thr Lys Asn Asp Asp Lys Arg Gly Phe Phe Cys Asp
370 375 380

Ala Ala Leu Asp Val Asp Gly Glu Thr Leu Arg Lys Asn Gln Ser Ser
385 390 395 400

Glu Leu Arg Val Leu Tyr Ala Pro Arg Leu Asp Asp Leu Asp Cys Pro
405 410 415

Arg Ser Trp Thr Trp Pro Glu Gly Pro Glu Gln Thr Leu His Cys Glu
420 425 430

Ala Arg Gly Asn Pro Glu Pro Ser Val His Cys Ala Arg Pro Asp Gly
435 440 445

Gly Ala Val Leu Ala Leu Gly Leu Leu Gly Pro Val Thr Arg Ala Leu
450 455 460

Ala Gly Thr Tyr Arg Cys Thr Ala Ile Asn Gly Gln Gly Gln Ala Val
465 470 475 480

Lys Asp Val Thr Leu Thr Val Glu Tyr Ala Pro Ala Leu Asp Ser Val
485 490 495

Gly Cys Pro Glu Arg Ile Thr Trp Leu Glu Gly Thr Glu Ala Ser Leu
500 505 510

Ser Cys Val Ala His Gly Val Pro Pro Pro Ser Val Ser Cys Val Arg
515 520 525

Ser Gly Lys Glu Glu Val Met Glu Gly Pro Leu Arg Val Ala Arg Glu
530 535 540

His Ala Gly Thr Tyr Arg Cys Glu Ala Ile Asn Ala Arg Gly Ser Ala
545 550 555 560

Ala Lys Asn Val Ala Val Thr Val Glu Tyr Gly Pro Ser Phe Glu Glu
565 570 575

100252001

Leu Gly Cys Pro Ser Asn Trp Thr Trp Val Glu Gly Ser Gly Lys Leu
 580 585 590
 Phe Ser Cys Glu Val Asp Gly Lys Pro Glu Pro Arg Val Glu Cys Val
 595 600 605
 Gly Ser Glu Gly Ala Ser Glu Gly Val Val Leu Pro Leu Val Ser Ser
 610 615 620
 Asn Ser Gly Ser Arg Asn Ser Met Thr Pro Gly Asn Leu Ser Pro Gly
 625 630 635 640
 Ile Tyr Leu Cys Asn Ala Thr Asn Arg His Gly Ser Thr Val Lys Thr
 645 650 655
 Val Val Val Ser Ala Glu Ser Pro Pro Gln Met Asp Glu Ser Ser Cys
 660 665 670
 Pro Ser His Gln Thr Trp Leu Glu Gly Ala Glu Ala Thr Ala Leu Ala
 675 680 685
 Cys Ser Ala Arg Gly Arg Pro Ser Pro Arg Val Arg Cys Ser Arg Glu
 690 695 700
 Gly Ala Ala Arg Leu Glu Arg Leu Gln Val Ser Arg Glu Asp Ala Gly
 705 710 715 720
 Thr Tyr Leu Cys Val Ala Thr Asn Ala His Gly Thr Asp Ser Arg Thr
 725 730 735
 Val Thr Val Gly Val Glu Tyr Arg Pro Val Val Ala Glu Leu Ala Ala
 740 745 750
 Ser Pro Pro Ser Val Arg Pro Gly Gly Asn Phe Thr Leu Thr Cys Arg
 755 760 765
 Ala Glu Ala Trp Pro Pro Ala Gln Ile Ser Trp Arg Ala Pro Pro Gly
 770 775 780
 Ala Leu Asn Leu Gly Leu Ser Ser Asn Asn Ser Thr Leu Ser Val Ala
 785 790 795 800
 Gly Ala Met Gly Ser His Gly Gly Glu Tyr Glu Cys Ala Ala Thr Asn
 805 810 815
 Ala His Gly Arg His Ala Arg Arg Ile Thr Val Arg Val Ala Gly Pro
 820 825 830
 Trp Leu Trp Val Ala Val Gly Gly Ala Ala Gly Gly Ala Ala Leu Leu
 835 840 845
 Ala Ala Gly Ala Gly Leu Ala Phe Tyr Val Gln Ser Thr Ala Cys Lys
 850 855 860
 Lys Gly Glu Tyr Asn Val Gln Glu Ala Glu Ser Ser Gly Glu Ala Val
 865 870 875 880
 Cys Leu Asn Gly Ala Gly Gly Thr Pro Gly Ala Glu Gly Gly Ala Glu
 885 890 895
 Thr Pro Gly Thr Ala Glu Ser Pro Ala Asp Gly Glu Val Phe Ala Ile
 900 905 910

TOGETHER

Gln Leu Thr Ser Ser
915

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 315 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..315

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCG GAT CGG GTA GAG CTA GTG CCT CTG CCT CCT TGG CAG CCT GTA GGT	48
Pro Asp Arg Val Glu Leu Val Pro Leu Pro Pro Trp Gln Pro Val Gly	
1 5 10 15	
GAG AAC TTC ACC TTG AGC TGC AGG GTC CCG GGG GCA GGA CCC CGA GCG	96
Glu Asn Phe Thr Leu Ser Cys Arg Val Pro Gly Ala Gly Pro Arg Ala	
20 25 30	
AGC CTC ACA TTG ACC TTG CTG CGA GGC GGA CAG GAG CTG ATT CGC CGA	144
Ser Leu Thr Leu Thr Leu Arg Gly Gly Gln Glu Leu Ile Arg Arg	
35 40 45	
AGT TTC GTA GGC GAG CCA CCC CGA GCT CGG TGT GCG ATG CTC ACC GCC	192
Ser Phe Val Gly Glu Pro Pro Arg Ala Arg Cys Ala Met Leu Thr Ala	
50 55 60	
ACG GTC CTG GCG CGC AGA GAG GAT CAC AGG GAC AAT TTC TCA TGC CTC	240
Thr Val Leu Ala Arg Arg Glu Asp His Arg Asp Asn Phe Ser Cys Leu	
65 70 75 80	
GCG GAG CTT GAC CTG CGG ACA CAC GGC TTG GGA CTG TTT GCA AAC AGC	288
Ala Glu Leu Asp Leu Arg Thr His Gly Leu Gly Leu Phe Ala Asn Ser	
85 90 95	
TCA GCC CCC AGA CAG CTC CGC ACG TTT	315
Ser Ala Pro Arg Gln Leu Arg Thr Phe	
100 105	

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1781 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 16..1659

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CAGCTCTCTG	TCAGA	ATG	GCC	ACC	ATG	GTA	CCA	TCC	GTG	TTG	TGG	CCC	AGG		51	
	Met	Ala	Thr	Met	Val	Pro	Ser	Val	Leu	Trp	Pro	Arg				
	1				5						10					
GCC	TGC	TGG	ACT	CTG	CTG	GTC	TGC	TGT	CTG	CTG	ACC	CCA	GGT	GTC	CAG	99
Ala	Cys	Trp	Thr	Leu	Leu	Val	Cys	Cys	Leu	Leu	Thr	Pro	Gly	Val	Gln	
	15						20					25				
GGG	CAG	GAG	TTC	CTT	TTG	CGG	GTG	GAG	CCC	CAG	AAC	CCT	GTG	CTC	TCT	147
Gly	Gln	Glu	Phe	Leu	Leu	Arg	Val	Glu	Pro	Gln	Asn	Pro	Val	Leu	Ser	
	30					35					40					
GCT	GGA	GGG	TCC	CTG	TTT	GTG	AAC	TGC	AGT	ACT	GAT	TGT	CCC	AGC	TCT	195
Ala	Gly	Gly	Ser	Leu	Phe	Val	Asn	Cys	Ser	Thr	Asp	Cys	Pro	Ser	Ser	
	45				50					55					60	
GAG	AAA	ATC	GCC	TTG	GAG	ACG	TCC	CTA	TCA	AAG	GAG	CTG	GTG	GCC	AGT	243
Glu	Lys	Ile	Ala	Leu	Glu	Thr	Ser	Leu	Ser	Lys	Glu	Leu	Val	Ala	Ser	
				65					70					75		
GGC	ATG	GGC	TGG	GCA	GCC	TTC	AAT	CTC	AGC	AAC	GTG	ACT	GGC	AAC	AGT	291
Gly	Met	Gly	Trp	Ala	Ala	Phe	Asn	Leu	Ser	Asn	Val	Thr	Gly	Asn	Ser	
			80					85					90			
CGG	ATC	CTC	TGC	TCA	GTG	TAC	TGC	AAT	GGC	TCC	CAG	ATA	ACA	GGC	TCC	339
Arg	Ile	Leu	Cys	Ser	Val	Tyr	Cys	Asn	Gly	Ser	Gln	Ile	Thr	Gly	Ser	
		95					100					105				
TCT	AAC	ATC	ACC	GTG	TAC	GGG	CTC	CCG	GAG	CGT	GTG	GAG	CTG	GCA	CCC	387
Ser	Asn	Ile	Thr	Val	Tyr	Gly	Leu	Pro	Glu	Arg	Val	Glu	Leu	Ala	Pro	
	110					115					120					
CTG	CCT	CCT	TGG	CAG	CCG	GTG	GGC	CAG	AAC	TTC	ACC	CTG	CGC	TGC	CAA	435
Leu	Pro	Pro	Trp	Gln	Pro	Val	Gly	Gln	Asn	Phe	Thr	Leu	Arg	Cys	Gln	
	125				130					135					140	
GTG	GAG	GGT	GGG	TCG	CCC	CGG	ACC	AGC	CTC	ACG	GTG	GTG	CTG	CTT	CGC	483
Val	Glu	Gly	Gly	Ser	Pro	Arg	Thr	Ser	Leu	Thr	Val	Val	Leu	Leu	Arg	
				145					150					155		
TGG	GAG	GAG	GAG	CTG	AGC	CGG	CAG	CCC	GCA	GTG	GAG	GAG	CCA	GCG	GAG	531
Trp	Glu	Glu	Glu	Leu	Ser	Arg	Gln	Pro	Ala	Val	Glu	Glu	Pro	Ala	Glu	
			160					165					170			
GTC	ACT	GCC	ACT	GTG	CTG	GCC	AGC	AGA	GAC	GAC	CAC	GGA	GCC	CCT	TTC	579
Val	Thr	Ala	Thr	Val	Leu	Ala	Ser	Arg	Asp	Asp	His	Gly	Ala	Pro	Phe	
		175					180					185				
TCA	TGC	CGC	ACA	GAA	CTG	GAC	ATG	CAG	CCC	CAG	GGG	CTG	GGA	CTG	TTC	627
Ser	Cys	Arg	Thr	Glu	Leu	Asp	Met	Gln	Pro	Gln	Gly	Leu	Gly	Leu	Phe	
	190					195					200					
GTG	AAC	ACC	TCA	GCC	CCC	CGC	CAG	CTC								

CAG Gln	GTC Val	TAC Tyr 255	CTG Leu	GCG Ala	CTG Leu	GGG Gly	GAC Asp 260	CAG Gln	ATG Met	CTG Leu	AAT Asn	GCG Ala 265	ACA Thr	GTC Val	ATG Met	819
AAC Asn	CAC His 270	GGG Gly	GAC Asp	ACG Thr	CTA Leu	ACG Thr 275	GCC Ala	ACA Thr	GCC Ala	ACA Thr	GCC Ala 280	ACG Thr	GCG Ala	CGC Arg	GCG Ala	867
GAT Asp 285	CAG Gln	GAG Glu	GGT Gly	GCC Ala	CGG Arg 290	GAG Glu	ATC Ile	GTC Val	TGC Cys	AAC Asn 295	GTG Val	ACC Thr	CTA Leu	GGG Gly	GGC Gly 300	915
GAG Glu	AGA Arg	CGG Arg	GAG Glu	GCC Ala 305	CGG Arg	GAG Glu	AAC Asn	TTG Leu	ACG Thr 310	GTC Val	TTT Phe	AGC Ser	TTC Phe	CTA Leu 315	GGA Gly	963
CCC Pro	ATT Ile	GTG Val	AAC Asn 320	CTC Leu	AGC Ser	GAG Glu	CCC Pro 325	ACC Thr	GCC Ala	CAT His	GAG Glu	GGG Gly	TCC Ser 330	ACA Thr	GTG Val	1011
ACC Thr	GTG Val	AGT Ser 335	TGC Cys	ATG Met	GCT Ala	GGG Gly	GCT Ala 340	CGA Arg	GTC Val	CAG Gln	GTC Val	ACG Thr 345	CTG Leu	GAC Asp	GGA Gly	1059
GTT Val	CCG Pro 350	GCC Ala	GCG Ala	GCC Ala	CCG Pro	GGG Gly 355	CAG Gln	ACA Thr	GCT Ala	CAA Gln	CTT Leu 360	CAG Gln	CTA Leu	AAT Asn	GCT Ala	1107
ACC Thr 365	GAG Glu	AGT Ser	GAC Asp	GAC Asp	GGA Gly 370	CGC Arg	AGC Ser	TTC Phe	TTC Phe	TGC Cys 375	AGT Ser	GCC Ala	ACT Thr	CTC Leu	GAG Glu 380	1155
GTG Val	GAC Asp	GGC Gly	GAG Glu	TTC Phe 385	TTG Leu	CAC His	AGG Arg	AAC Asn	AGT Ser 390	AGC Ser	GTC Val	CAG Gln	CTG Leu	CGA Arg 395	GTC Val	1203
CTG Leu	TAT Tyr	GGT Gly	CCC Pro 400	AAA Lys	ATT Ile	GAC Asp	CGA Arg	GCC Ala 405	ACA Thr	TGC Cys	CCC Pro	CAG Gln	CAC His 410	TTG Leu	AAA Lys	1251
TGG Trp	AAA Lys 415	GAT Asp	AAA Lys	ACG Thr	AGA Arg	CAC His	GTC Val 420	CTG Leu	CAG Gln	TGC Cys	CAA Gln	GCC Ala 425	AGG Arg	GGC Gly	AAC Asn	1299
CCG Pro	TAC Tyr 430	CCC Pro	GAG Glu	CTG Leu	CGG Arg	TGT Cys 435	TTG Leu	AAG Lys	GAA Glu	GGC Gly	TCC Ser 440	AGC Ser	CGG Arg	GAG Glu	GTG Val	1347
CCG Pro 445	GTG Val	GGG Gly	ATC Ile	CCG Pro	TTC Phe 450	TTC Phe	GTC Val	AAC Asn	GTA Val	ACA Thr 455	CAT His	AAT Asn	GGT Gly	ACT Thr	TAT Tyr 460	1395
CAG Gln	TGC Cys	CAA Gln	GCG Ala	TCC Ser 465	AGC Ser	TCA Ser	CGA Arg	GGC Gly	AAA Lys 470	TAC Tyr	ACC Thr	CTG Leu	GTC Val	GTG Val 475	GTG Val	1443
ATG Met	GAC Asp	ATT Ile	GAG Glu 480	GCT Ala	GGG Gly	AGC Ser	TCC Ser	CAC His 485	TTT Phe	GTC Val	CCC Pro	GTC Val	TTC Phe 490	GTG Val	GCG Ala	1491
GTG Val	TTA Leu	CTG Leu 495	ACC Thr	CTG Leu	GGC Gly	GTG Val 500	GTG Val	ACT Thr	ATC Ile	GTA Val	CTG Leu	GCC Ala 505	TTA Leu	ATG Met	TAC Tyr	1539

(2) INFORMATION FOR SEO ID NO:5:

(ii) MOLECULE TYPE: DNA (genomic)

CCGAACGCTC	CTCGGCCTCT	GGTCTNCTCT	GGNCCTGGGG	ATCCTAGGCA	TCTCAGGTAA	60
GAAGAGCCCG	CCCGTGAGC	NAGGTGGATA	AGGCGGGGGC	GGAATTGAAG	GACCAGAGAG	120
GGCGGCCCGG	GTGTCCCCCT	CCAGGCTCCG	CCCTCTTCTA	GCTTCCACG	CTTCTGTCAC	180
CACCTGGAGN	TCGGGGCTTC	TCCCCGTCCT	TCCTCCACCC	CAACACACCT	CAATCTTTCA	240
GANCTGAACC	CAGCACCTTT	TCTGGANTNG	GGGNNTTGCA	CCTAACCTGT	CTCAGGAGAN	300
ACTGTGGCTC	TCCTGTCTCT	TCCTGCTCTG	TNATGCCCTA	TGGTTCACAG	ACTGGCATCA	360
TCCCTATTCA	TGATCTCAA	AGACNCCATC	TCCTCAACTG	TCATAACTCA	GAGCTCTATT	420
CCCCCTCCAC	CTGGAGCCCT	GGAAACCGGC	TTTCTAGGGC	TTTTCTCCGC	GGTTCTTTCC	480
CGGAGTTCAG	CGTTGTGGCT	TTTTGTCCAA	GTTACTCAAG	TTTGGGGACA	ATCTCCTTTA	540
AGCCTTTGAC	TCAGTCTCAT	TTCCACTTTG	CTTTTGCCCC	AAGCCTCTGT	GTCTCTCCCC	600
CATTTCTTGA	CGATCTGTCA	GAGTCTTAAG	AGTGATTTGG	TTCCCCATCC	CCCCCTCCAAC	660
TGGAGTCTCC	TCCTCACTAT	TGATGTGTGC	ATCTGAGACC	CCCATCCCCG	CACCGAGTTT	720
CCCCATCTCT	GTCAGTAAAG	AGCAAGGCTT	CCAGAGACAA	CCCTCTAATA	GCGCGTCAGT	780
CCCGAATCTT	GAGTGGGATG	CGGGACTCCC	GTGCTATTTT	TTGGCGGAGG	TCTTTCTCTGG	840
TCCTTATGGA	CACCCCTGGT	TTGGGATATG	GGGGCCGCTA	AGATTTTCTA	GATGGGGTCC	900
CTAGGCTGAG	NCCGCGTTTT	CCCGGGCAGC	GGTCGCGCTA	GAACCTTTCT	GGGCGGACCT	960
TCAGCCCCGC	GTGGCGCTCG	TGGAGCGCGG	GGGCTCGCTG	TGGCTCAACT	GCAGCACTAA	1020
CTGTCCGAGG	CCGGAGCGCG	GTGGCCTGGA	GACCTCGCTA	CGCCGAAACG	GGACCCAGAG	1080

GGGTCTGNAC	TGNCTGGCTC	GACAGCTGGT	GGACATCCGA	GANCCTGAAA	CCCAGCCGGT	1140
CTGCTTCTTC	CNCTGCGCGC	GCCGCACACT	CCAAGCGCGT	GGGCTCATCC	GAACTTTCCG	1200
TGAGTTCAGG	GTGGGCACNC	CCCTTGGGTC	TCTGGACCTC	CCCCCTAAGC	TCCTCCCACC	1260
CGCCCTCTGA	TCCTCCTGCT	TGTTCTGAAA	GTACTACAGC	TGGCTAGAGC	GGAGTTTTTG	1320
GTCCCTTGCA	GAGCGACCGG	ATCGGGTAGA	GCTAGTGCCT	CTGCCTCCTT	GGCAGCCTGT	1380
AGGTGAGAAC	TTCACCTTGA	GCTGCAGGGT	CCCGGGGGCA	GGACCCCGAG	CGAGCCTCAC	1440
ATTGACCTTG	CTGCGAGGCG	GCCAGGAGCT	GATTCGCCGA	AGTTTCGTAG	GCGAGCCACC	1500
CCGAGCTCGG	GGTGCGATGC	TCACCGCCAC	GGTCCTGGCG	CGCAGAGAGG	ATCACAGGGC	1560
CAATTTCTCA	TGCCTCGCGG	AGCTTGACCT	GCGNCCACAC	GGCTTGGGAC	TGTTTGCANA	1620
CAGCTCAGCC	CCCAGACAGC	TCCGCACGTT	TGGTGAGTGT	GGACCCTAAC	TGACAGATTT	1680
TAAGAAGTTT	AGGGCAGCCA	GGCGTGGTGG	CATGGTGTCT	TAGGCCCTAA	GTCCCAGCCC	1740
AAGCAGANCT	AAGNCGGATC	TCTTGTGAAT	TAAAAGTCTA	GCTCGTCTAC	ATAACGAGGN	1800
CTGCATAGTT	AAATCCCCCA	AAAGTCTAAG	CAGCTAGCCC	TTACTTCCAA	CACAAGTACT	1860
AGCTTAAGTA	CTTTCTCCTG	TGAGCTTTTT	CCTTTATGTA	TTTACTCGTT	GAGAGAAAAA	1920
GAGAGTGTGT	GTACGTGCCT	TTATGCACAT	GCCGCAGTGC	TTGTATGGAA	GTTAAAGAAT	1980
AAGGAGGCGT	TCTGCCCTTC	CATCCTGTGG	GTCCTAGGGG	TGGTATTAGC	TCCTCAGGCT	2040
TTGTTAGTNA	CAAGCGCCTA	GGCTTGGGGA	GCCATCTCGC	CCGCTCCTCT	GTATCTTTAG	2100
GGTGAAACCA	GACAATGCAT	GCAAATTGGT	TGATCAACAC	TGAATGTTTA	GTTTCGTAAAT	2160
TCAAGCTCTG	TTCTTTGTCT	TCCTCAGCCA	TGCCTCCACT	TTCCCCCGAG	CCTTATTGCC	2220
CCACGATTCT	TAGAAGTGGG	CTCAGAAAGG	CCGGTGACKT	GCACTTTGGA	TGGACTGTTT	2280
CCTGCCCCAG	AAGCCGGGGT	TTACTTCTCT	CTGGGAGATC	AGAGGCTTCA	TCCTAATGTG	2340
ACCCTCGACG	GGGAGAGCCT	TGTGGCCACT	GCCACAGCTA	CAGCAAGTGA	AGAACAGGAA	2400
GGCACCAAAC	AGCTGATGTG	CATCGTGACC	CTCGGGGGCG	AAAGCAGGGA	GACCCAGGAA	2460
AACCTGACTG	TCTACAGTAA	GGGGAATCCA	ACAAGACCTT	CAATAGCTCA	GACTGGGGCT	2520
GGGGCTGGGT	CTGGGTCTGG	GGCCAGAGTC	TCACAAAGGC	GGAGCCTATA	AAGTGGGCGG	2580
GACCTCCACA	CCAGAACAAG	CCGGGCGGGA	GAGTTCCAGG	GCAGGAGCAG	ATAGAAGTTG	2640
GAAATTAATA	GATTGGGTTG	AGTTCCCTGA	GTGGGGAGTG	AACCCACACC	AATTCTCTGT	2700
CCCCAGGCTT	CCCGGCTCCT	CTTCTGACTT	TAAGTGAGCC	AGAAGCCCCC	GAGGGAAAGA	2760
TGGTGACCGT	AAGCTGCTGG	GCAGGGGCCC	GAGCCCTTGT	CACCTTGGAG	GGAATTCCAA	2820
GGACCCTCTT	ACCGGCCCCA	TCTTTAACCT	TATCGTATCC	CCTCTGCCTC	ATGCCCCGAG	2880
ACGCACCTCG	GCTGGATGAC	TTGGACTGTC	CCAGGAGCTG	GACGTGGCCA	GAGGGTCCAG	2940
AGCAGACCCT	CCACTGCGAG	GCCCGTGGAA	ACCCTGAGCC	CTCCGTGCAC	TGTGCAAGGC	3000

CTGACGGTGG	GGCGGTGCTA	GCGCTGGGCC	TGTTGGGTCC	AGTGACCCGT	GCCCTCGCGG	3060
GCACTTACCG	ATGTACAGCA	ATCAATGGGC	AAGGCCAGGC	GGTCAAGGAT	GTGACCCTGA	3120
CTGTGGAATG	TGAGTAGGGG	GAGGTGGGCA	TGCTTATCCC	TTTAAGGTCA	CGGAGTGTAC	3180
TGGGAGACTG	GCTATACGGA	AAGGAAAGAA	GCCTAGGTTC	AGCAGGGATT	GGGAAAACAC	3240
TGAAGGAAAAG	TGGTGTGGTG	TTTACAAACT	TAACGGTGGT	AACTGGGCAC	GGTCTGGCAA	3300
AAACAGACAG	CCAAGAGAGT	GTGCCTGGGA	AGCTGCAATG	GGGGCTTTGT	GGGAATTGGT	3360
CAACAGCACC	CTGAGATCTC	AGGAAAGGGG	CCTGAAGTTA	TCTCCAGAAC	CCATGTGAAG	3420
GCAGGAAGAG	AGAACGCCCA	CCTTTTCCTG	CTCCCCCACA	CCCCCCCCCA	CATATCACAC	3480
GGAGTATATA	AATAAATAAA	ATGGCTCCTG	CCGGAGGGAG	TGAGAAGCTG	TCTCCTGCAG	3540
GCTCAGAGCA	GTGGTAGTGC	ATGCCTTTAA	TCCCAGCACT	CGGTAGGCAA	AGGCAGGCAG	3600
ATCTCTGTGA	ATGTGGGGCC	AGCCTGGTCT	GTACAGAGAA	ATCCTGTCTC	AAAACAAACC	3660
AGCAAAGAAA	CAAAACCAAA	ATCAATTCCA	GATGCCCCAG	CGCTGGACAG	TGTAGGCTGC	3720
CCANGACGTA	TTACTTGNCT	GGAGGGGACA	GAGGCATCGC	TTAGCTGTGT	GGCACACGGG	3780
GTCCCACCAC	CTAGCGTGAG	CTGTGTGCGC	TCTGGAAAGG	AGGAAGTCAT	GGAAGGGCCC	3840
CTGCGTGTGG	CCCGGGAGCA	CGCTGGCACT	TACCGATGCG	AAGCCATCAA	CGCCAGGGGA	3900
TCAGCGGNCA	AAAATGTGGC	TGTCACGGTG	GAATGTGAGT	AGGGGTGGCT	ACGGAAATGT	3960
CCACACCTGC	GTCTCTGTGC	CTCAGTGTGA	ACTCCTATTT	CCCTGCTTCC	TAGATGGTCC	4020
CAGTTNTGAG	GAGTTGGGCT	GCCCCAGCAA	CTGGACTTGG	GTAGAAGGAT	CTGGAAAACCT	4080
GTTTTCTCTGT	GAAGTTGATG	GGAAGCCGGA	ACCACGCGTG	GAGTGCGTGG	GCTCGGAGGG	4140
TGCAAGCGAA	GGGGTAGTGT	TGCCCTGGT	GTCTCTGAAC	TCTGGTTCCA	GAAACTCTAT	4200
GACTCCTGGT	AACCTGTCAC	CGGGTATTTA	CCTCTGCAAC	GCCACCAACC	GGCATGGCTC	4260
CACAGTCAAA	ACAGTCGTCG	TGAGCGCGGA	ATGTGAGCAG	GGGCCCAGGT	GGGCGGAGAG	4320
TACCGGGTGT	CCCAGGATCT	TTCTTTTCCC	TGATGCCCCCT	CCTTATGGTG	GCTGATCTGC	4380
AGCACCGCCA	CAGATGGATG	AATCCAGTTG	CCCGAGTCAC	CAGACATGGC	TGGAAGGAGC	4440
CGAGGCTACT	GCGCTGGCCT	GCACTGACAG	GGGNCGCCCC	TCTCCACGCG	TGCGCTGTTC	4500
CAGGGAAGGT	GCAGCCAGGC	TGGAGAGGCT	ACAGGTGTCC	CGAGAGGATG	CGGGGACCTA	4560
CCTGTGTGTG	GCTACCAACG	CGCATGGCAC	GGATTACGG	ACCGTCACTG	TGGGTGTGGA	4620
ATGTGAGTGA	GGACAGCGCT	GAATGAAGAC	GACTCAGACC	GCCAGAAAAG	TGCCTTGAGG	4680
CCTGGGATGT	ATGATCCAGT	GGGTAGAGTG	CTCAATTAGC	ACTCACTAAA	ATGTATATTC	4740
TATTCCTAAT	ACTCTTTAAT	TTTANCCTTT	GGGAGGCAGA	GACAGGCAGA	TCTCTGTTCC	4800
GGGATAACCT	GCTCTCTGTC	TAGGACAGCT	TGGTCTACAG	AGGGGNTACA	GGCCCCCCTT	4860
CCCAAGATTG	NATAGCAACC	CTCTGGCTCC	CTGTCTCTCT			4900

TCCTCTCTCT

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1295 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

NGAATTCCGG CGGATCGGGT AGAGCTAGTG CCTCTGCCTC CTTGGCAGCC TGTAGGTGAG	60
AAC TTCACCT TGAGCTGCAG GGTCCCGGGG GCAGGACCCC GAGCGAGCCT CACATTGACC	120
TTGCTGCGAG GCGGCCAGGA GCTGATTCGC CGAAGTTTCG TAGGCGAGCC ACCCCGAGCT	180
CGGGGTGCGA TGCTCACCGC CACGGTCCTG GCGCGCAGAG AGGATCACAG GGCCAATTTT	240
TCATGCCTCG CGGAGCTTGA CCTGCGGCCA CACGGCTTGG GACTGTTTGC AAACAGCTCA	300
GCCCCAGAC AGCTCCGCAC GTTTGCCATG CCTCCACTTT CCCCAGACCT TATTGCCCCA	360
CGATTCTTAG AAGTGGGCTC AGAAAGGCCG GTGACTTGCA CTTTGGATGG ACTGTTTCCT	420
GCCCCAGAAG CCGGGGTTTA CCTCTCTCTG GGAGATCAGA GGCTTCATCC TAATGTGACC	480
CTCGACGGGG AGAGCCTTGT GGCCACTGCC ACAGCTACAG CAAGTGAAGA ACAGGAAGGC	540
ACCAAACAGC TGATGTGCAT CGTGACCCTC GGGGGCGAAA GCAGGGAGAC CCAGGAAAAC	600
CTGACTGTCT ACAGCTTCCC GGCTCCTCTT CTGACTTTAA GTGAGCCAGA AGCCCCCGAG	660
GGAAAGATGG TGACCGTAAG CTGCTGGGCA GGGGCCCGAG CCCTTGTCAC CTTGGAGGGA	720
ATTCCAAGGA CCCTCTTACC GGCCCCATCT TTAACCTTAT CGTATCCCCT CTGCCTCATG	780
CCCGCAGACG CACCTCGGCT GGATGACTTG GACTGTCCA GGAGCTGGAC GTGGCCAGAG	840
GGTCCAGAGC AGACCCTCCA CTGCGAGGCC CGTGGAACC CTGAGCCCTC CGTGCACTGT	900
GCAAGGCCTG ACGGTGGGGC GGTGCTAGCG CTGGGCCTGT TGGGTCCAGT GACCCGTGCC	960
CTCGCGGGCA CTTACCGATG TACAGCAATC AATGGGCAAG GCCAGGCGGT CAAGGATGTG	1020
ACCCTGACTG TGGAATATGC CCCAGCGCTG GACAGTGTAG GCTGCCCAGA ACGTATTACT	1080
TGGCTGGAGG GGACAGAGGC ATCGCTTAGC TGTGTGGCAC ACGGGGTCCC ACCACCTAGC	1140
GTGAGCTGTG TGCGCTCTGG AAAGGAGGAA GTCATGGAAG GGCCCCTGCG TTTTGGCCGG	1200
GAGCACGCTG GCACTTACCG ATGCGAAGCC ATCAACGCCA GGGGATCAGC GGCCAAAAAT	1260
GTGGCTGTCA CGGTGGAATA TGGTCCCCGG AATTC	1295

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2214 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGAATCTTGA GTGGGATGCG GGACTCCCGT GCTATTTCTT GGCGGAGGTC TTTCCTGGTC 60
CTTATGGACA CCCCTGGTTT GGGATATGGG GGCCGCTAAG ATTTCAAGAGA TGGGGTCCCT 120
AGGCTGAGCC CGCGTTTTCC CGGGCAGCGG TCGCGCTAGA ACCTTTCTGG GCGGACCTTC 180
AGCCCCGCGT GGCGCTCGTG GAGCGCGGGG GCTCGCTGTG GCTCAACTGC AGCACTAACT 240
GTCCGAGGCC GGAGCGCGGT GGYCTGGAGA CCTCGCTACG CCGAAACGGG ACCCAGAGGG 300
GTCTGCGCTG GCTGGCTCGA CAGMTGGTGG ACATCCGAGA GCCTGAAACC CAGTCGGTCT 360
GCTTCTTCCG CTGGGCGCGC CGCACACTCC AAGNGAGTGG GCTCATCCGA ACTTTCCAGC 420
GACCGGATCG GGTAGAGCTA GTGCCTCTGN CTCCTTGGCA GCCTGTAGGT GAGAACTTCA 480
CCTTGAGCTG CAGGGTCCCG GGGGCAGGAC CCCGAGCGAG CCTCACATTG ACCTTGCTGC 540
GAGGCGGCCA GGAGCTGATT CGCCGAAGTT TCGTAGGCGA GCCACCCGA GCTCGGGGTG 600
CGATGCTCAC CGCCACGGTC CTGGCGCGCA GAGAGGATCA CAGGGCCAAT TTCTCATGCC 660
TCGCGGAGCT TGACCTGCGG ACACACGGCT TGGGACTGTT TGCAAACAGC TCAGCCCCCA 720
GACAGCTCCG CACGTTTGGC ATGCCTCCAC TTTCCCCGAG CTTTATTGNC CCACGATTCT 780
TAGAAGTGGG CTCAGAAAGG CCGGTGACTT GCACTTTGGA TGGACTGTTT CCTGCCCCAG 840
AAGCCGGGGT TTACCTCTCT CTGGGAGATC AGAGGCTTCA TCCTAATGTG ACCCTCGACG 900
GGGAGAGCCT TGTGGCCACT GNCACAGMTA CAGCAAGTGA AGAACAGGAA GGCACCAAAC 960
AGCTGATGTG CATCGTGACC CTCGGGGGCG AAAGCAGGGA GACCCAGGAA AACCTGACTG 1020
TCTACAGCTT CCCGGCTCCT CTTCTGACTT TAAGTGAGCC AGAAGCCCCC GAGGGAAAGA 1080
TGGTGACCGT AAGCTGCTGG GCAGGGGCCC GAGCCCTTGT CACCTTGGAG GGAATTCCAG 1140
CTGCGGTCCC TGGGCAGCCC GCTGAGCTCC AGTTAAATGT CACAAAGAAT GACGACAAGC 1200
GGGGCTTCTT CTGCGACGCT GCCCTCGATG TGGACGGGGA AACTCTGAGA AAGAACCAGA 1260
GCTCTGAGCT TCGTGTCTG TACGCACCTC GGCTGGATGA CTTGGACTGT CCCAGGAGCT 1320
GGACGTGGCC AGAGGGTCCA GAGCAGACCC TCCACTGCGA GGCCCGTGGA AACCTGAGC 1380
CCTCCGTGCA CTGTGCAAGG CCTGACGGTG GGGCGGTGCT AGCGCTGGGC CTGTTGGGTC 1440
CAGTGACCCG TGCCCTCGCG GGAACCTACC GATGTACAGC AATCAATGGG CAAGGCCAGG 1500
CGGTCAAGGA TGTGACCCTG ACTGTGGAAT ATGCCCCAGC GCTGGACAGT GTAGGCTGCC 1560
CAGAACGTAT TACTTGGCTG GAGGGGACAG AGGCATCGCT TAGCTGTGTG GCACACGGGG 1620
TCCCACCACC TAGCGTGAGC TGTGTGCGCT CTGGAAAGGA GGAAGTCATG GAAGGGCCCC 1680
TGCGTGTGGC CCGGGAGCAC GCTGGCACTT ACCGATGCGA AGCCATCAAC GNCAGGGGAT 1740
CAGCGGWCAA AAATGTGGCT GTCACGGTGG AATATGGTCC CAGTTTGGAG GAGTTGGGCT 1800

GCCCCAGYAA	CTGGACTTGG	GTAGAAGGAT	CTGGAAAACT	GTTTTCCTGT	GAAGTTGATG	1860
GGAAGCCGGA	ACCACGCGTG	GAGTGCGTGG	GCTCGGAGGG	TGCAAGCGAA	GGGGTAGTGT	1920
TGCCCCCTGGT	GTCCTCGAAC	TCTGGTTCCA	GAAACTCTAT	GACTCCTGGT	AACCTGTCAC	1980
CGGGTATTTA	CCTCTGCAAC	GCCACCAACC	GGMATGGNTC	CACAGTCAAA	ACAGTCGTCG	2040
TGAGCGCGGA	ATCACCGCCA	CAGATGGATG	AATCCAGTTG	CCCGAGTCAC	CAGACATGGN	2100
TGGAAGGAGC	CGAGGNTACT	GCGCTGGCCT	GCAGTGCCAG	AGGNCGCCCC	TCTCCACGCG	2160
TGCGCTGTTC	CAGGGAAGGT	GCAGMCAGGC	TGGAGAGGNT	ACAGGTGTCC	CGAG	2214

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5077 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCGAACGCTC	CTCGGCCTCT	GGTCTNCTCT	GGNCCTGGGG	ATCCTAGGCA	TCTCAGGTAA	60
GAAGAGCCCG	CCCGTGGAGC	NAGGTGGATA	AGGCGGGGGC	GGAATTGAAG	GACCAGAGAG	120
GGCGGCCCCG	GTGTCCCCCT	CCAGGCTCCG	CCCTCTTCTA	GCTTCCCACG	CTTCTGTCAC	180
CACCTGGAGN	TCGGGGCTTC	TCCCCGTCCT	TCCTCCACCC	CAACACACCT	CAATCTTTCA	240
GANCTGAACC	CAGCACCTTT	TCTGGANTNG	GGGNNTTGCA	CCTAACCTGT	CTCAGGAGAN	300
ACTGTGGCTC	TCCTGTCTCT	TCCTGCTCTG	TNATGCCCTA	TGGTTCACAG	ACTGGCATCA	360
TCCCTATTCA	TGATCCTCAA	AGACNCCATC	TCCTCAACTG	TCATAACTCA	GAGCTCTATT	420
CCCCCTCCAC	CTGGAGCCCT	GGAAACCGGC	TTTCTAGGGC	TTTCTCCGC	GGTTCTTTCC	480
CGGAGTTCAG	CGTTGTGGCT	TTTTGTCCAA	GTTACTCAAG	TTTGGGGACA	ATCTCCTTTA	540
AGCCTTTGAC	TCAGTCTCAT	TTCCACTTTG	CTTTTGCCCC	AAGCCTCTGT	GTCTCTCCCC	600
CATTTCTGA	CGATCTGTCA	GAGTCTTAAG	AGTGATTTGG	TTCCCCATCC	CCCCTCCAAC	660
TGGAGTCTCC	TCCTCACTAT	TGATGTGTGC	ATCTGAGACC	CCCATCCCCG	CACCGAGTTT	720
CCCCATCTCT	GTCAGTAAAG	AGCAAGGCTT	CCAGAGACAA	CCCTCTAATA	GCGCGTCAGT	780
CCCGAATCTT	GAGTGGGATG	CGGGACTCCC	GTGCTATTTT	TTGGCGGAGG	TCTTTCCTGG	840
TCCTTATGGA	CACCCCTGGT	TTGGGATATG	GGGGCCGCTA	AGATTTTCAGA	GATGGGGTCC	900
CTAGGCTGAG	NCCGCGTTTT	CCCGGGCAGC	GGTCGCGCTA	GAACCTTTCT	GGGCGGACCT	960
TCAGCCCCGC	GTGGCGCTCG	TGGAGCGCGG	GGGCTCGCTG	TGGCTCAACT	GCAGCACTAA	1020
CTGTCCGAGG	CCGGAGCGCG	GTGGCCTGGA	GACCTCGCTA	CGCCGAAACG	GGACCCAGAG	1080
GGGTCTGNAC	TGNCTGGCTC	GACAGCTGGT	GGACATCCGA	GANCTTGAAA	CCCAGCCGGT	1140

CTGCTTCTTC	CNCTGCGCGC	GCCGCACACT	CCAAGCGCGT	GGGCTCATCC	GAACTTTCCG	1200
TGAGTTCAGG	GTGGGCACNC	CCCTTGGGTC	TCTGGACCTC	CCCCTCAAGC	TCCTCCCACC	1260
CGCCCTCTGA	TCCTCCTGCT	TGTTCTGAAA	GTACTACAGC	TGGCTAGAGC	GGAGTTTTTG	1320
GTCCCTTGCA	GAGCGACCGG	ATCGGGTAGA	GCTAGTGCCT	CTGCCTCCTT	GGCAGCCTGT	1380
AGGTGAGAAC	TTCACCTTGA	GCTGCAGGGT	CCCGGGGGCA	GGACCCCGAG	CGAGCCTCAC	1440
ATTGACCTTG	CTGCGAGGCG	GCCAGGAGCT	GATTTCGCCGA	AGTTTCGTAG	GCGAGCCACC	1500
CCGAGCTCGG	GGTGCGATGC	TCACCGCCAC	GGTCCTGGCG	CGCAGAGAGG	ATCACAGGGC	1560
CAATTTCTCA	TGCCTCGCGG	AGCTTGACCT	GCGNCCACAC	GGCTTGGGAC	TGTTTGCANA	1620
CAGCTCAGCC	CCCAGACAGC	TCCGCACGTT	TGGTGAGTGT	GGACCCTAAC	TGACAGATTT	1680
TAAGAAGTTT	AGGGCAGCCA	GGCGTGGTGG	CATGGTGTCG	TAGGCCCTAA	GTCCCAGCCC	1740
AAGCAGANCT	AAGNCGGATC	TCTTGTTGAAT	TAAAAGTCTA	GCTCGTCTAC	ATAACGAGGN	1800
CTGCATAGTT	AAATCCCCCA	AAAGTCTAAG	CAGCTAGCCC	TTACTTCCAA	CACAAGTACT	1860
AGCTTAAGTA	CTTTCTCCTG	TGAGCTTTTT	CCTTTATGTA	TTACTCGTT	GAGAGAAAAA	1920
GAGAGTGTGT	GTACGTGCCT	TTATGCACAT	GCCGCAGTGC	TTGTATGGAA	GTTAAAGAAT	1980
AAGGAGGCGT	TCTGCCCTTC	CATCCTGTGG	GTCCTAGGGG	TGGTATTAGC	TCCTCAGGCT	2040
TTGTTAGTNA	CAAGCGCCTA	GGCTTGGGGA	GCCATCTCGC	CCGCTCCTCT	GTATCTTTAG	2100
GGTGAAACCA	GACAATGCAT	GCAAATTGGT	TGATCAACAC	TGAATGTTTA	GTTTCGTAAAT	2160
TCAAGCTCTG	TTCTTTGTCT	TCCTCAGCCA	TGCCTCCACT	TTCCCCGAG	CCTTATTGCC	2220
CCACGATTCT	TAGAAGTGGG	CTCAGAAAGG	CCGGTGACKT	GCACTTTGGA	TGGACTGTTT	2280
CCTGCCCCAG	AAGCCGGGGT	TTACTTCTCT	CTGGGAGATC	AGAGGCTTCA	TCCTAATGTG	2340
ACCCTCGACG	GGGAGAGCCT	TGTGGCCACT	GCCACAGCTA	CAGCAAGTGA	AGAACAGGAA	2400
GGCACCAAAC	AGCTGATGTG	CATCGTGACC	CTCGGGGGCG	AAAGCAGGGA	GACCCAGGAA	2460
AACCTGACTG	TCTACAGTAA	GGGGAATCCA	ACAAGACCTT	CAATAGCTCA	GACTGGGGCT	2520
GGGGCTGGGT	CTGGGTCTGG	GGCCAGAGTC	TCACAAAGGC	GGAGCCTATA	AAGTGGGCGG	2580
GACCTCCACA	CCAGAACAAG	CCGGGCGGGA	GAGTTCCAGG	GCAGGAGCAG	ATAGAAGTTG	2640
GAAATTAATA	GATTGGGTTG	AGTTCCCTGA	GTGGGGAGTG	AACCCACCC	AATTCTCTGT	2700
CCCCAGGCTT	CCCGGCTCCT	CTTCTGACTT	TAAGTGAGCC	AGAAGCCCC	GAGGGAAAGA	2760
TGGTGACCGT	AAGCTGCTGG	GCAGGGGCCC	GAGCCCTTGT	CACCTTGAGG	GGAATTCCAG	2820
CTGCGGTCCC	TGGGCAGCCC	GCTGAGCTCC	AGTTAAATGT	CACAAAGAAT	GACGACAAGC	2880
GGGGCTTCTT	CTGCGACGCT	GCCCTCGATG	TGGACGGGGA	AACTCTGAGA	AAGAACCAGA	2940
GCTCTGAGCT	TCGTGTTCTG	TGTGAGTGGA	TGTTCACTTT	ATCTCTGTGA	ATTCCAAGGA	3000
CCCTCTTACC	GGCCCCATCT	TTAACCTTAT	CGTATCCCCT	CTGCCTCATG	CCCGCAGACG	3060

CACCTCGGCT	GGATGACTTG	GACTGTCCCCA	GGAGCTGGAC	GTGGCCAGAG	GGTCCAGAGC	3120
AGACCCTCCA	CTGCGAGGCC	CGTGGAAACC	CTGAGCCCTC	CGTGCCTGT	GCAAGGCCTG	3180
ACGGTGGGGC	GGTGCTAGCG	CTGGGCCTGT	TGGGTCCAGT	GACCCGTGCC	CTCGCGGGCA	3240
CTTACCGATG	TACAGCAATC	AATGGGCAAG	GCCAGGCGGT	CAAGGATGTG	ACCCTGACTG	3300
TGGAATGTGA	GTAGGGGGAG	GTGGGCATGC	TTATCCCTTT	AAGGTCACGG	AGTGTACTGG	3360
GAGACTGGCT	ATACGGAAAG	GAAAGAAGCC	TAGGTTTACG	AGGGATTGGG	AAAACACTGA	3420
AGGAAAGTGG	TGTGGTGTTT	ACAAACTTAA	CGGTGGTAAC	TGGGCACGGT	CTGGCAAAAA	3480
CAGACAGCCA	AGAGAGTGTG	CCTGGGAAGC	TGCAATGGGG	GCTTTGTGGG	AATTGGTCAA	3540
CAGCACCCCTG	AGATCTCAGG	AAAGGGGCCCT	GAAGTTATCT	CCAGAACCCA	TGTGAAGGCA	3600
GGAAGAGAGA	ACGCCACCT	TTTCTGCTC	CCCCCAACCC	CCCCCCACAT	ATCACACGGA	3660
GTATATAAAT	AAATAAAATG	GCTCCTGCCG	GAGGGAGTGA	GAAGCTGTCT	CCTGCAGGCT	3720
CAGAGCAGTG	GTAGTGATG	CCTTTAATCC	CAGCACTCGG	TAGGCAAAGG	CAGGCAGATC	3780
TCTGTGAATG	TGGGGCCAGC	CTGGTCTGTA	CAGAGAAATC	CTGTCTCAA	ACAAACCAGC	3840
AAAGAAACAA	AACCAAATC	AATTCCAGAT	GCCCCAGCGC	TGGACAGTGT	AGGCTGCCCCA	3900
NGACGTATTA	CTTGNCTGGA	GGGGACAGAG	GCATCGCTTA	GCTGTGTGGC	ACACGGGGTC	3960
CCACCACCTA	GCGTGAGCTG	TGTGCGCTCT	GGAAAGGAGG	AAGTCATGGA	AGGGCCCCCTG	4020
CGTGTGGCCC	GGGAGCACGC	TGGCACTTAC	CGATGCGAAG	CCATCAACGC	CAGGGGATCA	4080
GCGGNCAAAA	ATGTGGCTGT	CACGGTGGA	TGTGAGTAGG	GGTGGCTACG	GAAATGTCCA	4140
CACCTGCGTC	CTCTGTCTC	AGTGTGAACT	CCTATTTCCT	TGCTTCCTAG	ATGGTCCAG	4200
TTNTGAGGAG	TTGGGCTGCC	CCAGCAACTG	GACTTGGGTA	GAAGGATCTG	GAAAACTGTT	4260
TTCTGTGAA	GTTGATGGGA	AGCCGGAACC	ACGCGTGGAG	TGCGTGGGCT	CGGAGGGTGC	4320
AAGCGAAGGG	GTAGTGTTGC	CCCTGGTGTC	CTCGAACTCT	GGTTCCAGAA	ACTCTATGAC	4380
TCCTGGTAAC	CTGTCACCGG	GTATTTACCT	CTGCAACGCC	ACCAACCGGC	ATGGCTCCAC	4440
AGTCAAAACA	GTCGTCGTGA	GCGCGGAATG	TGAGCAGGGG	CCCAGGTGGG	CGGAGAGTAC	4500
CGGGTGTCCC	AGGATCTTTT	CTTTCCCTGA	TGCCCCCTCT	TATGGTGGCT	GATCTGCAGC	4560
ACCGCCACAG	ATGGATGAAT	CCAGTTGCCC	GAGTCACCAG	ACATGGCTGG	AAGGAGCCGA	4620
GGCTACTGCG	CTGGCCTGCA	GTGACAGGGG	NCGCCCTCT	CCACGCGTGC	GCTGTTCCAG	4680
GGAAGGTGCA	GCCAGGCTGG	AGAGGCTACA	GGTGTCCCGA	GAGGATGCGG	GGACCTACCT	4740
GTGTGTGGCT	ACCAACGCGC	ATGGCACGGA	TTCACGGACC	GTCCTGTGG	GTGTGGAATG	4800
TGAGTGAGGA	CAGCGCTGAA	TGAAGACGAC	TCAGACCGCC	AGAAAAGTGC	CTTGAGGCCT	4860
GGGATGTATG	ATCCAGTGGG	TAGAGTGCTC	AATTAGCACT	CACTAAAATG	TATATTCTAT	4920
TCCTAATACT	CTTTAATTTT	ANCTTTGGG	AGGCAGAGAC	AGGCAGATCT	CTGTTCCGGG	4980

ATAACCTGCT CTCTGTCTAG GACAGCTTGG TCTACAGAGG GGNTACAGGC CCCCCCTCCC 5040

AAGATTGNAT AGCAACCCTC TGGCTCCCTG TCTCTCT 5077

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1472 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

NGAATTCCGG CGGATCGGGT AGAGCTAGTG CCTCTGCCTC CTTGGCAGCC TGTAGGTGAG 60
AACTTCACCT TGAGCTGCAG GGTCCCGGGG GCAGGACCCC GAGCGAGCCT CACATTGACC 120
TTGCTGCGAG GCGGCCAGGA GCTGATTCGC CGAAGTTTCG TAGGCGAGCC ACCCCGAGCT 180
CGGGGTGCGA TGCTCACCGC CACGGTCCTG GCGCGCAGAG AGGATCACAG GGCCAATTC 240
TCATGCCTCG CGGAGCTTGA CCTGCGGCCA CACGGCTTGG GACTGTTTGC AAACAGCTCA 300
GCCCCAGAC AGCTCCGCAC GTTTGCCATG CCTCCACTTT CCCCAGCCT TATTGCCCCA 360
CGATTCTTAG AAGTGGGCTC AGAAAGGCCG GTGACTTGCA CTTTGATGG ACTGTTTCCT 420
GCCCCAGAAG CCGGGGTTTA CCTCTCTCTG GGAGATCAGA GGCTTCATCC TAATGTGACC 480
CTCGACGGGG AGAGCCTTGT GGCCACTGCC ACAGCTACAG CAAGTGAAGA ACAGGAAGGC 540
ACCAAACAGC TGATGTGCAT CGTGACCCTC GGGGGCGAAA GCAGGGAGAC CCAGGAAAAC 600
CTGACTGTCT ACAGCTTCCC GGCTCCTCTT CTGACTTTAA GTGAGCCAGA AGCCCCCGAG 660
GGAAAGATGG TGACCCTAAG CTGCTGGGCA GGGGCCCCGAG CCCTTGTCAC CTTGGAGGGA 720
ATTCCAGCTG CGGTCCCTGG GCAGCCCGCT GAGCTCCAGT TAAATGTCAC AAAGAATGAC 780
GACAAGCGGG GCTTCTTCTG CGACGCTGCC CTCGATGTGG ACGGGGAAAC TCTGAGAAAG 840
AACCAGAGCT CTGAGCTTCG TGTCTGTGTG GAGTGGATGT TCACTTTATC TCTGTGAATT 900
CCAAGGACCC TCTTACCGGC CCCATCTTTA ACCTTATCGT ATCCCCTCTG CCTCATGCCC 960
GCAGACGCAC CTCGGCTGGA TGA CTTGAC TGTCCCAGGA GCTGGACGTG GCCAGAGGGT 1020
CCAGAGCAGA CCCTCCACTG CGAGGCCCGT GGAAACCCTG AGCCCTCCGT GCACTGTGCA 1080
AGGCCTGACG GTGGGGCGGT GCTAGCGCTG GGCCTGTTGG GTCCAGTGAC CCGTGCCCTC 1140
GCGGGCACTT ACCGATGTAC AGCAATCAAT GGGCAAGGCC AGGCGGTCAA GGATGTGACC 1200
CTGACTGTGG AATATGCCCC AGCGCTGGAC AGTGTAGGCT GCCCAGAACG TATTACTTGG 1260
CTGGAGGGGA CAGAGGCATC GCTTAGCTGT GTGGCACACG GGGTCCCACC ACCTAGCGTG 1320
AGCTGTGTGC GCTCTGGAAA GGAGGAAGTC ATGGAAGGGC CCCTGCGTTT TGGCCGGGAG 1380
CACGCTGGCA CTTACCGATG CGAAGCCATC AACGCCAGGG GATCAGCGGC CAAAAATGTG 1440

GCTGTACGG TGGAATATGG TCCCCGGAAT TC

1472

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2550 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCTCTGCCTC CTTGGCAGCC TGTAGGTGAG AACTTCACCT TGAGCTGCAG GGTCCCCGGG	60
GCAGGACCCC GAGCGAGCCT CACATTGACC TTGCTGCGAG GCGGCCAGGA GCTGATTTCG	120
CGAAGTTTCG TAGGCGAGCC ACCCCGAGCT CGGGGTGCGA TGCTCACC GC CACGGTCCTG	180
GCGCGCAGAG AGGATCACAG GGCCAATTTC TCATGCCTCG CGGAGCTTGA CCTGCGGCCA	240
CACGGCTTGG GACTGTTTGC AAACAGCTCA GCCCCAGAC AGCTCCGCAC GTTTGCCATG	300
CCTCCACTTT CCCCAGAGCCT TATTGCCCCA CGATTCTTAG AAGTGGGCTC AGAAAGGCCG	360
GTGACTTGCA CTTTGGATGG ACTGTTTCCT GCCCAGAAG CCGGGGTTTA CCTCTCTCTG	420
GGAGATCAGA GGCTTCATCC TAATGTGACC CTCGACGGGG AGAGCCTTGT GGCCACTGCC	480
ACAGCTACAG CAAGTGAAGA ACAGGAAGGC ACCAAACAGC TGATGTGCAT CGTGACCCTC	540
GGGGGCGAAA GCAGGGAGAC CCAGGAAAAC CTGACTGTCT ACAGCTTCCC GGCTCCTCTT	600
CTGACTTTAA GTGAGCCAGA AGCCCCGAG GGAAAGATGG TGACCGTAAG CTGCTGGGCA	660
GGGGCCCGAG CCCTTGTCAC CTTGGAGGGA ATTCCAGCTG CGGTCCCTGG GCAGCCCGCT	720
GAGCTCCAGT TAAATGTCAC AAAGAATGAC GACAAGCGGG GCTTCTTCTG CGACGCTGCC	780
CTCGATGTGG ACGGGGAAAC TCTGAGAAAG AACCAGAGCT CTGAGCTTCG TGTCTGTAC	840
GCACCTCGGC TGGATGACTT GGA CTGTGCTCC AGGAGCTGGA CGTGGCCAGA GGGTCCAGAG	900
CAGACCCTCC ACTGCGAGGC CCGTGGA AAC CCTGAGCCCT CCGTGCACTG TGCAAGGCCT	960
GACGGTGGGG CGGTGCTAGC GCTGGGCCTG TTGGGTCCAG TGACCCGTGC CCTCGCGGGC	1020
ACTTACCGAT GTACAGCAAT CAATGGGCAA GGCCAGGCGG TCAAGGATGT GACCCTGACT	1080
GTGGAATATG CCCCAGCGCT GGACAGTGTA GGCTGCCAG AACGTATTAC TTGGCTGGAG	1140
GGGACAGAGG CATCGCTTAG CTGTGTGGCA CACGGGGTCC CACCACCTAG CGTGAGCTGT	1200
GTGCGCTCTG GAAAGGAGGA AGTCATGGAA GGGCCCCTGC GTGTGGCCCG GGAGCACGCT	1260
GGCACTTACC GATGCGAAGC CATCAACGCC AGGGGATCAG CGGCCAAAAA TGTGGCTGTC	1320
ACGGTGGAAT ATGGTCCCAG TTTTGAGGAG TTGGGCTGCC CCAGCAACTG GACTTGGGTA	1380
GAAGGATCTG GAAACTGTT TTCCTGTGAA GTTGATGGGA AGCCGGAACC ACGCGTGGAG	1440
TGCGTGGGCT CGGAGGGTGC AAGCGAAGGG GTAGTGTGTC CCCTGGTGTC CTCGAACTCT	1500

GGTTCCAGAA ACTCTATGAC TCCTGGTAAC CTGTCACCGG GTATTTACCT CTGCAACGCC	1560
ACCAACCGGC ATGGCTCCAC AGTCAAAACA GTCGTCGTGA GCGCGGAATC ACCGCCACAG	1620
ATGGATGAAT CCAGTTGCCC GAGTCACCAG ACATGGCTGG AAGGAGCCGA GGCTACTGCG	1680
CTGGCCTGCA GTGCCAGAGG CCGCCCCTCT CCACGCGTGC GCTGTTCCAG GGAAGGTGCA	1740
GCCAGGCTGG AGAGGCTACA GGTGTCCCGA GAGGATGCGG GGACCTACCT GTGTGTGGCT	1800
ACCAACGCGC ATGGCACGGA TTCACGGACC GTCACTGTGG GTGTGGAATA CCGGCCTGTG	1860
GTGGCTGAGC TGGCAGCCTC GCCCCAAGC GTGCGGCCTG GCGGAAACTT CACTCTGACC	1920
TGCCGTGCAG AGGCCTGGCC TCCAGCCCAG ATCAGCTGGC GCGCGCCCCC GGGAGCTCTC	1980
AACCTCGGTC TCTCCAGCAA CAACAGCACG CTGAGCGTGG CGGGTGCCAT GGGCAGCCAT	2040
GGTGGCGAGT ATGAGTGCGC AGCCACCAAT GCGCATGGGC GCCACGCACG GCGCATCACG	2100
GTGCGCGTGG CCGGTCCATG GCTGTGGGTC GCTGTGGGCG GTGCGGCAGG GGGCGCGGCG	2160
CTGCTGGCCG CAGGGGCCG CCTGGCCTTC TACGTGCAGT CCACCGCTTG CAAGAAGGGA	2220
GAGTACAACG TCCAGGAGGC TGAGAGCTCA GGCGAGGCGG TGTGTCTCAA TGGCGCGGGC	2280
GGGACACCGG GTGCAGAAGG CGGAGCAGAG ACCCCCGGCA CTGCCGAGTC ACCTGCAGAT	2340
GGCGAGGTTT TCGCCATCCA GCTGACATCT TCCTGAGCCT GTATCCAGCT CCCCAGGGG	2400
CCTCGAAAGC ACAGGGGTGG ACGTATGTAT TGTTCATCT CTATTTATTC AACTCCAGGG	2460
GCGTCGTCCC CGTTTTCTAC CCATTCCTT AATAAGTTT TTATAGGAGA AAAAAAAAAA	2520
AAAAAAAAA AAAAAAAAAA AAAAAAAAAA	2550

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 222 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AATTCGATCA CTCGCGCTCC CCTCGCCTTC TCGCTCTCC CCTCCCTGGC AGCGGCGGCA	60
ATGCCGGGGC CTTACCAGG GCTGCGCCGA ACGCTCCTCG GCCTCTGGGC TGCCCTGGGC	120
CTGGGGATCC TAGGCATCTC AGCGGTCGCG CTAGAACCTT TCTGGGCGGA CCTTCAGCCC	180
CGCGTGGCGC TCGTGGAGCG CGGGGGCTCG CTGTGGCTCA AC	222

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 292 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TGTGGAGCTG GCACCCCTGC CTCCTTGGCA GCCGGTGGGC CAGAACTTCA CCCTGCGCTG	60
CCAAGTGGAG GGTGGGTCGC CCCGGACCAG CCTCACGGTG GTGCTGCTTC GCTGGGAGGA	120
GGAGCTGAGC CGGCAGCCCCG CAGTGGAGGA GCCAGCGGAG GTCAGTGCCA CTGTGCTGGC	180
CAGCAGAGAC GACCACGGAG CCCCTTTCTC ATGCCGCACA GAACTGGACA TGCAGCCCCA	240
GGGGCTGGGA CTGTTCGTGA ACACCTCAGC CCCCCGCCAG CTCCGAACCT TT	292

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Pro Asp Arg Val Glu Leu Val Pro Leu Pro Pro Trp Gln Pro Val Gly	
1 5 10 15	
Glu Asn Phe Thr Leu Ser Cys Arg Val Pro Gly Ala Gly Pro Arg Ala	
20 25 30	
Ser Leu Thr Leu Thr Leu Leu Arg Gly Gly Gln Glu Leu Ile Arg Arg	
35 40 45	
Ser Phe Val Gly Glu Pro Pro Arg Ala Arg Cys Ala Met Leu Thr Ala	
50 55 60	
Thr Val Leu Ala Arg Arg Glu Asp His Arg Asp Asn Phe Ser Cys Leu	
65 70 75 80	
Ala Glu Leu Asp Leu Arg Thr His Gly Leu Gly Leu Phe Ala Asn Ser	
85 90 95	
Ser Ala Pro Arg Gln Leu Arg Thr Phe	
100 105	

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAACTCGAGG CCATGCCTCC ACTTTCC

27

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCATAAGCTT TATTCCACCG TGACAGCCAC

30

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AACGTGCGGA GCTGTCTG

18

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACGGAATTCG AAGCCATCAA CGCCAGG

27

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CATGAATTC GAATCTTGAG TGGGATG

27

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATAGAATTCC TCGGGACACC TGTAGCC

27

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CARGGTGACA AGGGCTCG

18

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TATGAATTCA GTTGAGCCAC AGCGAGC

27

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCGGGTCCTA GAGGTGGACA CGCA

24

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TGCAGTGTCT CCTGGCTCTG GTTC

24

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 992 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GCAGAAACCG GGAGACCCGG GAGAACGTGA CCATCTACAG CTTCCCGGCA CCACTCCTGA 60
CCCTGAGCGA ACCCAGCGTC TCCGAGGGGC AGATGGTGAC AGTAACCTGC GCAGCTGGGG 120
CCCAAGCTCT GGTCACTAGT GAGGGAGTTC CAGCCGCGGT CCCGGGGCAG CCCGCCCAGC 180
TTCAGCTAAA TGCCACCGAG AACGACGACA GACGCAGCTT CTTCTGCGAC GCCACCCTCG 240
ATGTGGACGG GGAGACCCTG ATCAAGAACA GGAGCGCAGA GCTTCGTGTC CTATACGCTC 300
CCCGGCTAGA CGATTCGGAC TGCCCCAGGA GTTGGACGTG GCCCGAGGGC CCAGAGCAGA 360
CGCTGCGCTG CGAGGCCCCG GGAACCCAG AACCTCAGT GCACTGTGCG CGCTCCGACG 420
GCGGGGCCGT GCTGGCTCTG GGCCTGCTGG GTCCAGTCAC TCGGGCGCTC TCAGGCACTT 480
ACCGCTGCAA GGCGGCCAAT GATCAAGGCG AGGCGGTCAA GGACGTAACG CTAACGGTGG 540
AGTACGCACC AGCGCTGGAC AGCGTGGGCT GCCCAGAACG CATTACTTGG CTGGAGGGAA 600
CAGAAGCCTC GCTGAGCTGT GTGGCGCACG GGTACCGCC GCCTGATGTG ATCTGCGTGC 660
GCTCTGGAGA ACTCGGGGCC GTCATCGAGG GGCTGTTGCG TGTGGCCCGG GAGCATGCGG 720
GCACTTACCG CTGCGAAGCC ACCAACCCTC GGGGCTCTGC GGCCAAAAAT GTGGCCGTCA 780
CGGTGGAATA TGGCCCCAGG TTTGAGGAGC CGAGCTGCCC CAGCAATTGG ACATGGGTGG 840
AAGGATCTGG GCGCCTGTTT TCCTGTGAGG TCGATGGGAA GCCACAGCCA AGCGTGAAGT 900
GCGTGGGCTC CGGGGGCACC ACTGAGGGGG TGCTGCTGCC GCTGGCACCC CCAGACCCTA 960
GTCCAGAGC TCCAGAATC CCTAGAGTCC TG 992

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2775 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCAGCCTCGC GTGGCGTTTC TGGAGCGCGG GGGCTCGCTG TGGCTGAATT GCAGCACCAA 60
CTGCCCTCGG CCGGAGCGCG GTGGCCTGGA GACCTCGCTG CGCCGAAACG GGACCCAGAG 120
GGGTTTGCGT TGGTTGGCGC GGCAGCTGGT GGACATTCGC GAGCCGGAGA CTCAGCCCGT 180
CTGCTTCTTC CGCTGCGCGC GGCACACACT ACAGGCGCGT GGGCTCATTC GCACTTTCCA 240

GCGACCAGAT	CGCGTAGAGC	TGATGCCGCT	GCCTCCCTGG	CAGCCGGTGG	GCGAGAACTT	300
CACCTTGAGC	TGTAGGGTCC	CCGGCGCCGG	GCCCCGTGCG	AGCCTCACGC	TGACCCTGCT	360
GCGGGGCGCC	CAGGAGCTGA	TCCGCCGCAG	CTTCGCCGGT	GAACCACCCC	GAGCGCGGGG	420
CGCGGTGCTC	ACAGCCACGG	TACTGGCTCG	GAGGGAGGAC	CATGGAGCCA	ATTTCTCGTG	480
TCGCGCCGAG	CTGGACCTGC	GGCCGCACGG	ACTGGGACTG	TTTGAAAACA	GCTCGGCCCC	540
CAGAGAGCTC	CGAACCTTCT	CCCTGTCTCC	GGATGCCCCG	CGCCTCGCTG	CTCCCCGGCT	600
CTTGGAAGTT	GGCTCGGAAA	GGCCCGTGAG	CTGCACTCTG	GACGGACTGT	TTCCAGCCTC	660
AGAGGCCAGG	GTCTACCTCG	CACTGGGGGA	CCAGAATCTG	AGTCCTGATG	TCACCCTCGA	720
AGGGGACGCA	TTCGTGGCCA	CTGCCACAGC	CACAGCTAGC	GCAGAGCAGG	AGGGTGCCAG	780
GCAGCTGGTC	TGCAACGTCA	CCCTGGGGGG	CGAAAACCGG	GAGACCCGGG	AGAACGTGAC	840
CATCTACAGC	TTCCCGGCAC	CACTCCTGAC	CCTGAGCGAA	CCCAGCGTCT	CCGAGGGGCA	900
GATGGTGACA	GTAACCTGCG	CAGCTGGGGC	CCAAGCTCTG	GTCACACTGG	AGGGAGTTCC	960
AGCCGCGGTC	CCGGGGCAGC	CCGCCCAGCT	TCAGCTAAAT	GCCACCGAGA	ACGACGACAG	1020
ACGCAGCTTC	TTCTGCGACG	CCACCCTCGA	TGTGGACGGG	GAGACCCTGA	TCAAGAACAG	1080
GAGCGCAGAG	CTTCGTGTCC	TATACGCTCC	CCGGCTAGAC	GATTCGGACT	GCCCCAGGAG	1140
TTGGACGTGG	CCCGAGGGCC	CAGAGCAGAC	GCTGCGCTGC	GAGGCCCGCG	GGAACCCAGA	1200
ACCCTCAGTG	CACTGTGCGC	GCTCCGACGG	CGGGGCCGTG	CTGGCTCTGG	GCCTGTGGG	1260
TCCAGTCACT	CGGGCGCTCT	CAGGCACTTA	CCGCTGCAAG	GCGGCCAATG	ATCAAGGCGA	1320
GGCGGTCAAG	GACGTAACGC	TAACGGTGGA	GTACGCACCA	GCGCTGGACA	GCGTGGGCTG	1380
CCCAGAACGC	ATTACTTGGC	TGGAGGGAAC	AGAAGCCTCG	CTGAGCTGTG	TGGCGCACGG	1440
GGTACCGCCG	CCTGATGTGA	TCTGCGTGCG	CTCTGGAGAA	CTCGGGGCCG	TCATCGAGGG	1500
GCTGTTGCGT	GTGGCCCGGG	AGCATGCGGG	CACTTACCGC	TGCGAAGCCA	CCAACCCTCG	1560
GGGCTCTGCG	GCCAAAATG	TGGCCGTCAC	GGTGGAATAT	GGCCCCAGGT	TTGAGGAGCC	1620
GAGCTGCCCC	AGCAATTGGA	CATGGGTGGA	AGGATCTGGG	CGCCTGTTTT	CCTGTGAGGT	1680
CGATGGGAAG	CCACAGCCAA	GCGTGAAGTG	CGTGGGCTCC	GGGGGCACCA	CTGAGGGGGT	1740
GCTGCTGCCG	CTGGCACCCC	CAGACCCTAG	TCCCAGAGCT	CCCAGAATCC	CTAGAGTCCT	1800
GGCACCCGGT	ATCTACGTCT	GCAACGCCAC	CAACCGCCAC	GGCTCCGTGG	CCAAAACAGT	1860
CGTCGTGAGC	GCGGAGTCGC	CACCGGAGAT	GGATGAATCT	ACCTGCCCAA	GTCACCAGAC	1920
GTGGCTGGAA	GGGGCTGAGG	CTTCCGCGCT	GGCCTGCGCC	GCCCGGGGTC	GCCCTTCCCC	1980
AGGAGTGCGC	TGCTCTCGGG	AAGGCATCCC	ATGGCCTGAG	CAGCAGCGCG	TGTCCCGAGA	2040
GGACGCGGGC	ACTTACCACT	GTGTGGCCAC	CAATGCGCAT	GGCACGGACT	CCCGGACCGT	2100
CACTGTGGGC	GTGGAATACC	GGCCAGTGGT	GGCCGAACCT	GCTGCCTCGC	CCCCTGGAGG	2160

CGTGCGCCCA GGAGGAAACT TCACGTTGAC CTGCCGCGCG GAGGCCTGGC CTCCAGCCCA	2220
GATCAGCTGG CGCGCGCCCC CGAGGGCCCT CAACATCGGC CTGTGAGCA ACAACAGCAC	2280
ACTGAGCGTG GCAGGCGCCA TGGGAAGCCA CGGCGGCGAG TACGAGTGG CACGCACCAA	2340
CGCGCACGGG CGCCACGCGC GGCGCATCAC GGTGCGCGTG GCCGGTCCGT GGCTATGGGT	2400
CGCCGTGGGC GGCGCGGCGG GGGGCGCGGC GCTGCTGGCC GCGGGGGCCG GCCTGGCCTT	2460
CTACGTGCAG TCCACCGCCT GCAAGAAGGG CGAGTACAAC GTGCAGGAGG CCGAGAGCTC	2520
AGGCGAGGCC GTGTGTCTGA ACGGAGCGGG CGGCGGCGCT GGCGGGGCGG CAGGCGCGGA	2580
GGGCGGACCC GAGGCGGCGG GGGGCGCGGC CGAGTCGCCG GCGGAGGGCG AGGTCTTCGC	2640
CATACAGCTG ACATCGGCGT GAGCCCGCTC CCCTCTCCGC GGGCCGGGAC GCCCCCAGA	2700
CTCACACGGG GGCTTATTTA TTGCTTTATT TATTTACTTA TTCATTTATT TATGTATTCA	2760
ACTCCAAGGG AATTC	2775

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1557 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CGCGCTCTCC TCGCCTCCTG TGCTTTCCCC GCGCGGCGGA TGCCAGGGCC TTCGCCAGGG	60
CTGCGCCGGG CGCTACTCGG CCTCTGGGCT GCTCTGGGCC TGGGGCTCTT CGGCCTCTCA	120
GCGGTCTCGC AGGAGCCCTT CTGGGCGGAC CTGCAGCCTC GCGTGGCGTT CGTGGAGCGC	180
GGGGGCTCGC TGTGGCTGAA TTGCAGCACC AACTGCCCTC GGCCGGAGCG CGGTGGCCTG	240
GAGACCTCGC TCGCCGAAA CGGGACCCAG AGGGGTTTGC GTTGGTTGGC GCGGCAGCTG	300
GTGGACATTC GCGAGCCGGA GACTCAGCCC GTCTGCTTCT TCCGCTGCGC GCGGCGCACA	360
CTACAGGCGC GTGGGCTCAT TCGCACTTTC CAGCGACCAG ATCGCGTAGA GCTGATGCCG	420
CTGCCTCCCT GGCAGCCGGT GGGCGAGAAC TTCACCCTGA GCTGTAGGGT CCCC GGCGCC	480
GGGCCCCGTG CGAGCCTCAC GCTGACCCTG CTGCGGGGCG CCCAGGAGCT GATCCGCCGC	540
AGCTTCGCCG GTGAACCACC CCGAGCGCGG GGCGCGGTGC TCACAGCCAC GGTACTGGCT	600
CGGAGGGAGG ACCATGGAGC CAATTTCTCG TGTCGCGCCG AGCTGGACCT GCGGCCGCAC	660
GGACTGGGAC TGTTTGAAAA CAGCTCGGCC CCCAGAGAGC TCCGAACCTT CTCCCTGTCT	720
CCGGATGCCC CGCGCCTCGC TGCTCCCCGG CTCTTGGAAG TTGGCTCGGA AAGGCCCGTG	780
AGCTGCACTC TGGACGGACT GTTTCAGCC TCAGAGGCCA GGGTCTACCT CGCACTGGGG	840
GACCAGAATC TGAGTCCTGA TGTCACCCTC GAAGGGGACG CATTCGTGGC CACTGCCACA	900

GCCACAGCTA GCGCAGAGCA GGAGGGTGCC AGGCAGCTGG TCTGCAACGT CACCCTGGGG 960
GGCGAAAACC GGGAGACCCG GGAGAACGTG ACCATCTACA GCTTCCCGGC ACCACTCCTG 1020
ACCCTGAGCG AACCCAGCGT CTCCGAGGGG CAGATGGTGA CAGTAACCTG CGCAGCTGGG 1080
GCCCCAAGCTC TGGTCACACT GGAGGGAGTT CCAGCCGCGG TCCCGGGGCA GCCCGCCAG 1140
CTTCAGCTAA ATGCCACCGA GAACGACGAC AGACGCAGCT TCTTCTGCGA CGCCACCCTC 1200
GATGTGGACG GGGAGACCTT GATCAAGAAC AGGAGCGCAG AGCTTCGTGT CCTATACGCT 1260
CCCCGGCTAG ACGATTCGGA CTGCCCCAGG AGTTGGACGT GGCCCCGAGGG CCCAGAGCAG 1320
ACGCTGCGCT GCGAGGCCCG CGGGAACCCA GAACCCTCAG TGCCTGTGC GCGCTCCGAC 1380
GGCGGGGCCG TGCTGGCTCT GGGCCTGCTG GGTCCAGTCA CTCGGGCGCT CTCAGGCACT 1440
TACCGCTGCA AGGCGGCCAA TGATCAAGGC GAGGCGGTCA AGGACGTAAC GCTAACGGTG 1500
GAGTACGCAC CAGCGCTGGA CAGCGTGGGC TGCCAGAAC GCATTACTTG GCTGGAG 1557

-- (2)--INFORMATION FOR SEQ-ID-NO:27:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2927 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 40..2814

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CGCGCTCTCC TCGCCTCCTG TGCTTTCCCC GCCGCGGCG ATG CCA GGG CCT TCG 54
Met Pro Gly Pro Ser
1 5

CCA GGG CTG CGC CGG GCG CTA CTC GGC CTC TGG GCT GCT CTG GGC CTG 102
Pro Gly Leu Arg Arg Ala Leu Leu Gly Leu Trp Ala Ala Leu Gly Leu
10 15 20

GGG CTC TTC GGC CTC TCA GCG GTC TCG CAG GAG CCC TTC TGG GCG GAC 150
Gly Leu Phe Gly Leu Ser Ala Val Ser Gln Glu Pro Phe Trp Ala Asp
25 30 35

CTG CAG CCT CGC GTG GCG TTC GTG GAG CGC GGG GGC TCG CTG TGG CTG 198
Leu Gln Pro Arg Val Ala Phe Val Glu Arg Gly Gly Ser Leu Trp Leu
40 45 50

AAT TGC AGC ACC AAC TGC CCT CGG CCG GAG CGC GGT GGC CTG GAG ACC 246
Asn Cys Ser Thr Asn Cys Pro Arg Pro Glu Arg Gly Gly Leu Glu Thr
55 60 65

TCG CTG CGC CGA AAC GGG ACC CAG AGG GGT TTG CGT TGG TTG GCG CGG 294
Ser Leu Arg Arg Asn Gly Thr Gln Arg Gly Leu Arg Trp Leu Ala Arg
70 75 80 85

CAG	CTG	GTG	GAC	ATT	CGC	GAG	CCG	GAG	ACT	CAG	CCC	GTC	TGC	TTC	TTC	342
Gln	Leu	Val	Asp	Ile	Arg	Glu	Pro	Glu	Thr	Gln	Pro	Val	Cys	Phe	Phe	
				90					95					100		
CGC	TGC	GCG	CGG	CGC	ACA	CTA	CAG	GCG	CGT	GGG	CTC	ATT	CGC	ACT	TTC	390
Arg	Cys	Ala	Arg	Arg	Thr	Leu	Gln	Ala	Arg	Gly	Leu	Ile	Arg	Thr	Phe	
			105					110					115			
CAG	CGA	CCA	GAT	CGC	GTA	GAG	CTG	ATG	CCG	CTG	CCT	CCC	TGG	CAG	CCG	438
Gln	Arg	Pro	Asp	Arg	Val	Glu	Leu	Met	Pro	Leu	Pro	Pro	Trp	Gln	Pro	
		120					125					130				
GTG	GGC	GAG	AAC	TTC	ACC	CTG	AGC	TGT	AGG	GTC	CCC	GGC	GCC	GGG	CCC	486
Val	Gly	Glu	Asn	Phe	Thr	Leu	Ser	Cys	Arg	Val	Pro	Gly	Ala	Gly	Pro	
	135					140					145					
CGT	GCG	AGC	CTC	ACG	CTG	ACC	CTG	CTG	GCG	GGC	GCC	CAG	GAG	CTG	ATC	534
Arg	Ala	Ser	Leu	Thr	Leu	Thr	Leu	Leu	Arg	Gly	Ala	Gln	Glu	Leu	Ile	
150					155					160					165	
CGC	CGC	AGC	TTC	GCC	GGT	GAA	CCA	CCC	CGA	GCG	CGG	GGC	GCG	GTG	CTC	582
Arg	Arg	Ser	Phe	Ala	Gly	Glu	Pro	Pro	Arg	Ala	Arg	Gly	Ala	Val	Leu	
				170					175					180		
ACA	GCC	ACG	GTA	CTG	GCT	CGG	AGG	GAG	GAC	CAT	GGA	GCC	AAT	TTC	TCG	630
Thr	Ala	Thr	Val	Leu	Ala	Arg	Arg	Glu	Asp	His	Gly	Ala	Asn	Phe	Ser	
			185					190					195			
TGT	CGC	GCC	GAG	CTG	GAC	CTG	CGG	CCG	CAC	GGA	CTG	GGA	CTG	TTT	GAA	678
Cys	Arg	Ala	Glu	Leu	Asp	Leu	Arg	Pro	His	Gly	Leu	Gly	Leu	Phe	Glu	
		200					205					210				
AAC	AGC	TCG	GCC	CCC	AGA	GAG	CTC	CGA	ACC	TTC	TCC	CTG	TCT	CCG	GAT	726
Asn	Ser	Ser	Ala	Pro	Arg	Glu	Leu	Arg	Thr	Phe	Ser	Leu	Ser	Pro	Asp	
		215				220					225					
GCC	CCG	CGC	CTC	GCT	GCT	CCC	CGG	CTC	TTG	GAA	GTT	GGC	TCG	GAA	AGG	774
Ala	Pro	Arg	Leu	Ala	Ala	Pro	Arg	Leu	Leu	Glu	Val	Gly	Ser	Glu	Arg	
230				235						240					245	
CCC	GTG	AGC	TGC	ACT	CTG	GAC	GGA	CTG	TTT	CCA	GCC	TCA	GAG	GCC	AGG	822
Pro	Val	Ser	Cys	Thr	Leu	Asp	Gly	Leu	Phe	Pro	Ala	Ser	Glu	Ala	Arg	
				250					255					260		
GTC	TAC	CTC	GCA	CTG	GGG	GAC	CAG	AAT	CTG	AGT	CCT	GAT	GTC	ACC	CTC	870
Val	Tyr	Leu	Ala	Leu	Gly	Asp	Gln	Asn	Leu	Ser	Pro	Asp	Val	Thr	Leu	
			265					270					275			
GAA	GGG	GAC	GCA	TTC	GTG	GCC	ACT	GCC	ACA	GCC	ACA	GCT	AGC	GCA	GAG	918
Glu	Gly	Asp	Ala	Phe	Val	Ala	Thr	Ala	Thr	Ala	Thr	Ala	Ser	Ala	Glu	
		280					285					290				
CAG	GAG	GGT	GCC	AGG	CAG	CTG	GTC	TGC	AAC	GTC	ACC	CTG	GGG	GGC	GAA	966
Gln	Glu	Gly	Ala	Arg	Gln	Leu	Val	Cys	Asn	Val	Thr	Leu	Gly	Gly	Glu	
		295				300					305					
AAC	CGG	GAG	ACC	CGG	GAG	AAC	GTG	ACC	ATC	TAC	AGC	TTC	CCG	GCA	CCA	1014
Asn	Arg	Glu	Thr	Arg	Glu	Asn	Val	Thr	Ile	Tyr	Ser	Phe	Pro	Ala	Pro	
310					315					320					325	
CTC	CTG	ACC	CTG	AGC	GAA	CCC	AGC	GTC	TCC	GAG	GGG	CAG	ATG	GTG	ACA	1062
Leu	Leu	Thr	Leu	Ser	Glu	Pro	Ser	Val	Ser	Glu	Gly	Gln	Met	Val	Thr	
				330					335					340		

TCGTC TCGTC

GTA Val	ACC Thr	TGC Cys	GCA Ala 345	GCT Ala	GGG Gly	GCC Ala	CAA Gln	GCT Ala 350	CTG Leu	GTC Val	ACA Thr	CTG Leu	GAG Glu 355	GGA Gly	GTT Val	1110
CCA Pro	GCC Ala	GCG Ala 360	GTC Val	CCG Pro	GGG Gly	CAG Gln	CCC Pro 365	GCC Ala	CAG Gln	CTT Leu	CAG Gln	CTA Leu 370	AAT Asn	GCC Ala	ACC Thr	1158
GAG Glu	AAC Asn 375	GAC Asp	GAC Asp	AGA Arg	CGC Arg	AGC Ser 380	TTC Phe	TTC Phe	TGC Cys	GAC Asp	GCC Ala 385	ACC Thr	CTC Leu	GAT Asp	GTG Val	1206
GAC Asp 390	GGG Gly	GAG Glu	ACC Thr	CTG Leu	ATC Ile 395	AAG Lys	AAC Asn	AGG Arg	AGC Ser	GCA Ala 400	GAG Glu	CTT Leu	CGT Arg	GTC Val	CTA Leu 405	1254
TAC Tyr	GCT Ala	CCC Pro	CGG Arg	CTA Leu 410	GAC Asp	GAT Asp	TCG Ser	GAC Asp	TGC Cys 415	CCC Pro	AGG Arg	AGT Ser	TGG Trp	ACG Thr 420	TGG Trp	1302
CCC Pro	GAG Glu	GGC Gly	CCA Pro 425	GAG Glu	CAG Gln	ACG Thr	CTG Leu	CGC Arg 430	TGC Cys	GAG Glu	GCC Ala	CGC Arg	GGG Gly 435	AAC Asn	CCA Pro	1350
GAA Glu	CCC Pro 440	TCA Ser	GTG Val	CAC His	TGT Cys	GCG Ala	CGC Arg 445	TCC Ser	GAC Asp	GGC Gly	GGG Gly	GCC Ala 450	GTG Val	CTG Leu	GCT Ala	1398
CTG Leu	GGC Gly 455	CTG Leu	CTG Leu	GGT Gly	CCA Pro 460	GTC Val	ACT Thr	CGG Arg	GCG Ala	CTC Leu	TCA Ser 465	GGC Gly	ACT Thr	TAC Tyr	CGC Arg	1446
TGC Cys 470	AAG Lys	GCG Ala	GCC Ala	AAT Asn	GAT Asp 475	CAA Gln	GGC Gly	GAG Glu	GCG Ala	GTC Val 480	AAG Lys	GAC Asp	GTA Val	ACG Thr	CTA Leu 485	1494
ACG Thr	GTG Val	GAG Glu	TAC Tyr 490	GCA Ala	CCA Pro	GCG Ala	CTG Leu	GAC Asp	AGC Ser 495	GTG Val	GGC Gly	TGC Cys	CCA Pro	GAA Glu 500	CGC Arg	1542
ATT Ile	ACT Thr	TGG Trp	CTG Leu 505	GAG Glu	GGA Gly	ACA Thr	GAA Glu	GCC Ala 510	TCG Ser	CTG Leu	AGC Ser	TGT Cys	GTG Val 515	GCG Ala	CAC His	1590
GGG Gly	GTA Val 520	CCG Pro	CCG Pro	CCT Pro	GAT Asp	GTG Val	ATC Ile 525	TGC Cys	GTG Val	CGC Arg	TCT Ser	GGA Gly 530	GAA Glu	CTC Leu	GGG Gly	1638
GCC Ala	GTC Val 535	ATC Ile	GAG Glu	GGG Gly	CTG Leu	TTG Leu 540	CGT Arg	GTG Val	GCC Ala	CGG Arg	GAG Glu 545	CAT His	GCG Ala	GGC Gly	ACT Thr	1686
TAC Tyr 550	CGC Arg	TGC Cys	GAA Glu	GCC Ala	ACC Thr 555	AAC Asn	CCT Pro	CGG Arg	GGC Gly	TCT Ser 560	GCG Ala	GCC Ala	AAA Lys	AAT Asn	GTG Val 565	1734
GCC Ala	GTC Val	ACG Thr	GTG Val	GAA Glu 570	TAT Tyr	GGC Gly	CCC Pro	AGG Arg	TTT Phe 575	GAG Glu	GAG Glu	CCG Pro	AGC Ser	TGC Cys 580	CCC Pro	1782
AGC Ser	AAT Asn	TGG Trp	ACA Thr 585	TGG Trp	GTG Val	GAA Glu	GGA Gly	TCT Ser 590	GGG Gly	CGC Arg	CTG Leu	TTT Phe 595	TCC Ser	TGT Cys	GAG Glu	1830

GTC	GAT	GGG	AAG	CCA	CAG	CCA	AGC	GTG	AAG	TGC	GTG	GGC	TCC	GGG	GGC	1878
Val	Asp	Gly	Lys	Pro	Gln	Pro	Ser	Val	Lys	Cys	Val	Gly	Ser	Gly	Gly	
		600					605					610				
ACC	ACT	GAG	GGG	GTG	CTG	CTG	CCG	CTG	GCA	CCC	CCA	GAC	CCT	AGT	CCC	1926
Thr	Thr	Glu	Gly	Val	Leu	Leu	Pro	Leu	Ala	Pro	Pro	Asp	Pro	Ser	Pro	
		615				620					625					
AGA	GCT	CCC	AGA	ATC	CCT	AGA	GTC	CTG	GCA	CCC	GGT	ATC	TAC	GTC	TGC	1974
Arg	Ala	Pro	Arg	Ile	Pro	Arg	Val	Leu	Ala	Pro	Gly	Ile	Tyr	Val	Cys	
		630			635					640					645	
AAC	GCC	ACC	AAC	CGC	CAC	GGC	TCC	GTG	GCC	AAA	ACA	GTC	GTC	GTG	AGC	2022
Asn	Ala	Thr	Asn	Arg	His	Gly	Ser	Val	Ala	Lys	Thr	Val	Val	Val	Ser	
				650					655					660		
GCG	GAG	TCG	CCA	CCG	GAG	ATG	GAT	GAA	TCT	ACC	TGC	CCA	AGT	CAC	CAG	2070
Ala	Glu	Ser	Pro	Pro	Glu	Met	Asp	Glu	Ser	Thr	Cys	Pro	Ser	His	Gln	
			665				670						675			
ACG	TGG	CTG	GAA	GGG	GCT	GAG	GCT	TCC	GCG	CTG	GCC	TGC	GCC	GCC	CGG	2118
Thr	Trp	Leu	Glu	Gly	Ala	Glu	Ala	Ser	Ala	Leu	Ala	Cys	Ala	Ala	Arg	
		680					685					690				
GGT	CGC	CCT	TCC	CCA	GGA	GTG	CGC	TGC	TCT	CGG	GAA	GGC	ATC	CCA	TGG	2166
Gly	Arg	Pro	Ser	Pro	Gly	Val	Arg	Cys	Ser	Arg	Glu	Gly	Ile	Pro	Trp	
		695				700					705					
CCT	GAG	CAG	CAG	CGC	GTG	TCC	CGA	GAG	GAC	GCG	GGC	ACT	TAC	CAC	TGT	2214
Pro	Glu	Gln	Gln	Arg	Val	Ser	Arg	Glu	Asp	Ala	Gly	Thr	Tyr	His	Cys	
					715					720					725	
GTG	GCC	ACC	AAT	GCG	CAT	GGC	ACG	GAC	TCC	CGG	ACC	GTC	ACT	GTG	GGC	2262
Val	Ala	Thr	Asn	Ala	His	Gly	Thr	Asp	Ser	Arg	Thr	Val	Thr	Val	Gly	
				730					735					740		
GTG	GAA	TAC	CGG	CCA	GTG	GTG	GCC	GAA	CTT	GCT	GCC	TCG	CCC	CCT	GGA	2310
Val	Glu	Tyr	Arg	Pro	Val	Val	Ala	Glu	Leu	Ala	Ala	Ser	Pro	Pro	Gly	
			745					750					755			
GGC	GTG	CGC	CCA	GGA	GGA	AAC	TTC	ACG	TTG	ACC	TGC	CGC	GCG	GAG	GCC	2358
Gly	Val	Arg	Pro	Gly	Gly	Asn	Phe	Thr	Leu	Thr	Cys	Arg	Ala	Glu	Ala	
		760					765					770				
TGG	CCT	CCA	GCC	CAG	ATC	AGC	TGG	CGC	GCG	CCC	CCG	AGG	GCC	CTC	AAC	2406
Trp	Pro	Pro	Ala	Gln	Ile	Ser	Trp	Arg	Ala	Pro	Pro	Arg	Ala	Leu	Asn	
		775				780					785					
ATC	GGC	CTG	TCG	AGC	AAC	AAC	AGC	ACA	CTG	AGC	GTG	GCA	GGC	GCC	ATG	2454
Ile	Gly	Leu	Ser	Ser	Asn	Asn	Ser	Thr	Leu	Ser	Val	Ala	Gly	Ala	Met	
					795					800					805	
GGA	AGC	CAC	GGC	GGC	GAG	TAC	GAG	TGC	GCA	CGC	ACC	AAC	GCG	CAC	GGG	2502
Gly	Ser	His	Gly	Gly	Glu	Tyr	Glu	Cys	Ala	Arg	Thr	Asn	Ala	His	Gly	
				810					815					820		
CGC	CAC	GCG	CGG	CGC	ATC	ACG	GTG	CGC	GTG	GCC	GGT	CCG	TGG	CTA	TGG	2550
Arg	His	Ala	Arg	Arg	Ile	Thr	Val	Arg	Val	Ala	Gly	Pro	Trp	Leu	Trp	
				825				830					835			
GTC	GCC	GTG	GGC	GGC	GCG	GCG	GGG	GGC	GCG	GCG	CTG	CTG	GCC	GCG	GGG	2598
Val	Ala	Val	Gly	Gly	Ala	Ala	Gly	Gly	Ala	Ala	Leu	Leu	Ala	Ala	Gly	
		840					845					850				

TCGTCCTT

GCC GGC CTG GCC TTC TAC GTG CAG TCC ACC GCC TGC AAG AAG GGC GAG 2646
Ala Gly Leu Ala Phe Tyr Val Gln Ser Thr Ala Cys Lys Lys Gly Glu
855 860 865

TAC AAC GTG CAG GAG GCC GAG AGC TCA GGC GAG GCC GTG TGT CTG AAC 2694
Tyr Asn Val Gln Glu Ala Glu Ser Ser Gly Glu Ala Val Cys Leu Asn
870 875 880 885

GGA GCG GGC GGC GGC GCT GGC GGG GCG GCA GGC GCG GAG GGC GGA CCC 2742
Gly Ala Gly Gly Gly Ala Glu Gly Gly Ala Ala Glu Gly Gly Pro
890 895 900

GAG GCG GCG GGG GGC GCG GCC GAG TCG CCG GCG GAG GGC GAG GTC TTC 2790
Glu Ala Ala Gly Gly Ala Ala Glu Ser Pro Ala Glu Gly Glu Val Phe
905 910 915

GCC ATA CAG CTG ACA TCG GCG TGAGCCCGCT CCCCTCTCCG CGGGCCGGGA 2841
Ala Ile Gln Leu Thr Ser Ala
920 925

CGCCCCCAG ACTCACACGG GGGCTTATTT ATTGCTTTAT TTATTTACTT ATTCATTTAT 2901

TTATGTATTC AACTCCAAGG GAATTC 2927

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 924 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met Pro Gly Pro Ser Pro Gly Leu Arg Arg Ala Leu Leu Gly Leu Trp
1 5 10 15
Ala Ala Leu Gly Leu Gly Leu Phe Gly Leu Ser Ala Val Ser Gln Glu
20 25 30
Pro Phe Trp Ala Asp Leu Gln Pro Arg Val Ala Phe Val Glu Arg Gly
35 40 45
Gly Ser Leu Trp Leu Asn Cys Ser Thr Asn Cys Pro Arg Pro Glu Arg
50 55 60
Gly Gly Leu Glu Thr Ser Leu Arg Arg Asn Gly Thr Gln Arg Gly Leu
65 70 75 80
Arg Trp Leu Ala Arg Gln Leu Val Asp Ile Arg Glu Pro Glu Thr Gln
85 90 95
Pro Val Cys Phe Phe Arg Cys Ala Arg Arg Thr Leu Gln Ala Arg Gly
100 105 110
Leu Ile Arg Thr Phe Gln Arg Pro Asp Arg Val Glu Leu Met Pro Leu
115 120 125
Pro Pro Trp Gln Pro Val Gly Glu Asn Phe Thr Leu Ser Cys Arg Val
130 135 140

Pro Gly Ala Gly Pro Arg Ala Ser Leu Thr Leu Thr Leu Leu Arg Gly
145 150 155 160

Ala Gln Glu Leu Ile Arg Arg Ser Phe Ala Gly Glu Pro Pro Arg Ala
165 170 175

Arg Gly Ala Val Leu Thr Ala Thr Val Leu Ala Arg Arg Glu Asp His
180 185 190

Gly Ala Asn Phe Ser Cys Arg Ala Glu Leu Asp Leu Arg Pro His Gly
195 200 205

Leu Gly Leu Phe Glu Asn Ser Ser Ala Pro Arg Glu Leu Arg Thr Phe
210 215 220

Ser Leu Ser Pro Asp Ala Pro Arg Leu Ala Ala Pro Arg Leu Leu Glu
225 230 235 240

Val Gly Ser Glu Arg Pro Val Ser Cys Thr Leu Asp Gly Leu Phe Pro
245 250 255

Ala Ser Glu Ala Arg Val Tyr Leu Ala Leu Gly Asp Gln Asn Leu Ser
260 265 270

Pro Asp Val Thr Leu Glu Gly Asp Ala Phe Val Ala Thr Ala Thr Ala
275 280 285

Thr Ala Ser Ala Glu Gln Glu Gly Ala Arg Gln Leu Val Cys Asn Val
290 295 300

Thr Leu Gly Gly Glu Asn Arg Glu Thr Arg Glu Asn Val Thr Ile Tyr
305 310 315 320

Ser Phe Pro Ala Pro Leu Leu Thr Leu Ser Glu Pro Ser Val Ser Glu
325 330 335

Gly Gln Met Val Thr Val Thr Cys Ala Ala Gly Ala Gln Ala Leu Val
340 345 350

Thr Leu Glu Gly Val Pro Ala Ala Val Pro Gly Gln Pro Ala Gln Leu
355 360 365

Gln Leu Asn Ala Thr Glu Asn Asp Asp Arg Arg Ser Phe Phe Cys Asp
370 375 380

Ala Thr Leu Asp Val Asp Gly Glu Thr Leu Ile Lys Asn Arg Ser Ala
385 390 395 400

Glu Leu Arg Val Leu Tyr Ala Pro Arg Leu Asp Asp Ser Asp Cys Pro
405 410 415

Arg Ser Trp Thr Trp Pro Glu Gly Pro Glu Gln Thr Leu Arg Cys Glu
420 425 430

Ala Arg Gly Asn Pro Glu Pro Ser Val His Cys Ala Arg Ser Asp Gly
435 440 445

Gly Ala Val Leu Ala Leu Gly Leu Leu Gly Pro Val Thr Arg Ala Leu
450 455 460

Ser Gly Thr Tyr Arg Cys Lys Ala Ala Asn Asp Gln Gly Glu Ala Val
465 470 475 480

Lys Asp Val Thr Leu Thr Val Glu Tyr Ala Pro Ala Leu Asp Ser Val
 485 490 495
 Gly Cys Pro Glu Arg Ile Thr Trp Leu Glu Gly Thr Glu Ala Ser Leu
 500 505 510
 Ser Cys Val Ala His Gly Val Pro Pro Pro Asp Val Ile Cys Val Arg
 515 520 525
 Ser Gly Glu Leu Gly Ala Val Ile Glu Gly Leu Leu Arg Val Ala Arg
 530 535 540
 Glu His Ala Gly Thr Tyr Arg Cys Glu Ala Thr Asn Pro Arg Gly Ser
 545 550 555 560
 Ala Ala Lys Asn Val Ala Val Thr Val Glu Tyr Gly Pro Arg Phe Glu
 565 570 575
 Glu Pro Ser Cys Pro Ser Asn Trp Thr Trp Val Glu Gly Ser Gly Arg
 580 585 590
 Leu Phe Ser Cys Glu Val Asp Gly Lys Pro Gln Pro Ser Val Lys Cys
 595 600 605
 Val Gly Ser Gly Gly Thr Thr Glu Gly Val Leu Leu Pro Leu Ala Pro
 610 615 620
 Pro Asp Pro Ser Pro Arg Ala Pro Arg Ile Pro Arg Val Leu Ala Pro
 625 630 635 640
 Gly Ile Tyr Val Cys Asn Ala Thr Asn Arg His Gly Ser Val Ala Lys
 645 650 655
 Thr Val Val Val Ser Ala Glu Ser Pro Pro Glu Met Asp Glu Ser Thr
 660 665 670
 Cys Pro Ser His Gln Thr Trp Leu Glu Gly Ala Glu Ala Ser Ala Leu
 675 680 685
 Ala Cys Ala Ala Arg Gly Arg Pro Ser Pro Gly Val Arg Cys Ser Arg
 690 695 700
 Glu Gly Ile Pro Trp Pro Glu Gln Gln Arg Val Ser Arg Glu Asp Ala
 705 710 715 720
 Gly Thr Tyr His Cys Val Ala Thr Asn Ala His Gly Thr Asp Ser Arg
 725 730 735
 Thr Val Thr Val Gly Val Glu Tyr Arg Pro Val Val Ala Glu Leu Ala
 740 745 750
 Ala Ser Pro Pro Gly Gly Val Arg Pro Gly Gly Asn Phe Thr Leu Thr
 755 760 765
 Cys Arg Ala Glu Ala Trp Pro Pro Ala Gln Ile Ser Trp Arg Ala Pro
 770 775 780
 Pro Arg Ala Leu Asn Ile Gly Leu Ser Ser Asn Asn Ser Thr Leu Ser
 785 790 795 800
 Val Ala Gly Ala Met Gly Ser His Gly Gly Glu Tyr Glu Cys Ala Arg
 805 810 815

TEST "1234567890"

Thr Asn Ala His Gly Arg His Ala Arg Arg Ile Thr Val Arg Val Ala
820 825 830

Gly Pro Trp Leu Trp Val Ala Val Gly Gly Ala Ala Gly Gly Ala Ala
835 840 845

Leu Leu Ala Ala Gly Ala Gly Leu Ala Phe Tyr Val Gln Ser Thr Ala
850 855 860

Cys Lys Lys Gly Glu Tyr Asn Val Gln Glu Ala Glu Ser Ser Gly Glu
865 870 875 880

Ala Val Cys Leu Asn Gly Ala Gly Gly Gly Ala Gly Gly Ala Ala Gly
885 890 895

Ala Glu Gly Gly Pro Glu Ala Ala Gly Gly Ala Ala Glu Ser Pro Ala
900 905 910

Glu Gly Glu Val Phe Ala Ile Gln Leu Thr Ser Ala
915 920

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 65 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GTACTTACAG GATCCGCGGT CTCGCAGGAG CCCTTCTGGG CGGACCTACA GCCTGCGTGG 60
CGTTC 65

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

ATTTCTCTCG AGGATGGTCA CGTTCTCCCG G 31

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

ATTTCTGGAT CCTACAGCTT CCCGGCACCA CTC

33

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATTTCTCTCG AGTTCCACGC CCACAGTGAC GG

32

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1687 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GGATCCTTTG AGCCCTGAAA GTCGAGGTTG CAGTGAGCCT TGATCGTGCC ACTGCACTCC	60
AGCCTGGGGG ACAGAGCACG ACCCTGTCTC CAAAAATAAA ATAAAAATAA AAATAAATAT	120
TGGCGGGGGA ACCCTCTGGA ATCAATAAAG GCTTCCTTAA CCAGCCTCTG TCCTGTGACC	180
TAAGGTCCG CATTACTGCC CTTCTTCGGA GGAAGTGGTT TGTTTTTGTGTT GTTGTTGTTG	240
TTTTTGCGAT CACTTTCTCC AAGTTCCTTG TCTCCCTGAG GGCACCTGAG GTTTCCTCAC	300
TCAGGGCCCA CCTGGGGTCC CGAAGCCCCA GACTCTGTGT ATCCCCAGCG GGTGTCACAG	360
AAACCTCTCC TTCTGCTGGC CTTATCGAGT GGGATCAGCG CGGCCGGGGA GAGCCACGGG	420
CAGGGGCGGG GTGGGGTTCA TGGTATGGCT TTCCTGATTG GCGCCGCCGC CACCACGCGG	480
CAGCTCTGAT TGGATGTTAA GTTTCCTATC CCAGCCCCAC CTTAGACCC TGTGCTTTCC	540
TGGAGGCCAA ACAACTGTGG AGCGAGAACT CATCTCCAAA ATAACCTTACC ACGCTGGAGT	600
GAGACCACGA ATGGTGGGGA GGGGAGGGTC CCACGGACAT ATTGAGGGAC GTGGATACGC	660
AGAAGAGGTA TCCATGTGGT GGCAGCCGGG AAGGGGTGAT CAGATGGTCC ACAGGGAATA	720
TCACAACTC GAATTCTGAC GATGTTCTGG TAGTCACCCA GCCAGATGAG CGCATGGAGT	780
TGGCGGTGGG GGGTGTCAAA GCTTGGGGCC CGGAAGCGGA GTCAAAAGCA TCACCCTCGG	840
TCCCTTGTTT TCGCGTGGAT GTCAGGGCCT CCACCCACCG AGCAGAAGGC GGAAGTACGG	900
GCGCTCCAGG GTGGCTCGAG CTCACACACG CTGAGTAGAC ACGTGCCCGC TGCACCCTGG	960
GTAAATACAG ACCCGGAGCC GAGCGGATTC TAATTTAGAC GCCCGGAAC GCTGCGCGCA	1020
CGCACACGTG TCCTCGGCTC GCTGGCACTT TCGTCCCGCC CCCTCCGTCG CGTGCCGGAG	1080

CTGACCCGGA GGGGTGCTTA GAGGTATGGC TCCGCGGGGT CAAAAGGAGA AGGATCAGTG	1140
AGAGAGGATC CCCACACCCT CCCCTAGAAC TGTCTTTTCC CCATCCAGTG CCTCCCAAAT	1200
CTCTCTTAGT CCCCAAATGT ATCCCCGCCC TAAGGGGCGC TGGTGGGAGG AGCTAAATGT	1260
GGGGGCGGAG CTCGGAGTCC AGCTTATTAT CATGGCATCT CAGCCAGGGC TGGGGTAGGG	1320
GTTTGGGAAG GGCAACCCAG CATCCCCCGA TCCCAGAGTC GCGGCCGGGG ATGACGCGAG	1380
AGAGCGTGGT CGCCCCCAGA AGGCCCTGGG CCATCATGCC GGCCTCCACG TAGACCCAG	1440
GGGTCGCTCA CTCCTGCCAG CTCGCCTTCA CCAAGGCCAG GAGCTTAGCG CACGCTCGCC	1500
TCCCGCCCCC CCGCCGCTC TGCCGCCGCC CCCTCCTTGG AAACCAAGTT ACCAACGTTA	1560
AACCAATCCC CAAGCGCAAC TCTGTCTCCC CCACACCCCA CCCGCCGCGC CGCGCGGAGC	1620
CGTCCTCTAG CCCAGCTCCT CGGCTCGCGC TCTCCTCGCC TCCTGTGCTT TCCCGCCGCG	1680
GGCGATG	1687

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CAGAACTAAG CTTACAGGAG GCGAGGAGAG CGCGAG	36
---	----

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CAACAATGCT AGCCAAGCGC AACTCTGTCT C	31
------------------------------------	----

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CAACAATGCT AGCCTTGGAA ACCAAGTTAC C	31
------------------------------------	----

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CAACAATGCT AGCAGGAGCT TAGCGCACGC TCG

33

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CAACAATGCT AGCCATGCCG GCCTCCACGT AG

32

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CAACAATGCT AGCGTCCAGC TTATTATCAT G

31

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CAACAATGCT AGCCTTAGTC CCCAAATGTA TC

32

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CAACAATGCT AGCGGAGAAG GATCAGTGAG

30

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CAACAATGCT AGCCTCCACC CACCGAGCAG AAG

33

100554-1401